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ABSTRACT 
 
 
COPD is a leading cause of morbidity and mortality worldwide and it is believed that the 
neutrophil is key to the pathology. Evidence to date suggests that neutrophils migrate less 
accurately in patients with COPD, although the precise mechanisms by which this occurs 
have not been defined. 
 
We have shown that COPD neutrophils migrate faster (chemokinesis) but less accurately 
(chemotaxis) in various chemokine gradients. It appears to be an intrinsic cell defect, as 
incubation of healthy neutrophils in COPD plasma did not alter migratory dynamics. This 
phenomenon does not occur in other respiratory diseases and is unrelated to age, disease 
severity, smoking status or the presence of emphysema. Furthermore, there were no 
differences in markers of neutrophil activation or maturity, although degranulation markers 
were higher in COPD. 
 
Expression of certain chemokine receptors was lower on quiescent COPD neutrophils, but 
these differences were abolished after stimulation. Receptors localised to the leading edge 
effectively in COPD neutrophils and there were no differences in receptor shedding. PI3K 
phosphorylation was increased in COPD and inhibition of γ and δ isoforms improved 
chemotaxis. Neither Akt phosphorylation nor intracellular calcium signalling was altered. 
Simvastatin also improved chemotaxis of COPD neutrophils but CXCR1/2 inhibitors did not. 
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NORMAL RESPIRATORY PHYSIOLOGY 
 
 
1.1.1   Anatomy & Physiology 
The primary function of the respiratory system is the exchange of respiratory gases 
between the external atmosphere and the body. This involves the uptake of oxygen, which is 
required by the tissues for aerobic respiration, and the removal of carbon dioxide, which is 
the waste product of cellular respiration. The mammalian respiratory system is highly 
evolved, and consists of two subsystems. The external respiratory system is comprised of the 
lungs (the organs of respiration) and the pulmonary circulation, and the internal respiratory 
system consists of the tissue cells. The lungs are specifically adapted to gaseous exchange by 
virtue of their large internal surface area, relative permeability, and extensive blood supply. 
The lungs are contained within the thoracic cavity, which is a closed compartment 
consisting of the thoracic muscles, ribcage, sternum, thoracic vertebrae, and connective 
tissue. The anatomy of the thorax is illustrated in Figure 1.1. 
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The process of respiration begins by air entering the respiratory passage via the nose or 
mouth, and passing through the pharynx and larynx into the trachea, which subsequently 
leads into the thorax. The trachea then branches at the major carina into the left and right 
bronchi, which connect to the respective left or right lung. Following a series of successive 
branching leading to a fine network of bronchioles, the airways finally terminate at the 
Figure 1.1: A diagram to show the viscera of the thorax. 
 
Legend: An anterior view of including the lungs, diaphragm and 
cardiovascular system as well as the skeletal structures encasing the thoracic 
cavity (Adapted from http://infogrphic.blogspot.com/2011/04/viscera-of-
thorax.html). 
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alveoli, which are the respiratory acini. Each progressive division of the bronchial tree is 
referred to as a “generation”. There are twenty-four generations in total, although gaseous 
exchange only occurs within the last eight, which include the terminal respiratory 
bronchioles, alveolar ducts, and the alveoli. 
Structural support in the larger airways is provided by cartilage, which surrounds the 
epithelial, muscular, nervous, lymphoid and vascular components of the airway wall. As the 
generations increase and the airways become smaller, the cartilaginous support is 
progressively lost and is replaced by smooth muscle and elastic connective tissue. The alveoli 
are lined with two types of squamous epithelial cells; type I and type II pneumocytes. Type I 
cells form a thin, permeable layer throughout the alveoli that is primarily involved in gaseous 
exchange but also prevents fluid loss. Type II cells are granular and cuboidal and, although 
more numerous than type I cells, constitute only a small percentage of the alveolar surface 
area (Crapo et al. 1982). Their main function is to produce surfactant, a group of 
phospholipids which lower the surface tension within the alveoli. In addition, they can 
replicate in the alveoli and replace type I cells, which are susceptible to toxic insults and are 
unable to replicate (Evans et al. 1975). 
The structure and physical properties of the lungs are elastic in nature, comprising both 
elastin and collagen fibers, hence they have a tendency to collapse inward. In contrast, the 
chest wall has a tendency to spring outwards (up to approximately 65% of full inspiration). 
These two opposing forces balance each other at rest, thus maintaining the overall shape of 
the thoracic cage. Ventilation is achieved by the expansion and relaxation of the lungs within 
the thoracic cavity. During tidal ventilation, or “quiet” breathing, inspiration is an active 
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process involving muscular contraction, whereas expiration is a normally passive, occurring 
due to the relaxation of inspiratory muscles and the elastic properties of the lung. 
 
1.1.2   Pulmonary Blood Supply 
Cells continually use oxygen for the metabolic processes that release energy from 
nutrient molecules. Therefore, oxygen must be continually absorbed from the atmosphere 
into the circulation and carbon dioxide (a waste product of metabolism) must be continually 
excreted. This is achieved during normal ventilation, which is increased during periods of 
activity/exercise to match the increased respiratory demands. 
The pulmonary circulation is a separate component of the cardiovascular system that 
carries oxygen-depleted blood from the heart to the lungs and returns oxygenated blood back 
to the heart. Each airway within in the pulmonary tree is supplied by a branch of the 
pulmonary artery that divides at each progressive bifurcation, ultimately forming an intricate 
capillary network in the alveolar wall. The extent of this blood supply and the proximity of 
the capillary network to the alveolar airspaces both serve to maximise gaseous exchange. 
A separate system, called the bronchial circulation, supplies blood to the conducting 
airways in the lungs down to the terminal bronchioles. The bronchial arteries originate from 
either the aorta or the intercostal arteries and supply arterial blood to the tissues and 
structures throughout the lungs. This circulation is also important in the “air-conditioning” of 
inspired air and controlling heat exchange in the lungs. 
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1.1.3   Immunity 
To accomplish gaseous exchange, the large surface area of the lungs must be in continual 
contact with ambient air. As a result, the thin, permeable layer of cells that comprise the lung 
epithelium is continually exposed to airborne pathogens that could potentially lead to 
infection. Therefore, the respiratory tract requires effective mechanisms to prevent microbial 
proliferation. The lung has therefore evolved with effective physical barriers, mechanical 
defences and inflammatory cell responses to prevent microbial colonisation and infection. 
Pathogens that enter the lower respiratory tract are initially trapped in the epithelial lining 
fluid, which comprises complex secretions, including a mucus blanket and surfactant. These 
secretions are then moved upwards on the “mucociliary escalator” (Green et al. 1977) 
towards the oropharynx where the cough and swallow mechanism clears the pathogens 
physically from the respiratory tract. Pathogens that evade this clearance mechanism can 
adhere to the lung epithelium, begin to proliferate and initiate a more specific 
immune/inflammatory response designed to combat the infection at a cellular level. 
The immune system includes many specific and non-specific mechanisms and diverse 
cell types, each with individual functions that provide defence against microorganisms and 
other foreign antigens. A rapid innate response is the first line of defence and is relatively 
non-specific. This primary response includes resident airway phagocytes, local non-specific 
(IgA) immunity and a variety of antimicrobial peptides. This is followed (when the primary 
innate immune system is overwhelmed) by a secondary inflammatory cell response including 
recruitment of circulating neutrophils and monocytes, as well as leakage of plasma proteins 
such as complement and more specific immunoglobulins. If the infection persists, a highly 
specific adaptive response, which offers a cognate/specific recognition of individual antigens, 
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develops over days to weeks although, on subsequent exposure to the same antigen, this 
response occurs earlier as part of the “memory” function. 
Innate and adaptive immunity are interlinked in part via toll-like receptors (TLRs), which 
are pattern recognition receptors found on the cell surface and in endosomal compartments of 
the various host inflammatory cells (Akira et al. 2006). Once TLRs recognise microbial-
derived molecules common to foreign pathogens (such as bacterial endotoxin), they initiate 
many subsequent stages of the immune response, including secretion of pro-inflammatory 
cytokines (Galanos et al. 1993). Innate immunity involves several cell types including 
monocytes/macrophages, neutrophils, eosinophils, basophils, natural killer (NK), natural 
killer T (NKT) cells and dendritic cells (DCs), some of which are resident, although most are 
recruited from the circulation in response to infection. The process is mediated by a vast 
number of pro-inflammatory cytokines that modulate the features of inflammation and, 
hence, bacterial clearance. The final stage of adaptive immunity is antigen-specific and 
predominantly based on T and B lymphocyte-mediated mechanisms. 
The mechanical defences of the lungs are thus continuously supported by the immune 
system and lung immunity is dynamically mediated by both the innate and adaptive arms of 
the immune system (Meyer 2001). This complex, interrelated sequence of events is 
summarised in Figure 1.2. More detailed accounts of these processes are described in (Martin 
et al. 2005, Zaas et al. 2005, Sheehan et al. 2006). 
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Figure 1.2: A simplified model of the interrelated sequence of events involved in pulmonary immunity. 
 
Legend: The inflammatory processes include the release of regulatory cytokines (such as TNFα and IL-8), recruitment and proliferation 
of numerous inflammatory cells as well as specific defence mechanisms of the epithelium. 
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1.2   THE NEUTROPHIL 
 
1.2.1   Development & Structure 
Neutrophil polymorphonuclear leukocytes or “neutrophils” are the most abundant white 
blood cell in the circulation, accounting for 40-65% of all leukocytes. Normal concentrations 
range between 3 and 5 x 10
6
 cells/ml of blood, though this number can increase dramatically 
during periods of infection.  
Traditionally, it was believed that their circulating half-life is relatively short at 8-20 
hours (Dancey et al. 1976), which may extend to several days if they leave the circulation 
and enter the tissue. A recent in vivo study suggests a much longer neutrophil lifespan of 5.4 
days (Pillay et al 2010) although, due to the method by which the neutrophils were labelled 
with 
2
H2O, neutrophils present in the bone marrow were almost certainly labelled as well as 
peripheral blood neutrophils, hence the longevity of blood neutrophils was likely to be 
overestimated. Furthermore, the majority of recent data also suggest the lifespan of 
circulating neutrophils is relatively short, though the evolutionary advantage of this rapid 
turnover remains unclear (Summers et al. 2010). 
The development and maturation of neutrophils has been well described (Edwards 2005) 
but key points will be summarised here. Neutrophils differentiate and mature within the bone 
marrow. Due to the large number of neutrophils and their short half-life, large numbers of 
neutrophils must be produced and released daily by the bone marrow, a process which is 
regulated by cytokines such as Granulocyte Colony-Stimulating Factor (G-CSF) and may be 
amplified as much as tenfold during periods of infection. The development of mature 
neutrophils in the bone marrow occurs via the differentiation of generic stem cells into 
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precursor, or “progenitor” cells that follow the developmental lineage specific to neutrophils. 
The first identifiable cells in this lineage are myeloblasts, which are relatively 
undifferentiated and contain a large nucleus. These then proliferate and differentiate into 
promyelocytes, at which stage the cells develop a large number of “primary” or “azurophile” 
granules. These contain a number of different enzymes that become important for the specific 
immune functions of mature neutrophils. They include myeloperoxidase (MPO), antibacterial 
peptides (azurocidin, defensins and lysozyme) and serine proteinases such as Cathepsin G 
(CG), neutrophil elastase (NE) and Proteinase-3 (PR3). As the cells mature into myelocytes, 
they synthesise a large number of peroxidise-negative granules termed “secondary” or 
“specific” granules. These granules also contain enzymes as well as various membrane 
receptors. From here, the cells mature further to form metamyelocytes and subsequently band 
cells, where they lose their ability to divide. At this stage, the last of the granules are formed, 
namely the “tertiary” or “small storage” granules, which contain cathepsins and gelatinases. 
In fully mature neutrophils, there are over 200 granules with vast array of antibacterial 
enzymes, collectively forming a robust defence against pathogens. The developmental stages 
of mature neutrophils are summarised in Figure 1.3. 
When mature neutrophils leave the bone marrow, they are in a quiescent, non-activated 
state. At the end of their lifespan (if not activated), they return to marginated pools within the 
vasculature of various organs such as the spleen and bone marrow (Burnett 1997). Here, they 
undergo apoptosis, or “programmed cell death”, and are phagocytosed by macrophages. This 
process is important as a number of neutrophil granular contents are damaging to structural 
tissue proteins (for instance, elastin degradation by NE). Apoptosis and subsequent 
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phagocytosis prevents the contents of the neutrophil being released into the local 
environment as the cell enters secondary necrosis. 
Sites of margination include the liver, spleen and bone marrow (Peters et al. 1985, Ussov 
et al. 1995). It was originally believed that the lungs were the major site of neutrophil 
margination (Hogg et al. 1995), though subsequent work by a different group challenged this 
and it is now accepted that the pulmonary involvement is only modest (Peters et al. 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: A summary of the stages involved in neutrophil differentiation 
and maturation. 
 
Legend: As neutrophils mature (left to right), they develop various types of 
granules. A mature neutrophil contains over 200 granules that are essential for 
immune functions such as migration and bacterial killing (Adapted from Edwards 
2005). 
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1.2.2   Neutrophil Migration 
The migration of leukocytes from the circulation into the tissues occurs through a series 
of distinct steps. The cell must adhere to the blood vessel wall (margination), pass through 
the endothelial layer (transmigration/diapedesis) and subsequently migrate through the tissue 
to the site of inflammation. The process is initiated by the interaction activation of adhesion 
molecules and their respective ligands on the surface of both leukocytes and endothelial cells 
(Lawrence et al. 1991, von Andrian et al. 1991, Konstantopoulos et al. 1996). Neutrophils, 
monocytes and lymphocytes all migrate in this manner but differences occur in their response 
to chemoattractants and other inflammatory signals. 
 
Adhesion 
Neutrophil migration begins with the “capture” of neutrophils from the blood flow as 
they roll along the surface of the endothelium. This initial tethering is a result of the 
reversible binding of transmembrane glycoprotein adhesion molecules called selectins, which 
are present on both neutrophils and endothelial cells (Bevilacqua et al. 1993, Albelda et al. 
1994, Luscinskas et al. 1994, Crockett-Torabi et al. 1995; Tedder et al. 1995a, Wagner et al. 
2000). Selectins contain three different domains: A C-type lectin domain, an epidermal 
growth-factor-like domain and several regulatory domains. The dominant selectin expressed 
on the surface of a neutrophil is Leukocyte Selectin (L-Selectin). Under normal, non-
pathological conditions, quiescent neutrophils can bind briefly to endothelial cells as they 
make contact in a “stick and release” manner. This leads to a progressive loss of L-Selectin 
molecules as they are shed and cannot be replaced (Walchek et al. 1996) and low expression 
of L-Selectin is associated with neutrophil apoptosis and may incite their removal from the 
13 
 
circulation (Matsuba et al. 1997). Cleavage of L-Selectin from the plasma membrane is 
predominantly regulated in vivo by the sheddase; A Disintegrin and Metalloprotease-17 
(ADAM-17) (Li et al. 2006). This process is amplified in the presence of various pro-
inflammatory cytokines including Tumour Necrosis Factor Alpha (TNFα), 
Lipopolysaccharide (LPS), Interleukin-8 (IL-8) and Formyl-Methionyl-Leucyl-Phenylalanine 
(fMLP) (Drost et al. 2002). 
The two other selectins that are known to facilitate neutrophil-endothelial cell adhesion 
are Platelet Selectin (P-Selectin) and Endothelial Cell Selectin (E-Selectin). These are both 
bound to the endothelium and are only expressed when certain inflammatory stimuli are 
present. P-Selectin (CD62P) is stored intracellularly in Weibel-Palade bodies of endothelial 
cells as well as the α-granules of platelets (Malik et al. 1996). In response to inflammatory 
stimuli, it is rapidly mobilised to the cell surface where, following the initial interactions with 
L-Selectin (CD62L), it binds to P-Selectin Glycoprotein Ligand-1 (PSGL-1; CD162) on the 
surface of neutrophils, forging more durable neutrophil-endothelium associations and 
eventual tethering (Alon et al. 1997, Davenpeck et al. 1997). As with L-Selectin however, 
this interaction is not permanent and is reversed in the absence of subsequent adhesive 
mechanisms (Lawrence et al. 1991, Finger et al. 1996, Davenpeck et al. 1997). E-Selectin 
(CD62E) is not stored intracellularly and requires gene transcription for expression. Peak 
expression in vitro is achieved between 4 and 6 hours after exposure to inflammatory 
cytokines (Klein et al. 1995, Scholz et al. 1996). E-Selectin also promotes the rolling and 
tethering of neutrophils to the endothelium by binding to E-Selectin ligand 1 (Steegmaier et 
al. 1995), which may help to maintain these functions after P-Selectin has been down-
regulated (Malik et al. 1996, Yang et al. 1999). 
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The next stage is the “firm adhesion” of neutrophils to the endothelium. This is achieved 
by the activation of additional neutrophil receptors called integrins, which mediate cell-cell 
and cell-extracellular matrix adhesions (Hynes 1992, Luscinskas et al. 1994, Crockett-Tobari 
et al. 1995, Williams et al. 1999). Integrins are a ubiquitous group of heterodimeric 
transmembrane glycoproteins found on all hematopoietic cells. They comprise an α- and β-
subunit, which form the extracellular ligand binding site and a cytoplasmic tail, which 
provides phosphorylation sites and linkages to cytoskeletal proteins involved in signal 
transduction (Alpin et al. 1998). There are a number of different α- and β-subunits that 
associate in different combinations to form at least 23 known integrins that are found in a 
variety of cells including leukocytes, lymphocytes and platelets. In neutrophils, the two most 
important integrins are Macrophage Antigen-1 (Mac-1; CD11b/CD18) and Lymphocyte-
Associated Function Antigen-1 (LFA-1; CD11a/CD18), which both have the same β-subunit 
(CD18). Of these, Mac-1 appears to be the dominant integrin involved in neutrophil 
migration (Diamond et al. 1990, Rainger et al. 1997). 
In neutrophils, Mac-1 is stored intracellularly in the secretory, specific and gelatinase 
granules (Sengelov 1996, Borregaad et al. 1997). Following exposure to degranulation 
stimuli (such as fMLP) or weaker stimuli (including TNFα and LPS that only act on 
secretory vesicles), it is quickly mobilised to the cell surface where it binds with high affinity 
to Intercellular Adhesion Molecule-1 (ICAM-1) on the endothelium. However, only a small 
percentage (approximately 10%) of Mac-1 incorporated into the cell membrane may be 
capable of ligand binding. This was suggested by in vitro work using a monoclonal antibody 
(CBRM1/5), which recognised only a fraction of Mac-1 on activated neutrophils, but still 
blocked Mac-1-dependent adhesion to fibrinogen and ICAM-1 (Diamond et al. 1993). Mac-
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1/ICAM-1 interactions in turn causes an increase in endothelial surface expression of both 
ICAM-1 and a similar molecule, Vascular Cell Adhesion Molecule-1 (VCAM-1), suggesting 
that both molecules may be integral to neutrophil migration (Clayton et al. 1998). In addition, 
inflammatory stimuli can promote transcription/translation of the Mac-1 genes, thereby 
extending integrin involvement during inflammation. 
 
Transmigration/Diapedesis 
Once firmly attached, neutrophils must then pass through the endothelial cell barrier 
before progressing through the surrounding tissue to the site of inflammation. Initial evidence 
suggests that transendothelial migration occurs paracellularly, where three or more adjacent 
endothelial form a “tricellular corner” (Burns et al. 1997, Su et al. 2002). At these junctions, 
there is a localisation of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1; CD31), 
which is thought to attract neutrophils (that also express PECAM-1) to these specific areas. 
Selective blocking of PECAM-1 with antibodies on neutrophils or endothelial cells prevents 
transmigration (Muller et al. 1995). Furthermore, Mac-1 deficient neutrophils are unable to 
crawl along the endothelium and subsequently develop pseudopods that probe the endothelial 
cell membrane (Phillipson et al. 2006, Phillipson et al. 2008). Under these experimental 
conditions, neutrophils are seen to migrate transcellularly through the body of endothelial 
cells, a process that may occur to a greater extent when the paracellular route is unavailable. 
The proportion of neutrophils that normally undergo transcellular migration remains unclear. 
Some studies suggest that the majority utilise this route (Feng et al. 1998, Williams et al. 
2010), but this is at variance with other research (Ionescu et al. 2003, Yang et al. 2005, 
Carman et al. 2007, Phillipson et al. 2008), particularly Woodfin et al. who have quantified 
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by real-time confocal imaging in vivo that 90% of neutrophils migrate via the paracellular 
route (Woodfin et al. 2011). 
Endothelial/neutrophil PECAM-1 interactions result in an increased expression of Very 
Late Activation Antigen-6 (VLA-6; CD49f) on the surface of neutrophils. This integrin binds 
to components of the extracellular matrix (such as collagen and laminin), which facilitates 
neutrophil migration beyond the vasculature and through the tissue. Migration through the 
matrix is further aided by the release of neutrophil proteinases, particularly NE (Wright et al. 
1979). However, it is currently unclear as to whether proteinase release is actually necessary 
for migration through the extracellular matrix. Some studies have shown that chemotaxis 
through artificial substrates in the presence of fMLP can be partially inhibited by inhibitors 
of NE and Matrix Metalloproteinase-9 (MMP-9) (Stockley et al. 1990, Declaux et al. 1996). 
In contrast, studies of neutrophil migration across endothelial monolayers and basement 
membrane matrices show that chemotaxis is unaffected by proteinase inhibitors (Allport et al. 
1997, Mackeral et al. 1999). However, the role of CG and NE in neutrophil migration is 
unclear as the evidence is conflicting. In one study, CG and NE knockout animal models 
exhibit normal neutrophil migration both in vitro and in vivo (Tkalcevic et al. 2000), whereas 
a more recent animal model demonstrated an attenuation of neutrophil influx into areas of 
inflammation following the administration of a similar peptidase inhibitor (Oliveira C et al. 
2010). 
The variability of these results may be reflective of the type of substrate used but also 
different migratory processes adopted by neutrophils. In non-cross linked collagen 3D 
matrix, neutrophils will preferentially migrate along the fibres but can squeeze through the 
gaps between fibres when proteinases are inhibited. In contrast, in a more densely 
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concentrated cross-linked collagen 3D matrix, neutrophils seem to require proteinases to 
migrate through as the gaps are not large enough to facilitate proteinase-independent 
migration. Therefore, it seems that neutrophils may prefer to use proteinases to ease their 
migratory passage through artificial or biological matrices but can still migrate effectively 
through them when gaps between fibres are sufficiently large. The processes involved in 
neutrophil adhesion and migration are summarised in Figure 1.4. 
 
 
Figure 1.4: A summary of the sequential processes involved in neutrophil adhesion and 
migration. 
 
Legend:  Peripheral blood neutrophils (1) begin their adhesion to the endolthelium by rolling 
along the suface in a “stick and release” manner (2) before they become firmly adhered (3). 
They then crawl along the endothelium until a suitable point for transmigration is found. This 
may either occur between endothelial cells (4. paracellular transmigration) or through an 
endothelial cell (5. transcellular migration). Following passage through the endothelium and 
basement membrane, neutrophils migrate through the extracellular matrix to the site of 
inflammation (6). 
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Chemotaxis 
Chemotaxis is fundamental to neutrophil inflammatory function. Without accurate 
chemotaxis, the ability of neutrophils to reach the site of inflammation and subsequently 
locate invading pathogens would be significantly impaired. 
Neutrophils migration is mediated by a large number of different chemical stimuli. Pro-
migratory stimuli can be classed as either non-chemotactic cytokines or chemoattractants. 
For instance, TNFα and Interleukin-1 (IL-1) may induce expression of adhesion molecules 
on neutrophils and endothelial cells, but they do not possess chemoattractive qualities. 
Neutrophils migrating towards a site of inflammation are continually exposed to a large 
number of chemoattractants from a variety of different sources (including endothelial, 
epithelial and inflammatory cells as well as pathogenic organisms), with each chemical 
eliciting a different response. At the start of migration, neutrophils follow a chemoattractive 
gradient toward an initial signal up to its peak. At this point, the concentration of 
chemoattractant is so high that the receptors become saturated and the signal is ineffective 
(Foxman et al. 1997). Neutrophils then start along a new gradient from a second signal and 
so on until they reach the target inflammatory site. The resulting effect is a “chemoattractant 
hierarchy”, where neutrophils initially follow relatively weak host chemoattractants, then 
proceed to followed more potent ones and, finally, terminal chemoattractants that originate 
from invading pathogens. 
Neutrophil movement is achieved by the formation of actin-rich protrusions called 
“pseudopods” (Devreotes et al. 1988). Following stimulation by chemoattractants, the cell 
polarises into a leading edge, which is made up of numerous small cytoskeletal projections, 
rich in filamentous Actin (F-Actin), called “lamellipodia” and a trailing edge or “uropod”. To 
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facilitate effective migration, there is a reorganisation of cell surface receptors, where the 
chemoattractant and integrin receptors are localised to the pseudopods (Gomez-Mouton et al. 
2001) and the adhesion molecules to the uropod (Fais et al. 2003). Pseudopods are 
continually and randomly generated at the leading edge of the cell. For a neutrophil to direct 
itself down a concentration gradient, the pseudopods projecting in the direction of the 
gradient are sustained, thereby allowing the cell to alter its trajectory and follow the correct 
course. (Andrew et al. 2007). 
 
1.2.3   Signalling to Migration 
Once chemoattractants bind to their specific receptors on the neutrophil cell surface, they 
initiate a signal pathway that results in cytoskeletal rearrangement and motility. The 
signalling pathways involved are similar for all chemoattractant receptors. The first step in 
the cascade is the activation of heterotrimeric Gi proteins, which comprise an α-,β- and γ-
subunit. Activation leads to the hydrolysis of Guanosine-5’-Triphosphate (GTP) to 
Guanosine Diphosphate (GDP) on the α-subunit, resulting in its dissociation from the βγ-
subunit (Hofmann et al. 2009). Following this, the βγ-subunit activates a number of cellular 
mediators including Phospholipase-C (PLC) and calcium ions (Boyer et al. 1992), 
Phosphatidylinositol 3-Kinase-γ (PI3Kγ) (Stephens et al. 1994), G Protein-Coupled Receptor 
(GPCR) Kinases, P21-Activated Kinase-1 (PAK-1) (Li et al. 1993). 
Protein phosphorylation is a widely used post-translational biological signalling 
mechanism. Families of protein phosphatases also catalyse opposite reactions, making 
phosphorylation–dephosphorylation a reversible process. Protein kinases play a key role in 
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the regulation of almost every aspect of cell biology. The human protein kinase family is one 
of the largest gene families, consisting of 518 genes (Manning et al. 2002). 
 
PI3K/Akt Pathway 
Receptor-ligand binding activates a number of cellular mediators including 
phosphatidylinositol-3 kinase (PI3K). PI3Ks are a family of enzymes that catalyse the 
phosphorylation of one or more inositol lipids in the 3 position of the inositol ring early in the 
signalling cascade (Rickert et al. 2000). They are intimately involved in a number of cellular 
functions such as growth, proliferation, differentiation, and survival, and are key regulators 
of neutrophil migration (Stephens et al. 2002, Hannigan et al. 2002). There are eight 
mammalian PI3K isoforms that are classified into three families defined by their structure, 
substrate specificity and function. These include four Class I isoforms (PI3Kα, β, γ and δ), 
three Class II isoforms (PI3KCα, β, γ) and one Class III (Vanhaesebroeck 2010, Okkenhaug 
2013). Each Class I isoform catalyses the same reaction but are distinct in their upstream 
activation by receptor transduction pathways (Vanhaesebroeck 2010, Fritsch et al 2013). 
PI3K catalyses the phosphorylation of phosphatidylinositol 4,5 bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5 trisphosphate (PIP3) at the plasma membrane. 
Class I PI3Ks are soluble enzymes that are activated by a number of factors, resulting in 
their recruitment to the membrane and conformational changes that increase their catalytic 
efficiency. The α and β isoforms are broadly expressed in a variety of tissues and have a 
fundamental role in cellular function (such as proliferation), whereas the δ and γ isoforms 
have a more restricted cellular distribution and have a more focussed mediatory role in an 
inflammatory response.  All class I isoforms are heterodimers that comprise both a catalytic 
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subunit and one of four different regulatory subunits. Depending on the coupling of these 
subunits, Class I PI3Ks are further classified into Class 1a and Class 1b. Class Ia isoforms 
(PI3Kα, β, and δ) comprise a p110 catalytic subunit and a p85 regulatory subunit (Carpenter 
et al. 1990). There are five variants of the p85 regulatory subunit variants (p85α, p55α, p50α, 
p85β, and p55γ) and three variants of the p110 catalytic subunit (p110α, β, or δ), resulting in 
fifteen potential heterodimers. The first three p85 regulatory subunits (p85α, p55α, p50α) are 
all splice variants of the same gene (PIK3R1), whereas p85β and p55γ are encoded by the 
PIK3R2 and PIK3R3 genes, respectively. The p85 regulatory subunits contains several 
domains, including two Src Homology (SH)2 domains and a SH3 domain (Krasilnikov et al. 
2000). Together, these regulate the binding of Class Ia PI3Ks to tyrosine-phosphorylated 
receptor tyrosine kinases. This interaction has two consequences that must both occur in 
order for PI3K to become fully activated (Songyang et al. 1993, Yoakim et al. 1994). Firstly, 
PI3K translocates from the cytosol to the inner leaflet of the plasma membrane, which allows 
the p110 catalytic subunit access to PIP2 (Gillham et al. 1999).  Secondly, conformational 
changes of the p85 regulatory subunit occur that negate its inhibitory effect of catalytic 
activity of p110 (Yu et al. 1998). 
At present, only one Class Ib isoform (PI3Kγ) has been identified. PI3Kγ comprises a 
p110γ catalytic subunit (Stoyanov et al. 1995) and either a p84 (Suire et al. 2005, Voight et 
al. 2005, Voight et al. 2006) or p101 regulatory subunit (Stephens et al. 1997). PI3Kγ is 
activated by chemokines through GPCRs and direct interaction with the G-βγ subunit 
(Ferguson et al. 2007, Stephens et al. 2008). Therefore, the primary chemokine-mediated 
responses occur through PI3Kγ, although PI3Kδ may also play a later role by sustaining this 
response in a “biphasic” manner (Condliffe et al. 2005).  Interaction between regulatory p101 
22 
 
and catalytic p110 subunits is very tight, although the precise activation mechanism remains 
unclear. The p101 regulatory subunit binds readily to G-βγ and it has been proposed that this 
acts as an essential anchor linking G-βγ with the catalytic p110 subunit (Stephens et al. 
1997). In contrast, a different study demonstrated that p101 is not required for G-βγ 
activation of PI3Kγ (Stoyanov et al. 1995). Later studies support this hypothesis by showing 
that binding of the G-βγ subunit to the different subunits of PI3Kγ actually induces different 
mechanisms of its activation. They demonstrated that direct stimulation of the catalytic 
subunit p110 was sufficient to induce PIP3 formation but that binding to the p101 regulatory 
subunit mediates PI3Kγ recruitment to the membrane (Brock et al. 2003) and substrate 
selectivity (Maier et al. 1999). Far less is understood about p84/p110 interactions, which are 
less well described, although studies have shown that, despite strong association, the 
p84/p110γ complex is less sensitive to G-Protein βγ activation than p101/p110γ (Suire et al. 
2005, Kurig et al. 2009). p110γ also contains a Ras-Binding Domain (RBD), which binds 
selectively to Ras-GTP. Ras-GTP synergises the co-localise PI3K and PIP2 before its 
phosphorylation occurs (Suire et al. 2006) and in vitro studies have shown that it can activate 
p110γ directly as well as the p84/p110γ and p101/p110γ complexes (Pacold et al. 2000). A 
more recent study suggests that Ras-GTP exclusively activates p84/p110γ, whereas 
p101/p110γ activation only occurs via the G-Protein βγ-subunit binding (Kurig et al. 2009). 
Although this evidence is conflicting (at least partially), collectively it suggests that 
p84/p110γ activation may be controlled by ligands capable of activating Ras (such as 
tyrosine kinases) rather than GPCRs.  
Formation of PIP3 results in the recruitment of Akt to the cell membrane during 
neutrophil polarisation (Burelout et al. 2007). Akt comprises an amino-terminal pleckstrin 
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homology (PH) domain, a serine-threonine kinase domain and a COOH-terminal regulatory 
tail. Phosphorylation of Akt at both S473 by the pyruvate dehydrogenase kinase 2 (PDK2) 
class of kinases (including mammalian Target of Rapamycin Complex 2 (mTORC2)) and, 
subsequently, T308 by phosphoinositide dependent kinase 1 (PDK1) is necessary for full 
kinase activity (Scheid et al. 2003, Hanada et al. 2004, Ananthanarayanan et al. 2005). 
Furthermore, Akt stabilises the organisation of the actin cytoskeleton during cell migration, 
where its activity is regulated by PI3K as well as mTORC2 (Lee et al. 2005). 
PIP3 and Akt localisation at the leading edge results in the formation of F actin-rich 
pseudopodia (Yoo et al. 2010). These may either induce forward movement (in migration) or 
pathogenic engulfment (in phagocytosis).  A number of studies have implicated Akt as a key 
regulator of neutrophil chemotaxis (Hannigan et al. 2002, Heit et al. 2002, Sasaki et al 2006, 
Lane et al. 2006, Kolsch et al. 2008). The phosphorylation of Akt is also considered to be a 
strong indicator of the activation of PI3K and its pathway (Weiner 2002, Inoue et al. 2008). 
 
Rho GTPases 
PI3K signalling is also mediated by small (~21kDa) G-proteins belonging to the Rho 
family of GTPases that act as molecular “switches” for many other biological processes, 
including survival and organelle development (Boureux et al. 2007, Bustelo et al. 2007). 
They are regulated by GTPase-activating proteins (GAPs), guanine nucleotide exchange 
factors (GEFs) and guanine nucleotide dissociation inhibitors (GDIs). GAPs mediate the 
hydrolysis of GTP to GDP by GTPase, thereby regulating the rate of transition from the 
active to inactive status. GEFs activate Rho proteins by catalysing the exchange of GDP for 
GTP. GDIs combine with Rho-GTPases to form a large complex and prevent their diffusion 
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into the cytosol, thereby allowing for tightly regulated spatial control of rho activation 
(Ellenbroek et al 2007).  Spatially regulating Rho GTPases in this manner at the leading edge 
of the cell is important in polarity but may also act as a directional compass during 
chemotaxis (Rickert et al. 2000). 
In mammals, the Rho family contains 22 members (Ridley et al. 2006) and a number of 
these are essential for neutrophil migration. These include Rac1 and Rac2, which mediate 
actin polymerisation at the leading edge of the cell (Srinivasan et al. 2003), Cdc42, which 
limits PTEN activity to the rear of the cell and is involved in the formation of the PIP3 
gradient and cell polarity (Srinivasan et al. 2003), Rho and Rho Kinase (ROCK), which drive 
cell propulsion by orchestrating myosin light chains and Myosin II contraction at the rear of 
the cell (Wu et al. 2005, Charest et al. 2007).  
 
Neutrophil Polarity 
There is substantial evidence suggesting that PI3K signalling has a pivotal role in 
neutrophil polarisation. Servent et al. showed that Akt is selectively mobilised to the leading 
edge of neutrophils following exposure to a chemoattractive stimulant (Servent et al. 2000). 
In a follow-up study, Weiner at al. investigated the spatial distribution of PIP3 using 
neutrophil-like differentiated HL-60 cells. They demonstrated that, using a cationic lipid 
shuttling mechanism, exogenous delivery of PIP3 elicits accumulation of endogenous PIP3 at 
the cell’s leading edge. They describe the paradox that PIP3 and Rho GTPases (Rac and 
Cdc42) function both upstream and downstream of one another appears to be a positive 
feedback loop mechanism that results in a self-organised intracellular PIP3 gradient that leads 
to cell polarity (Weiner et al. 2002). 
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In a similar study using exogenous introduction of PIP3 to the inner leaflet of the 
neutrophil plasma membrane, Tian et al. showed a number of separate effects related to 
neutrophil polarity (Tian et al. 2003). Firstly, exogenous PIP3 was incorporated into the 
membrane in distinct regions and this increased the random formation of small pseudopodia 
and, later, the formation of the single, large pseudopod that is associated with cell 
polarisation. During this process, PIP3 was subsequently excluded from the site of pseudopod 
extension to the uropod, where it was inactivated, only to return the original site following 
pseudopod relaxation. Interestingly, they found that pseudopodia did not form in the PIP3-
containing regions when neutrophils were stimulated by fMLP. They suggest this may be 
because the exogenous PIP3 induced the formation of an artificial ‘uropod-like’ structure. 
Lastly, the introduction of exogenous PIP3 resulted in repetitive global calcium (Ca
2+
) 
signalling event, the onset of which precedes morphological polarisation. Importantly, the 
Ca
2+
 signalling was inhibited by a PI3K inhibitor (LY294002), suggesting that it was 
mediated (at least in part) by increased PI3K. 
PI3K activity is regulated by both SH2 domain-containing inositol phosphatase 1 
(SHIP1) and phosphatase and tensin homologue (PTEN), which both hydrolyse PIP3 (to 
phosphatidylinositol 3,4 bisphosphate (PI(3,4)P2) and phosphatidylinositol 4,5 bisphosphate 
(PI(4,5)P2), respectively) and prevent pseudopod extension (Sly et al. 2003, Heit et al. 2008). 
Evidence suggests that SHIP1 is essential for chemoattractant-mediated neutrophil migration. 
It is believed that PTEN and SHIP1 are both important  in establishing a PIP3 gradient, with 
PTEN co-ordinating a front-to-back gradient and SHIP1 co-ordinating a top-to-bottom 
gradient, together ensuring PIP3 is exclusively expressed at the leading edge (Mondal et al. 
2012). It has also been suggested that SHIP1 is the predominant phospholipid phosphatase in 
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this process as disruption of SHIP1 (not PTEN) results in uniform F-actin polymerisation 
across the cell membrane rather than localisation to the leading edge. As a result, these 
neutrophils become flattened, do not correctly polarise and migrate at a dramatically slower 
rate (Nishio et al. 2007, Mondal et al. 2012). 
A recent in vivo study using zebrafish embryos has also provided novel insight into how 
neutrophil polarity is regulated by PI3K (Yoo et al. 2010). The authors firstly demonstrated 
that neutrophil recruitment to a laser-induced wound was inhibited by both LY294002 and a 
PI3Kγ-specific inhibitor.  Secondly, high-resolution ratiometric imaging revealed that both 
PIP3 and PI(3,4)P2 (following hydrolysis by SHIP1) were located at the leading edge 
pseudopods during neutrophil migration. Lastly, activation of Rac at specific areas rapidly 
induced pseudopod extension and directional migration, supporting the hypothesis that there 
is a positive feedback loop between Rac and PIP3 at the leading edge. Interestingly, activation 
of Rac at the leading edge of PI3K-inhibited neutrophils was sufficient to induce pseudopod 
extension but not migration or uropod contraction (due to an inability to rescue normal 
polarity of F-actin dynamics). 
Bound integrins traffic to the rear of the cell, where they detach for recycling (Pierini et 
al. 2000). Integrins also facilitate cell polarity, activating the Rho family of GTPases 
(Huttunlocher et al. 2005, Caswell et al. 2009). Phagocytosis is also PI3K and β2 integrin-
dependent (Schnitzler et al. 1999, Dewitt et al. 2003), leading to PI3K-driven PIP3 
accumulation at the leading edge of the cell where engulfment occurs (Botelho et al. 2000, 
Hannigan et al. 2003, Kennedy et al. 2008). 
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The orientation of the predominant signalling mediators and the movement machinery 
within a polarised neutrophil are represented graphically in Figure 1.5. 
 
 
 
 
Figure 1.5:  A polarised neutrophil showing the localisation of signalling mediators and 
movement machinery. 
 
 
The signalling molecules associated with F-actin polymerisation, including Akt, PIP3, Rac and Cdc42 
are located at the leading edge to facilitate pseudopod extension. In contrast, myosin II and Rho 
localise at the rear of the cell to detach the uropod and enable continual migration. PTEN and SHIP1 
orientate towards the back and at the bottom of the cell, respectively to limit PIP3 to the leading edge. 
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Mitogen-Activated Protein Kinases 
Until relatively recently, it was believed that chemotaxis was exclusively regulated by 
PI3K. However, a plethora of other signalling molecules have subsequently been implicated 
in regulating neutrophil chemotaxis, thereby creating a complex web of inter-related 
signalling pathways. The Mitogen-Activated Protein Kinases (MAPKs) are family of 
serine/threonine protein kinases involved regulating a variety of cellular activities ranging 
from gene expression to mitosis, proliferation, apoptosis, phagocytosis and chemotaxis (Heit 
et al. 2007). They include c-Jun N-terminal kinases (JNK) which phosphorylates paxillin 
(inhibiting Rac at the cell sides and back), Extracellular Signal-Related Kinase (Erk) which 
phosphorylates myosin light chain kinase and p38 which phosphorylates MAPK-activated 
protein kinase 2/3 that is involved in directionality (Huang et al. 2004).  It has also been 
suggested that p38 and Erk act as the migratory “stop” and “go” signal, respectively (Li et al. 
2012).  
The PI3K pathway is together with the involvement of these other associated signalling 
pathways is summarised diagrammatically in Figure 1.6. 
 
  
 
Figure 1.6:  A simplified diagram of the PI3K signalling pathway.   
Legend:  G-Protein coupled receptor (GPCR) binding with ligand up-regulates PI3K phosphorylation of PIP2 to PIP3.  PIP3 accummulation at the leading 
edge of the cell  leads to F-actin localisation and pseudopod protrusion, which is coordinated by Rac and Cdc42.  PI3K and PTEN activate Rho at the rear 
of the cell, which inhibits F-actin polymerisation while inducing Myosin localisation.  PI3K up-regulates integrin expression and recycling at the rear of 
the cell  and increases GPCR recycling to the leading edge. The Mitogen-Activated Protein Kinases (MAPKinases) JNK, Erk and p38 are also directly 
involved in cell migration by regulating the phosphorylation of downstream mediators. 
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Calcium Signalling 
Calcium (Ca
2+
) is a simple and incredibly diverse second messenger and is one of the 
most extensively studied signalling molecules in biology. Ca
2+
 signalling has been implicated 
in a wide variety of important physiological roles (Allbritton et al. 1992). Most notably, these 
include muscle contraction, neuronal transmission, fertilisation, cell growth and proliferation 
and cell motility. The level of intracellular (cytoplasmic) calcium has been specifically linked 
to neutrophil polarisation and migration and is believed to play a key role in chemotaxis 
(Meshulam et al. 1986, Marks et al. 1990). Neutrophil polarisation is an essential precursor to 
accurate cell migration, which contributes to an adequate innate immune response 
(O’Donnell et al. 1992, Onsum et al. 2007). Other recent studies (Evans et al. 2007, Wei et 
al. 2011) further support this model, where local calcium signals were shown to occur at the 
leading edge of polarised and migrating cells. Collectively, these studies suggest that calcium 
is a critical component of cell polarisation and/or directed migration. 
The resting concentration of cytoplasmic Ca
2+
 is generally maintained at low levels 
between 10–100 nM. To maintain this, Ca2+ is actively pumped from the cytosol to the 
extracellular space and into the endoplasmic reticulum (ER), and sometimes in the 
mitochondria (Clapham 2007). Specific signals can induce rapid and dramatic increases in 
the cytoplasmic Ca
2+
 level (up to 1000 nM) by opening channels in the ER or the plasma 
membrane. Indeed, calcium spikes at the plasma membrane have been shown to synchronise 
neutrophil arrest and migration during rolling and adhesion by integrating chemotactic and 
adhesive signals (Schaff et al. 2008). In addition, Ca
2+
 accumulation in the uropod has been 
demonstrated, which may be important for cell polarisation (Clark et al. 2008) and Ca
2+
-
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dependent myosin II activation may be required for uropod retraction during neutrophil 
migration (Eddy et al. 2000). 
The most common signalling pathway by which this occurs is the PLC pathway. 
Numerous surface receptors, including G protein-coupled receptors activate PLC, which in 
turn hydrolyses PIP2 to form the downstream messengers, inositol 1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG). IP3 then diffuses to the ER, where it binds to its receptor and 
induces the release of Ca
2+
. DAG activates protein kinase C (PKC), which is important in 
several other signal transduction cascades as well as PI3K. The GPCR/Ca
2+
 signalling 
cascade is illustrated simply in Figure 1.7. 
Many of calcium-mediated physiological functions occur when released Ca
2+
 binds to 
and activates the regulatory protein calmodulin (calcium-modulated protein). In migration, 
this includes the regulation of calcium/calmodulin-dependent myosin light chain kinase and 
suppression of β1 and β3 integrin release at the rear of the cell (Niggli 2003). A number of the 
proteins that calmodulin binds to are unable to bind calcium themselves, and use calmodulin 
as a calcium sensor and signal transducer (Chin et al. 2000). 
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Figure 1.7:  A simplified diagram of the Ca
2+
 signalling pathway.   
Legend.  G-Protein coupled receptor (GPCR) binding with ligand activates PLC. 
This catalyses the hydrolysis of PIP2 to IP3 and DAG. IP3 diffuses to the ER, 
where it binds to its receptor and induces Ca
2+
 release, while DAG activates PKC 
(a messenger of other signalling cascades). 
 
 
The importance of Ca
2+
 in cell migration has been highlighted in a number of previous 
studies. Calpain is an intermediate signalling molecule downstream of chemoattractant-
induced membrane lipid reorganisation and has previously been implicated as an important 
Ca
2+
-dependent regulator of actin and the cytoskeletal rearrangement associated with cell 
migration (Huttenlocher et al. 1997, Kulkarni et al. 1999, Dourdin et al 2001). A later study 
showed that the intracellular Ca
2+
-dependent protease calpain is active in quiescent 
neutrophils and its inhibition enhances random cell movement (Lokuta et al. 2003). In a 
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follow-up study, the same group demonstrated that calpain 2 (but not calpain 1) was 
associated with the “frontness” signal during neutrophil polarisation (Nuzzi et al. 2007). A 
more recent study using differentiated HL-60 neutrophil-like cells showed that filling of Ca
2+
 
stores in the endoplasmic reticulum (termed store-operated Ca
2+
 entry (SOCE) activates Akt, 
Rac and Cdc42 and this could be the primary Ca
2+
 mechanism involved in cell polarisation 
(Zou et al. 2012). 
  
1.2.4   Chemoattractants 
Gradient sensing is achieved by receptor occupancy, distribution, and desensitisation 
(Wu et al. 2007). Neutrophils have at least five different types of receptor for chemoattractive 
stimuli, which include unique receptors for Complement Protein 5a (C5a), Leukotriene B4 
(LTB4), Platelet Activating Factor (PAF), and fMLP. A number of other receptors also exist 
that share similarities in structure and bind to a group of chemoattractants called 
“chemokines”. Chemokines contain similar cysteinyl-containing structures at the NH2 
terminus that form disulphide bridges. They are classified into CC chemokines (where the 
cysteines are adjacent) and CXC chemokines (where the cysteines are separated by an amino 
acid). CXC chemokines include, amongst others, IL-8 and Growth-Related Oncogene Alpha 
(GROα). 
 
Interleukin-8 
IL-8 (CXCL8) is the most extensively studied and one of the most important chemokines 
in neutrophil migration. It is a small 8 kDa protein primarily produced by leukocytes 
(monocytes, NK cells, neutrophils and T-Cells), though it is also produced by epithelial and 
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endothelial cells. Its production is induced by a variety of factors including pro-inflammatory 
cytokines such as IL-1β and TNFα (Matsushima et al. 1988), bacteria and their products such 
as fMLP (Dimango et al. 1995, Khair et al. 1996), certain viruses and oxidants in tobacco 
smoke (Deforge et al. 1993). On neutrophils, IL-8 binds with high affinity to both neutrophil 
chemokine receptors, CXCR1 and CXCR2. Once bound, it may induce a number of effects, 
although the dominant function appears to be the recruitment of neutrophils to sites of 
inflammation (Roberts et al. 1993). In support of this hypothesis, it has been demonstrated 
that IL-8 increases adhesion through up-regulation of integrin expression (Von Andrian et al. 
1992). Furthermore, IL-8 induces migration via induction of the PI3K pathway (Knall et al. 
1997), which also contributes to cell directionality during chemotaxis (Stephens et al. 2002, 
Hannigan et al. 2002, Wang et al. 2002, Wu 2005, Sapey et al. 2011). 
 
Growth-Related Oncogene Alpha 
GROα (CXCL1), together with a number of other chemokines, acts primarily through 
CXCR2 as they have only a low affinity for CXCR1 (Wagner et al. 2000, Tsai et al. 2002). It 
is secreted by human melanoma cells, has mitogenic properties and has been implicated in 
melanoma pathogenesis (Richmond et al. 1988, Anisowicz et al. 1987). It is expressed by 
macrophages, neutrophils and epithelial cells (Iida et al. 1990, Becker et al. 1994) and has 
neutrophil chemoattractant properties (Moser et al. 1990, Schumacher et al. 1992). 
 
Leukotriene B4 
Leukotrienes are generated via the activities of lipoxygenases on arachadonic acid. LTB4 
is a powerful chemoattractant for neutrophils that is primarily produced by monocytes, 
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macrophages and activated neutrophils (Werz 2002). In addition, it can also induce 
neutrophil adherence to the endothelium, aggregation and, at higher concentrations, 
degranulation. The LTB4 receptor (LTB4R1) may exist in a high affinity state (where binding 
leads to chemotaxis and adhesion through Mac-1 (Tonnesen et al. 1989) and a low affinity 
state (where binding leads to secretion and oxidase activity). 
 
Complement Fragment C5a 
The binding of an antibody to its antigen often triggers this complement system, which 
helps or “complements” the ability of antibodies and phagocytes to clear pathogens. When 
stimulated by one of several triggers, proteinases in the system cleave specific proteins to 
release cytokines and initiate an amplifying cascade of further cleavages. C5-derived 
products are chemoattractants for various leukocytes including basophils, eosinophils, 
monocytes and neutrophils. C5a is the most potent chemoattractant of these products and can 
bind to neutrophils in the circulation (Kohl et al. 1983). In addition, epithelial cells and tissue 
macrophages produce C5a via the alternative complement system (Strunk et al. 1988). 
 
Formyl-Methionyl-Leucyl-Phenylalanine 
Peptides of bacterial origin, such as fMLP, are potent activators of neutrophils and fMLP 
is commonly used for this role in in vitro studies. The fMLP receptor (Formyl Peptide 
Receptor 1; FPR1) is expressed on the surface of quiescent neutrophils, although activation 
induces a dramatic and rapid increase in expression via the mobilisation of internal secretory 
vesicles (Borregard et al. 1997). It binds rapidly to the fMLP receptor, causing polarisation 
even in the absence of a concentration gradient. Depending on the concentration of fMLP, a 
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variety of effects on neutrophils may be activated. These include aggregation, Reactive 
Oxygen Species (ROS) production, degranulation, cytoskeletal changes and chemotaxis 
(Wagner et al. 2000). 
 
1.2.5   Receptor Recycling 
Following ligand binding, GPCRs become reversibly desensitised and are internalised 
for recycling or degradation or are shed. Internalisation, therefore, results in a reduction in 
surface receptor expression (Painter et al. 1995,  Fan et al. 2003). This process occurs via 
GPCR Kinases (GRKs), which phosphorylate the respective receptors (Prossnitz et al. 1995) 
and allow accessory proteins (such as arrestins) to bind, inducing cleavage of the receptor 
from its G protein. If internalisation of one receptor is high enough, migration may be 
attenuated, at which point the neutrophil may follow a new gradient formed by a more potent 
chemoattractant. The importance of receptor recycling in the maintenance of chemotaxis has 
been demonstrated, whereby interruption of recycling results in reduced cell migration 
(Samanta et al. 1990). 
FPR1 is endocytosed into receptosomes while still bound to fMLP. Receptosomes 
contain surface membrane neutral endopeptidase (NEP) that degrades fMLP, thereby 
preventing it from rebinding to unoccupied receptors. The receptors are then recycled to the 
cell surface (Painter et al. 1995). CXCR1 and CXCR2 are recycled by the same processes, 
though evidence suggests that CXCR1 and CXCR2 may recycle through different 
endosomes; CXCR1 is re-expressed far more quickly than CXCR2 following stimulation 
with and subsequent removal of IL-8. Only partial re-expression of CXCR2 was observed 60 
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minutes after IL-8 removal (Chuntharapai et al. 1995). The mechanisms of receptor 
internalisation and re-expression are illustrated in Figure 1.8. 
 
 
 
 
Figure 1.8: The mechanisms of receptor internalisation and recycling. 
Legend: Once ligands bind to their respective GPCRs, they are internalised in clathrin-
coated pits that subsequently form vesicles. Once internalised, the ligand is degraded and the 
receptor can be recycled back to the cell surface in endosomes. This process is actin-
dependant. 
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1.2.6   Neutrophil Defence Mechanisms 
Clearance of inhaled bacteria is essential in maintaining a sterile environment within the 
lungs. In addition to mechanical clearance via the mucocilliary escalator, inflammatory cells 
also assist in the clearance and killing of invading pathogens. Neutrophils have a number of 
defence mechanisms which are outlined below. 
 
Phagocytosis 
Phagocytosis is an important defence mechanism. The dominant phagocytes in the lungs 
are macrophages (Martin et al. 2005), though during certain periods (such as infection) when 
the bacterial load becomes overwhelming, neutrophils are recruited to assist with this 
clearance process (Zhang et al. 2000). 
Before an invading particle can be engulfed by a phagocyte it must be recognised as 
foreign. Most commonly, this occurs through opsonisation, where invading particles are 
coated with soluble proteins in the serum such as complement fragments or 
immunoglobulins. These are then recognised by their specific complement or 
immunoglobulin receptors on the phagocyte cell surface, such as Mac-1 and CD16 
respectively. Activation of these receptors induces cytoskeletal rearrangement, formation of a 
phagosome and particle engulfment. This process varies slightly depending on which 
receptors are activated. Complement-mediated phagocytosis results in a pit formation on the 
cell surface into which the foreign particle sinks (Allen et al. 1996, Aderem et al. 1999) 
whereas, during immunoglobulin-mediated phagocytosis, pseudopods form and reach out to 
capture opsonised particles (Allen et al. 1996). Both processes lead to the formation of a 
phagosome, which fuses with lysosomes and results in bacterial killing via bombardment 
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from an array of cytotoxic molecules, including proteinases and ROS. However, within the 
airways of healthy lungs, serum is not present in great quantities and phagocytosis 
predominantly occurs through non-opsonic mechanisms. The precise mechanisms by which 
this occurs have yet to be elucidated, though Mac-1 may still be involved (Heale et al. 2001). 
Studies have shown that PI3Ks are required at certain stages of phagocytosis. It has been 
demonstrated that PIP3 occurs transiently on regions of the phagosomal cup close to the 
ingested particle (Marshall et al. 2001, Vieira et al. 2001). This PI3K activity is related to 
both the extension of pseudopodia around target particles and the formation of phagosome by 
their closure (Araki et al. 1996, Marshall et al. 2001). In support of this, myosin X (a 
downstream PIP3-binding protein) is required for optimal pseudopodal extension (Cox et al. 
2002). Moreover, the addition of new membranes to an extending pseudopod is governed by 
PI3K-dependant control of ADP Ribosylation Factors (ARF) GTPases where, in the 
formation of a phagosome, PI3K activates ARF1 and inhibits ARF6 (Beemiller et al. 2006). 
The precise mechanisms of PI3K involvement have not been determined and PI3K is not 
required for all phagocytosis (Anderson et al. 2008). However, it does seem that PI3K 
signalling is necessary for optimal phagocytosis to occur in most instances. 
 
Anti-Microbial Peptides (Proteinases) 
There are over 500 different proteinases in humans, most of which are serine, cysteine 
and metalloproteinases (Lόpez-Otín et al. 2006). They act by degrading large proteins into 
smaller protein fragments and amino acids. Neutrophils store three major serine proteinases 
(NE, PR3 and CG), predominantly within the azurophile granules, which they use for 
(amongst other things) bacterial killing. Both NE and CG are stored within the granules, PR3 
40 
 
is also constitutively expressed on the cell surface (Csernok et al. 1990, Halbwachs-Mecarelli 
et al. 1995). Upon neutrophil activation, these granular proteinases are mobilised to both 
intracellular phagosomes (where they assist in the digestion microorganisms) and to the 
plasma membrane (where they are secreted extracellularly to kill free-roaming or trapped 
pathogens) (Owen et al. 1999; Owen 2008). Although proteinases play a significant role in 
innate immune defence, they are also destructive. Extracellular proteinase activity is tightly 
regulated by anti-proteinases (see Section 1.3), though chronic dysfunction of this system can 
result in disease (discussed in greater detail in Sections 1.5.4 and 1.6). 
 
Oxidative Burst 
In addition to microbicidal peptides and proteinases, neutrophils also generate ROS upon 
activation in a process called oxidative or respiratory burst. Activation leads to the 
production of superoxide anions (O2
●-
), which dismutate either spontaneously or via the 
catalyst superoxide dismutase (SOD). This process generates other ROS including hydrogen 
peroxide (H2O2), which is subsequently converted into hypochlorous acid (HOCl) by MPO 
and hydroxyl radicals (OH
●
). All of these contribute to bacterial killing (Hampton et al. 1998, 
Baboir 2000, Klebanoff 2005), although HOCl in particular has a strong effect as it oxidises a 
wide variety of bacterial components (Weiss 1999). 
The initial production of superoxide is catalysed by the multicomponent nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase (Chanock et al. 1994, Baboir 1999, Quinn 
et al. 2004, El-Benna et al. 2005, Groemping et al. 2005), which oxidises NADPH and 
transfers two electrons onto an O2 molecule. NADPH oxidase comprises 6 subunits; a Rho 
GTPase (Rac2 in human neutrophils) and five “phox” units including p91phox (also known as 
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NOX2), p22
phox
, p40
phox
, p47
phox
 and p67
phox
. After activation, the cytosolic heterotrimeric 
p47
 phox
-p67
 phox
-p40
phox
 complex is phosphorylated by protein kinases such as p38 MAPK 
and PI3K (Yamamori et al. 2000). Following this, it translocates to the plasma membrane, 
where it interacts with the membrane and other oxidases (Nauseef 1999). Activation also 
leads to the translocation of phox components (together with Rac2) to specific granules, 
where they can produce superoxide for short periods (Ambruso et al. 2004). Within these 
granules, NADPH oxidase activity is regulated by PKCδ and PI3K (Sergeant et al. 1997, 
Brown et al. 2003). The microbicidal effects of ROS once granules have fused with 
phagosomes contribute to bacterial killing following phagocytosis. 
In addition to their microbicidal function, ROS at non-toxic levels are also implicated in 
the regulation of signalling pathways involved in various cellular functions including 
differentiation, proliferation, homeostasis and immune function (Touyz 2005). Furthermore, 
alteration of the redox state by ROS can influence many stages of a number of intracellular 
signalling pathways such as receptor function, enzyme activity, transcription factors and gene 
expression (Suzuki et al. 2005, Tonks 2005, Fialkow et al. 2007). 
 
Neutrophil Extracellular Traps 
Neutrophil Extracellular Traps (NETs) are complex, extracellular structures comprising 
a chromatin “backbone” together with anti-microbial peptides originating from intracellular 
neutrophil granules (Brinkman et al. 2004). They are made up of a series of threads that have 
globuli at intervals along their length. Single threads are often wound together to form thicker 
cables that, in turn, form large web-like structures that are capable of trapping microbes. NET 
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formation (NETosis) occurs in response to various stimuli that collectively stimulate external 
neutrophil receptors including TLRs, cytokine receptors and Fragment Crystallizable (Fc) 
receptors (Brinkman et al. 2004, Clark et al. 2007). Receptor stimulation then activates PKC 
which, in turn, leads to the activation of the NADPH oxidase complex. ROS, such as H2O2, 
have been implemented in NET formation, and can induce NET release in vitro at 
physiological concentrations (Fuchs et al. 2007). However, the processes that connect ROS 
production and the changes in morphology preceding cell rupture and NET release are not 
understood. Not only can NETosis immobilise pathogens, thereby preventing further spread 
and facilitating phagocytosis, but it is thought to kill pathogens directly though the action of 
antimicrobial histones and peptides (Papayannopoulos et al. 2009). Despite the 
immunological advantages of NETs, their accumulation due to chronic, increased activity 
and/or ineffective clearance could have pathological effects. For example, the accumulation 
of neutrophil DNA in the mucus of cystic fibrosis patients was traditionally though to 
originate exclusively from necrotic cells (Lethem et al. 1990). More recently, however, 
studies have suggested that the source of this DNA is actually from NETs (Marcus et al. 
2010, Marcus et al. 2011, Manzenreiter et al. 2012). 
The various processes by which neutrophils can eliminate pathogens are illustrated in 
Figure 1.9. 
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Figure 1.9: Neutrophil defence mechanisms. 
Legend: Neutrophils can eliminate pathogens through various mechanisms, both intra- and 
extracellularly. When a pathogen is encountered, they phagocytose them and kill them by 
release of toxic agents (such as ROS & microbicidal peptides) from granules into the 
phagosome. These ROS and antibacterial peptides may also be releases into the 
extracellular milieu (degranulation), although this is often harmful to the host. NETs can 
immobilise pathogens preventing their proliferation and aiding subsequent phagocytosis as 
well as killing pathogens directly. However, NETosis also results in the death of the 
neutrophil. 
 
 
1.3   ANTI-PROTEINASES 
Anti-proteinases are important inhibitors of enzymatic damage mechanisms that 
minimise (by neutralisation) the proteinase destruction to tissues as neutrophils migrate 
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through the extracellular matrix. The three major serine anti-proteinases in the lungs are 
discussed below in order of prominence. 
 
α1-Antitrypsin 
α1-Antitrypsin (α1-AT) is a proteinase inhibitor of the serpin superfamily. It is a 52 kDa, 418 
amino acid glycoprotein primarily synthesised in the liver by hepatocytes (Rogers et al. 
1983). It inhibits a wide variety of proteinases (Gettins 2002) and is the dominant inhibitor of 
free NE as well as CG and PR3 (Lee et al. 2001). It is considered to be the predominant 
elastase inhibitor in tissues and has a fundamental role in the distal (small) airways and the 
alveoli (Stockley 1997). During inflammation, the plasma concentration of α1-AT increases 
causing increased diffusion into the lungs. In its absence, the breakdown of elastin by NE is 
uninhibited and contributes to a far greater degree of tissue destruction and accelerated 
emphysematous change, which may in turn lead to respiratory complications (see Section 
1.6; “Alpha 1-Antitrypsin Deficiency”). 
 
Secretory Leukoprotease Inhibitor 
Secretory Leukoprotease Inhibitor (SLPI) is an 11.7 kDa, highly cationic protein that is 
present in fluids lining mucosal surfaces (McElvany et al. 1997). It inhibits a number of 
proteinases including Leukocyte Elastase, CG, Trypsin and NE and is considered to be the 
major elastase inhibitor in secretions. In the lungs, it is secreted by club cells (previously 
referred to as “Clara” cells) and goblet cells epithelium and serous cells in the submucosal 
glands (Hiemstra 2002) and inhibits elastase in the proximal (larger) airways. In addition to 
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this protective role, SLPI is also recognised as an anti-microbial factor, possessing anti-
bacterial, anti-fungal and anti-viral qualities (Tomee et al. 1998). 
 
Elafin 
The third most prominent proteinase in the lungs is Elafin, or Elastase-Specific Inhibitor 
(ESI). It is a small (6 kDa), cationic non-glycosylated member of the chelonianin family that 
also includes SLPI (Zani et al. 2004). It is a secreted protein, primarily expressed by 
epithelial surfaces such as skin (Alkemade et al. 1994, Nonomura et al. 1994, Pfundt et al. 
1996) or lung epithelium (Sallenave et al. 1994, van Wetering et al. 2000), though it can also 
be expressed by various inflammatory cells including alveolar macrophages (Mihaila et al. 
2001) and neutrophils (Sallenave et al. 1997). It is also found in plasma (Alkemade et al. 
1995) and bronchial secretions (Sallenave et al. 1992, Nara et al. 1994), where it constitutes 
up to 20% of all anti-elastase molecules in Bronchoalveolar Lavage Fluid (BALF) from 
healthy individuals. 
 
1.4   AGEING AND IMMUNE FUNCTION 
 
1.4.1   The Ageing Lung 
Ageing is associated with a gradual systemic decrease in organ and cell function, which 
includes both a loss of immune function as well as physiological lung impairment and 
throughout life there is a gradual loss of lung structure and function (Knudson 1991, Crapo 
1993, Janssens et al. 1999). For example, it has been demonstrated that the ability of the 
lungs to exchange gases decreases significantly with age (Guenard et al. 1996), although the 
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patient cohort studied contained ex-smokers, some of whom may have had smoke-related 
damage, thereby exaggerating the true effects of age on gas transfer. However, a subsequent 
study, including only never-smokers demonstrated a similar decline in gas exchange (Neas et 
al. 1996), although the average age of this group was younger making it difficult to predict 
the true change in more elderly subjects. The reduction in gas transfer appears to be due to a 
loss of alveolar surface volume (Butler et al. 1970) and a gradual increase in ventilation-
perfusion mismatching (Sorbini et al. 1968). In general, the decline in pulmonary diffusing 
capacity is unlikely to lead to significant symptoms due to the adoption of a more sedentary 
lifestyle in old age and a large remaining pulmonary reserve. 
Another factor that may contribute to the loss of lung function with age is lifetime 
neutrophil migration through the lung parenchyma, where neutrophils release proteolytic 
enzymes (such as NE) during their passage, inflicting non-specific damage to healthy tissue 
as they migrate (Cepinskas et al. 1997). It is widely accepted that this process is central to the 
development of Chronic Obstructive Pulmonary Disease (COPD), especially the 
emphysematous process (Blackwood et al. 1973, Snider et al. 1974, Damiano et al. 1986), 
and similar structural changes are observed in the aged lung. However, there still remains 
uncertainty because of a potential cause and effect relationship between ageing and COPD 
(Fukuchi 2009, Sharma et al. 2009). This is discussed in greater detail in Section 1.5.8. 
In addition to structural changes, there is a decrease in both mucociliary clearance of the 
lungs and bronchial secretions in older subjects (Gyetko et al. 1993, Puchelle et al. 1979), 
which may not only increase the risk of pathogen adherence and, hence, lung epithelial 
damage, but also prolong the retention time. This is most likely a key predisposing factor for 
the higher incidence of respiratory infections in elderly people. Studies have also suggested 
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that the total number of immune cells (such as neutrophils and T-cells) in the pulmonary 
airspace may be significantly increased with age (Thompson et al. 1992, Meyer et al. 1996). 
 
1.4.2   The Ageing Immune System 
During normal human ageing, many of the innate and adaptive immune functions and 
their interactions become less efficient. Collectively, the degradation of the immune system 
with age is termed “immunosenescence” and is largely responsible for the reduced ability of 
elderly subjects to mount an effective secondary innate or adaptive immune response to 
antigenic insult. Although our current knowledge on the effects of immunosenescence is 
incomplete, many specific functional changes in various cell types have been observed and 
documented. There is a wealth of knowledge on the various aspects of immunosenescence 
available (Panda et al. 2009, Agarwal et al. 2010). However, certain key issues will be 
discussed briefly to summarise the potential problems of altered immunity with ageing. 
It has been demonstrated that the absolute monocyte numbers are increased in elderly 
subjects (Della Bella et al. 2007) and there have been several studies into the effects of 
ageing on macrophage function, though the outcomes are somewhat conflicting. Earlier 
studies showed impairment in both chemotaxis and phagocytosis in humans and mice (De La 
Fuenta et al. 1985, Fietta et al. 1993) whereas, more recently, studies using rats showed the 
opposite effect (Corsini et al. 2005, Hilmer et al. 2007) and one study found no change in 
aged macrophage function (Miller et al. 2007). However, increased levels of circulatory 
inflammatory cytokines, such as TNFα and IL-6 are observed in aged humans (so-called 
“inflammaging” (Franceschi et al. 2000)), but output of these cytokines by monocytes is 
decreased. This is associated with a decreased expression of associated TLRs on the surface 
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of monocytes (van Duin et al. 2007) meaning that, although the basal activity of 
macrophages may be increased in ageing, a reduction their TLR expression could attenuate 
their activation and lead to overall reduction in macrophage function. 
Granulocytes, including neutrophils, eosinophils and basophils are also recruited to the 
tissues as an early part of the secondary innate response. The suggestion that granulocyte 
function may be altered with age is strongly supported by the presence of increased 
morbidity and mortality as a result of bacterial infections in the elderly (Snider et al. 1974, 
Laupland et al. 2003) and that fact that age is an independent risk factor for the development 
of a number chronic inflammatory diseases, where these cells play a central role. To date, 
there have been few studies of any age-associated changes in eosinophils (Leng et al. 2005, 
Mathur et al. 2008) and basophils (Schwarzenbach et al. 1982, Marone et al. 1986). In 
contrast, there is far more information available on the loss of neutrophil function with age 
(Lord et al. 2001, Schroder et al. 2003, Tortorella et al. 2007, Fortin et al. 2008, Lord et al. 
2009). Evidence to date suggests that most aspects of neutrophil function decrease with age, 
although findings are variable.  The majority of previous work indicates that neutrophil 
phagocytosis is impaired in the elderly (Antonaci et al. 1984, Fulop et al. 1985, Esparza et al. 
1996, Butcher et al. 2000, Tortorella et al. 2000, Wenisch et al. 2000, Alonzo-Fernandes et 
al. 2008), with only one study reporting no difference (Placket et al. 2004). In contrast, the 
effects of ageing on neutrophil oxidative burst are less clear. Some in vitro studies describe a 
constant ROS production by neutrophils from elderly donors following stimulation by fMLP 
or gram-negative bacteria (Ito et al. 1998, Butcher et al. 2000, Lord et al. 2001), whereas a 
number of other studies found that the processes that lead to intracellular oxidative killing 
could not be fully activated by multiple stimuli (McLaughlin et al. 1986, Whitelaw et al. 
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1992, Seres et al. 1993, Fulop et al. 1994, Polignano et al. 1994, Braga et al. 1997, Tortorella 
et al. 1999, Tortorella et al. 2000, Tortorella et al. 2007, Panda et al. 2009). The effect of 
ageing on neutrophil migration is also poorly understood as findings are variable. Some 
studies have shown that neutrophil migration is unaltered in aged individuals (MacGregor et 
al. 1990, Esparza et al. 1996), while others report a reduced chemotaxis with age (Niwa et al. 
1989, Wenisch et al. 2000, Fulop et al. 2004). Recent, data from our research group also 
clearly demonstrates reduced chemotaxis in neutrophils from peripheral blood of aged 
individuals compared to young control subjects (Sapey et al. 2014). 
It has also been demonstrated that the ability of neutrophils to respond to survival 
signals, particularly granulocyte-monocyte colony stimulating factor (GM-CSF), may also be 
reduced in the elderly (Fortin et al. 2007) leading to premature apoptosis. Since these cells 
provide the major phagocytic function in the airways via non-specific receptors or specific 
opsonophagocytic receptors involving antibodies provided by adaptive immunity, defects in 
their function is likely to have a marked effect on host defence. 
In addition to innate immunosenescence, there are also changes in adaptive immunity 
with age. For instance, thymic involution results in a diminished production of new T-cells 
with age, thereby reducing or limiting overall T-cell receptor diversity (Naylor et al. 2005). 
Therefore, there is a slow shift in T-cell population towards fewer naïve T cells and more 
memory T-cells (Akbar et al. 2005), which reduces the ability of the host to efficiently 
recognise new or mutated pathogen epitopes. Memory responses to pathogens encountered 
previously are also reduced, as repeated stimulation leads to the shortening of telomeres and 
cellular senescence (Moro-García et al. 2012). Other effects of adaptive immunosenescence 
include reduced T-cell survival (Aggarwal et al. 1998) and T-cell signalling due to increased 
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differentiation of T-cells and loss of co-stimulating molecules such as CD28 (Haynes et al. 
1999, Eaton et al. 2004, Larbi et al. 2004, Fulop et al. 2005, Sadighi et al. 2005, Kovaiou et 
al. 2006, Weng et al. 2009). The effects of ageing on these and the other cells of the immune 
system are summarised in Table 1.1. 
 
Immune Cell Type  Changes With Age  
Monocytes  numbers,  surface expression of TLRs  
Macrophages  basal activity,  activation  
Neutrophils 
 chemotaxis,  phagocytosis,  ROS production,            
 response to survival signals  
Basophils Generally maintained degranulation  
Eosinophils  ROS production,  neurotoxin production  
Natural Killer Cells 
 numbers,  cytotoxic function,                                          
 cytokine/chemokine production  
Natural Killer T-Cells 
 cytotoxic function (certain types), 
 cytotoxic function (TCRγδ+ cells)  
T-Cells 
 naïve T-cell numbers,  memory T-cell numbers,           
 survival,  signalling  
B-Cells  numbers,  antibody diversity  
Dendritic Cells 
Maintained antigen presentation, 
 TLR-induced cytokine production in pDCs  
 
Table 1.1: A summary of the effects of ageing on the cells of the immune system. 
Legend: This phenomenon, collectively referred to as immunosenescence, is largely 
responsible for the impaired ability of elderly subjects to mount an effective immune 
response. 
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1.5   CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Chronic Obstructive Pulmonary Disease (COPD) is a disorder that encompasses a 
number of different disease pathologies and clinical syndromes, including emphysema (tissue 
destruction), chronic bronchitis (mucous gland hyperplasia) and bronchiolitis (small airways 
disease) that may exist concurrently (Saetta et al. 2001). It has been defined by the Global 
Initiative for Chronic Obstructive Pulmonary Disease (GOLD) as “a disease state 
characterised by airflow limitation [on exhalation] that is not fully reversible [by 
bronchodilation]. The airflow limitation is usually both progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases” (Pauwels et al. 
2001). In 2007, GOLD defined COPD by the degree of airflow limitation measured by 
spirometry. Spirometric measures of ventilation include the Forced Expired Volume in 1 
Second (FEV1) and Forced Vital Capacity (FVC), where an FEV1/FVC percentage ratio post-
maximal bronchodilation below 70% is indicative of airflow limitation. GOLD further 
characterised COPD severity into Stage 1 (FEV1 ≥ 80% predicted), Stage 2 (FEV1 = 50-79% 
predicted), Stage 3 (FEV1 = 30-49% predicted) and Stage 4 (FEV1 < 30% predicted) (GOLD 
2007). Although widely accepted, these definitions were limited as they did not account for 
the age-related predicted normal range of spirometric parameters (where an FEV1/FVC ratio 
slightly below 70% may be normal for elderly subjects), individual variability of associated 
symptom severity (including cough, expectoration, wheeze, shortness of breath and exercise 
limitation) or other more direct measures of lung function such as Gas Transfer and High 
Resolution Computerised Tomography (HRCT) scan. More recently, GOLD have revised 
their guidelines to include the degree of patient dyspnoea and their exacerbation history 
(GOLD 2011). 
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1.5.1   Epidemiology 
COPD is a leading cause of mortality and morbidity worldwide. Recent estimates in 
2007 by the World Health Organisation (WHO) suggested that, globally, it affected 210 
million people and accounted for 5% of all deaths (WHO 2007). Furthermore, the WHO 
predicts these values are likely to increase significantly in the next 10 years, particularly the 
number of related deaths which is predicted to rise by more than 30% (WHO 2007). 
 
1.5.2   Pathogenesis 
COPD is a chronic inflammatory disease of the lungs with an insidious progression. 
Over the last 50 years, there have been an abundance of comprehensive publications 
regarding the pathology of COPD (Reid 1967, Heard 1969, Thurlbeck 1976).  Since the first 
experimental model of emphysema was inadvertently induced in guinea pigs (Gross et al. 
1964), understanding of COPD pathology has grown significantly and there is now 
substantial evidence implicating the neutrophil as the dominant effector cell, with particular 
reference to the destructive effect of NE. Chronic tobacco smoke inhalation is the single most 
important risk factor for COPD (Doll et al. 1994), though only 20% of smokers are 
susceptible to the disease (Tashkin et al. 1984) and the reasons for this still remain unclear. It 
is likely that there may be an element of genetic predisposition to COPD susceptibility, 
although specific genes have yet to be identified and current evidence is conflicting (Hallberg 
et al. 2008, Smolonska et al. 2009, van Durme et al. 2009). 
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1.5.3   Neutrophils in the COPD Lung 
A wealth of cumulative evidence implicates the neutrophil as the key effector cell in the 
disease pathology. Studies have shown that neutrophils are present in greater numbers 
throughout the lungs in patients with COPD compared to healthy controls in large airway 
secretions (Stanescu et al. 1996, Rutgers et al. 2000), BALF (Martin et al. 1985) and biopsies 
of the lung epithelium (Pilette et al. 2007). Furthermore, increased neutrophil numbers in 
these areas of the COPD lung positively correlate with the degree of airflow limitation, the 
severity of emphysema on high resolution computer tomography scanning (Ekberg-Jansson 
et al. 2003, Parr et al. 2006) and the presence of chronic bronchitis (Hill et al. 2000).  NE is 
of particular importance as it causes all of the pathological features of COPD in vitro and in 
animal models; emphysema (Senior et al. 1977), secretory cell metaplasia (Lucey et al. 
1985), endothelial activation, damage (Amitani et al. 1991) and apoptosis (Ballieux et al 
1994) and a reduction in ciliary beat frequency on the respiratory epithelium (Smallman et al. 
1984). NE triggers a state of oxidative stress in cells (Aoshiba et al. 2001), degrades all of the 
components of the extracellular matrix (Kafienah et al. 1998), activates the clotting cascade 
(Vogt 2000), damages the opsonophagocytic receptor, C3bi (Berger et al. 1989), and 
activates matrix metalloproteinases (Ferry et al. 1997) while inhibiting tissue inhibitors of 
metalloproteinases (Itoh et al. 1995) thereby enhancing the destructive capacity of 
macrophage proteinases. Both neutrophil numbers and NE concentration in the COPD lung 
decrease following smoking cessation (Rennard et al. 1990), supporting not only the 
association between smoking and increased neutrophil activity in the lungs but also 
highlighting the importance of smoking cessation as the major therapeutic option COPD. 
Moreover, exposure to cigarette smoke results induces an inflammatory cascade including 
54 
 
the release of numerous inflammatory cytokines and growth factors that lead to the 
recruitment of inflammatory cells such as neutrophils (Saetta et al. 1997). However, as only 
20% of smokers develop COPD (Tashkin et al. 1984), it is clear that this inflammation is not 
a universal response to smoking. 
The increased neutrophil presence in the lungs of COPD patients appears to be due 
primarily to an increased transmigration from the peripheral blood. Tobacco smoke induces 
an increase in the production and release of neutrophils from the bone marrow into the 
circulation (Corre et al. 1971, Van Eeden et al. 2000) which, in turn, results in a greater 
degree of influx to the airways in smokers. The increased neutrophil migration through the 
lung parenchyma in smokers susceptible to COPD appears to result in an accelerated rate of 
alveolar and airway destruction by NE, although the precise mechanisms by which this 
occurs have yet to be elucidated. It has also been suggested that neutrophils that have 
migrated to the lungs survive longer, which would further increase lung damage, although the 
current evidence is conflicting (Pletz et al. 2004, Uller et al. 2006, Rytila et al. 2006). A 
HRCT scan showing the destruction of lung tissue and enlargement of airspace in the COPD 
lung compared to the preserved airspaces in a healthy lung is shown in Figure 1.10 (Taken 
from; http://www.ctsnet.org/portals/thoracic/newtechnology/article-4.html). 
There is both direct and indirect evidence of abnormal neutrophil function in patients 
with COPD.  Altered functions include an increased ROS production (Noguera et al. 2001), 
increased phagocytosis with potentially enhanced migration (Burnett et al. 1987) and 
improved adhesion to endothelial cells under flow (Woolhouse et al. 2005). The reasons for 
these differences remain unclear. They may either arise during neutrophil maturation in the 
bone marrow or at some point after their release into the circulation, for example by 
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cytokines in the circulation or during transmigration. It has been demonstrated that 
neutrophils change phenotype between initial activation and the end of migration in healthy 
subjects (Dangerfield et al. 2002, Yadav et al. 2002) but this has not yet been studied in 
COPD. 
 
 
          A             B 
Figure 1.10: HRCT scans comparing healthy and COPD lungs. 
Legend: Image showing the preserved airspaces in a healthy lung (A) and the enlarged 
airspaces in a COPD lung caused by persistent tissue destruction (B). 
 
 
 
1.5.4   Proteinases and COPD 
Proteinases are believed to play a key role in the pathogenesis of COPD. The 
proteinase/anti-proteinase theory suggests that lung damage occurs when the level of anti-
proteinase is insufficient to neutralise the presence of proteinases (Tetley 1993). This 
imbalance may occur due to a loss of anti-proteinases (by genetic origin (α1-Antitrypsin 
Deficiency) or proteolytic/oxidative damage) or excessive recruitment or activation of 
proteinases. 
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Proteinases are classified into three groups; the serine proteinases (including NE, CG and 
PR3), cysteine proteinases (Cathepsins) and Matrix Metalloproteinases (MMPs). The serine 
proteinases are stored with MPO in the azurophile granule (Ohlsson et al. 1977). Of these 
enzymes, NE was the first to be shown to produce emphysema in animal models (Janoff et al. 
1977, Senior et al. 1977). The main physiological role of NE is bacterial killing, although it 
has the potential to be extremely destructive and its role in the pathogenesis of COPD 
(particularly emphysema) is well documented in animal models and in vitro (Snider et al. 
1974, Stockley 2002). In further support, studies have also shown that NE damage in the lung 
can be prevented by elastase inhibitors (Lucey et al. 1989, Rudolphus et al. 1994). 
The mechanisms of neutrophil migration are not fully understood. It may be that serine 
proteinases are not required for migration through tissue or that their function is not specific 
to matrix degradation and tissue destruction is merely a side-effect. The imbalance of 
proteinase and anti-proteinase may allow NE to diffuse further from the neutrophil before it 
is neutralised, thereby causing the breakdown of elastin (Campbell et al. 1999). NE has also 
been implicated in mucous cell metaplasia and mucus hypersecretion that is associated with 
the chronic bronchitis element of COPD (Lucey et al. 1985), which may be inhibited by NE 
inhibitors (Takeyama et al. 1998). 
Far less is understood about the role of cysteine proteinases in COPD, though they 
possess similar properties to serine proteinases. Of particular note is Cathepsin B, which is 
produced by macrophages, is present in the BALF of COPD patients and increasing during 
periods of exacerbation (Burnett et al. 1983). It is known that NE induces Cathepsin B 
activity in sputum via activation of pro-enzymes (Buttle et al. 1991) and this may form a 
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positive feedback loop as Cathepsin B also inactivates SLPI (the local NE inhibitor) (Taggart 
et al. 2001). 
In contrast, more is understood about the potential role of MMPs in COPD. Both 
macrophages and neutrophils secrete large amounts of MMPs and their inhibitors; “Tissue 
Inhibitors of Metalloproteinases” (TIMPs). To date, there are over 24 mammalian MMPs 
described, although only a few have been implicated in COPD. They have a variety of 
functions including degradation of extracellular matrix proteins as well as the breakdown of 
anti-proteinases (such as α1-AT) and other proteins (such as adhesion factors), activation of 
clotting cascade enzymes and modification of cytokines. Examination of BALF from patients 
with emphysema has demonstrated a presence of MMPs compared to a control group of 
healthy smokers (Burnett et al. 1988). Tissue destruction by MMPs may be associated with 
macrophages more so than neutrophils as alveolar macrophages that reside within the lungs 
are able to continually secrete MMPs. However, it is likely that there is a high degree of 
interaction between neutrophils, macrophages, MMPs and their other respective secretory 
enzymes. For example, NE can not only activate various MMPs (Okada et al. 1989, Rice et 
al. 1995, Ferry et al. 1997) but also degrade TIMPs (Itoh et al. 1995). In addition, a number 
of macrophage enzymes have been shown to degrade NE inhibitors such as α1-AT (Banda et 
al. 1980, Sires et al. 1994, Lui et al. 2000). 
 
1.5.5   Oxidative Damage 
ROS are products of normal metabolism and are produced primarily by mitochondria 
(Halliwell et al. 1999) and are found throughout the lungs. The predominant defence against 
ROS and other free radicals are anti-oxidants, which rapidly neutralise ROS. The toxicity of 
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oxygen in the lung has recognised for many years (Halliwell et al. 1999, van der Vliet et al. 
1999) and there is mounting evidence for potential oxidative damage in COPD (Rahman et al 
1996, Rahman et al. 1999, Anderson et al. 2004). In the lungs and other organs there is a 
balance between ROS and anti-oxidants and an increase in ROS and/or depletion of anti-
oxidants induces disequilibrium and results in “oxidative stress”. 
Cigarette smoke comprises a mixture of at least 5000 different chemical compounds 
including free radicals and other oxidants, both present in high concentrations (10
15
 free 
radical molecules per inhalation) (Church et al. 1985, Pryor et al. 1993). Direct exposure of 
the lung epithelium to inhaled smoke makes it particularly vulnerable to associated oxidative 
damage. Oxidants in cigarette smoke can directly damage elastin and collagen in the lung 
matrix (Cantin et al. 1985) as well as impairing the ability to regenerate elastin (Laurent et al. 
1983), which may enhance emphysematous damage. However, smokers who are not 
susceptible to COPD do not endure lung damage through smoking alone, so tobacco smoke-
induced ROS alone is not sufficient to cause COPD. The oxidative burden in COPD is 
amplified by release of ROS from macrophages and neutrophils, which migrate in greater 
numbers into the lungs of smokers, particularly those susceptible to COPD (Hunninghake et 
al. 1983). Furthermore, there is also evidence supporting increased systemic oxidative stress 
as circulating neutrophils in COPD patients appear to have an increased capacity to release 
ROS (Noguera et al. 1998). The effects of cigarette smoke-induced oxidative stress within 
the lung environment are summarised in Figure 1.11 (Adapted from; http://healthy-
lifestyle.most-effective-solution.com/2007/10/01/oxidative-stress-and-free-radicals/). 
 
  
 
 
 
Figure 1.11: Oxidative damage in COPD. 
Legend: Oxidants in cigarette smoke aggravate epithelial cells in the lung (A), causing the release of inflammatory cytokines 
(B). This prompts the recruitment of neutrophils that release cell-derived oxidants (C) and proteinases (D). Anti-proteinases 
inhibit proteinases (E) and anti-oxidants inhibit damage caused by oxidants (F). Due to an oxidant/anti-oxidant imbalance, 
oxidative stress occurs (G), resulting in activation of macrophages (H) that release more proteinases (I) and inhibition of anti-
proteinases (J). This ultimately leads to inflammation, mucus hypersecretion and lung tissue destruction (K). 
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1.5.6   Bacteria and Viruses in COPD 
Bacterial colonisation can occur in the airways of patients with COPD (particularly those 
with severe disease) even when clinically stable (Monso et al. 1995). As the lungs are 
continuously in contact with the external environment, they are not completely sterile in 
healthy subjects. However, the differential speciation and increased bacterial load in the 
lungs of COPD patients (Hassett et al. 2014) suggests that they may potentially have a 
causative role in the disease pathogenesis. The contribution of infection to the pathogenesis 
and progression of COPD may be multifactorial (Murphy et al. 1992). However, the specific 
role of bacteria has been a topic of debate for some years, with hypotheses ranging from a 
fundamental and causative role to more secondary and coincidental one (Leeder 1975, Tager 
et al. 1975, Hirschmann 2000, Murphy et al. 2000). 
Latent adenoviral infection has also been implicated in the pathogenesis of COPD. 
Evidence of persistent adenoviral infection has been demonstrated in the lungs of 
asymptomatic adults (Matsuse et al. 1992) and expression of the adenovirus E1A protein on 
lung epithelial cells persists even after the virus has ceased replication and symptoms have 
abated (Elliot et al. 1995). In addition, the adenovirus E1A protein has been associated with 
an amplification of inflammation in emphysema (Retamales et al. 2001). 
Studies also suggest that 20-40% of exacerbation in COPD have a viral genesis, which 
would also amplify lung damage through different mechanisms such as increased neutrophil 
influx, increased ROS release and increased expression of pro-inflammatory cytokines 
(Sapey et al. 2006). 
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1.5.7   Systemic Effects of COPD 
Although COPD is primarily a disorder of the lungs, it is also associated with a variety 
of systemic effects and comorbidities (Decramer et al. 2008, Fabri et al. 2008). The most 
common comorbidities include ischaemic heart disease, osteoporosis, cachexia, chronic 
kidney disease and lung cancer as well as cognitive and affective manifestations such as 
depression (Decramer et al. 2008, Casanova et al. 2010). Diabetes was also originally thought 
to be a primary comorbidity of COPD but is now more frequently associated with restrictive 
lung disease (van den Borst et al. 2010). These comorbidities clearly affect health outcomes 
and may also provide plausible explanation, at least in part, as to the heterogeneic nature of 
COPD and why its clinical features do not correlate strongly with FEV1 (Celli et al. 2004). 
The causal link between COPD and its comorbidities is difficult to establish. In some 
instances, comorbidities could simply be a reflection of poor lifestyle as smokers may lead a 
more sedentary lifestyle and eat less healthily (Booth et al. 2000, Health 2008). However, it 
has been suggested that there is a direct link between COPD and its comorbidities (Fabbri et 
al. 2007), either due to a systemic “spillover” of pro-inflammatory mediators from the lungs, 
or because of a general systemic effect impacting on multiple organs (Barnes et al. 2009). All 
of the comorbidities can develop in patients without COPD but, as they are commonly 
associated with the disorder (particularly severe cases), common risk factors seem likely. 
Chronic tobacco smoke inhalation is a major risk factor for COPD but it is also a risk factor 
for cardiovascular disease, osteoporosis and lung cancer (Edwards 2004). Lastly, ageing is a 
major risk factor for the development of chronic disease and nearly half of the world’s 
population over the age of 65 have three or more chronic medical disorders (Boyd et al. 
2005). 
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The common factor between all comorbidities is the presence of systemic inflammation. 
Increased plasma levels of pro-inflammatory cytokines (TNFα, IL-6 and IL-8), adipokines 
(leptin, ghrelin) and acute-phase proteins (C-Reactive Protein (CRP), fibrinogen) are seen in 
the majority of these diseases and the independent risk factors have all been linked to the 
presence of systemic inflammation (Fabbri et al. 2007, Mora et al. 2007, Yanbaeva et al. 
2007). However, whether these systemic inflammatory markers are in fact overspill from the 
pulmonary system or reflect a more general inflammatory state remains unclear (Fabbri et al. 
2004, Barnes et al. 2009, Sinden et al. 2010). 
 
1.5.8   Ageing and COPD 
It has been proposed that the pathology of many chronic diseases, including COPD, may 
in fact be an accelerated form of the processes that occur with natural ageing. The incidence 
of COPD is clearly greater in older individuals (Fukuchi et al. 2004, Buist et al. 2007), 
although this could simply be because COPD usually progresses very slowly and, by the time 
symptoms have manifested and patients are diagnosed, they are often of middle to old age. 
Hence, the cause and effect relationship between ageing and COPD is unclear. It could be 
that the natural changes in lung structure associated with ageing, coupled with the 
progressive loss of immune function with age (immunosenescence) may increase 
susceptibility to or even cause COPD. In contrast, it could be that the repetitive toxic insults 
associated with COPD (most commonly tobacco smoke inhalation) directly influence the 
pulmonary environment and amplify natural inflammatory processes (such as leukocyte 
migration) that, over time, exaggerate pulmonary damage and manifest as disease. 
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The changes that occur in the ageing lung in the absence of disease lead to a detrimental 
shift in pulmonary physiology. A reduction in the elastic recoil of the lungs is coupled with 
an increase in cell wall rigidity and there is also a loss of respiratory muscle strength (Turner 
et al. 1968, Knudson et al. 1977). These can lead to a modest impairment in ventilation that is 
indicated by a reduced FEV1/FVC ratio and an increased residual volume (RV) but the fact 
that elderly individuals usually adopt a more sedentary lifestyle means that these changes are 
generally asymptomatic. 
Importantly, the histological changes observed in lung with advanced age are not 
analogous to those in COPD. Even though there is alveolar enlargement at autopsy in human 
aged lungs, the concurrent alveolar wall destruction and distension of alveolar ducts seen in 
COPD is absent (Verbeken et al. 1992). Mouse models of accelerated senescence also 
demonstrate that normal ageing is associated with alveolar enlargement without emphysema, 
indicating that ageing per se did not cause COPD (Fukuchi et al. 2009). However, this study 
also showed that mice with accelerated ageing developed more emphysema than age-resistant 
mice when exposed to equal amounts of tobacco smoke, which suggests that ageing does 
increase susceptibility to COPD. 
 
1.5.9   Current and Emerging Therapies 
Despite the huge global impact of COPD on mortality and the burden on healthcare, 
there are currently no drug therapies that have been shown to significantly prevent the 
progression of the disease, reduce exacerbation frequency or reduce mortality. For many 
years, bronchodilators have been the cornerstone of COPD treatment and the only significant 
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advancements in therapy have been the development of long-acting β2-agonists (LABAs) and 
long-acting muscarinic agents (LAMAs) (Cazzola et al. 2008). 
The once-daily muscarinic agent, tiotropium bromide, has been used as a first line 
treatment for moderate-severe COPD since 2002 in over 100 countries (Boehringer 
Ingelheim GmbH 2011). It has been shown to improve a variety of outcome measures 
including expiratory airflow, lung hyperinflation, exercise capacity and quality of life as well 
as a reduction in exacerbation frequency and mortality (Tashkin et al. 2008, GOLD 2011). In 
addition, in vitro studies have shown that tiotropium bromide may possess anti-inflammatory 
properties, such as suppression of IL-8 release from bronchial epithelial cell lines (Suzaki et 
al. 2011) as well as reduction of ROS production by alveolar macrophages and inhibition of 
alveolar macrophage-mediated neutrophil migration (Vacca et al. 2011). Until recently, 
tiotropium bromide was the only once-daily LAMA available but, due to its commercial 
success and efficacy in the treatment of COPD symptoms, two other products have now been 
licensed (glycopyrronium bromide and aclidinium bromide). 
Salmeterol and formoterol are both LABAs with an extended duration of action that may 
last up to 12 hours following administration (Ball et al. 1991). These twice-daily 
bronchodilators have been in use for many of years but there are now a number of new once-
daily LABAs in production. Indacaterol is currently the only bronchodilator of this type on 
the market, though others are in development such as vilanterol trifenatate (Kempsford et al. 
2013). Indacaterol is an ultra-long acting LABA that has a rapid onset of action as well as a 
2-fold greater efficacy than salmeterol at the target β2 adrenergic receptors in airway smooth 
muscle cells (Batram et al. 2006). 
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As useful as bronchodilators may be in relieving symptoms, they offer no long-term 
solutions to disease progression. Smoking cessation is certainly the most important and 
effective intervention for halting or slowing disease progression (Godtfredsen et al. 2008), 
though current strategies are relatively ineffective. Furthermore, in moderate-severe COPD, 
smoking cessation may not be sufficient to resolve established neutrophil inflammation and 
the disease can often progress in a self-perpetuating manner (Willemse et al. 2005). 
Development of new pharmaceutical agents for the treatment of COPD has proven 
difficult. This is predominantly due to limited understanding of the underlying molecular 
mechanisms behind the diseases pathology (in contrast to asthma, for example). Furthermore, 
it is unclear how to test drugs for COPD. Animal models to date have focused exclusively on 
emphysema and have not investigated other components of COPD, such as small airways 
disease (which may relate more closely to certain physiological measures and symptoms 
(Boswell-Smith et al. 2007)). Moreover, animal models of drug testing are generally 
unreliable as positive therapeutic effects are rarely mirrored in subsequent human trials (Seok 
et al. 2013). For human subjects, the large phenotypic variation in COPD make it difficult to 
differentiate which patient groups may benefit from certain treatments, as clinical trials have 
included numerous clinical phenotypes (Barnes 2012).  In addition, a large proportion of 
COPD patients have co-morbidities (such as cardiovascular disease and diabetes) that may 
exclude them from participating in clinical trials of new treatments (Majo et al. 2001). Lastly, 
as COPD progression is slow and insidious, clinical trials can require long study periods and 
prove extremely costly (Banner et al. 1995). 
Due to the large number of inflammatory mediators implicated in the pathophysiology of 
COPD (Cortijo et al. 1993, Hatzelmann et al. 2001), blockade of these mediators seemed an 
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attractive target for novel therapies. Unfortunately, clinical trials to date have yielded no truly 
effective anti-inflammatory drugs, where results have been either negative or shown only 
modest improvement in outcome measures but often with undesirable side-effects. Of 
particular note, the phoshodiesterase 4 (PDE4) inhibitor, roflumilast, has been the subject of 
a number of clinical trials with moderate-severe COPD patients. The studies reported a 
number of promising outcomes including decreased exacerbation frequency, improved 
health-related quality of life and improved post-bronchodilator FEV1 (Calverley et al. 2007, 
Calverley et al 2009, Fabri et al. 2009,  Martinez et al. 2010, AURA Study, HERMES Study, 
OPUS Study, Ratio Study) and roflumilast has now reached the market for treatment of 
COPD. However, the clinical benefits were frequently coupled with significant side effects 
including diarrhoea, nausea and weight loss, resulting in intolerance for many COPD 
patients. As a result, roflumilast is not currently recommended for the general treatment of 
COPD and is not available in the UK. 
Blockage of both LTB4R1 (with a major receptor antagonist) and TNFα (with 
infliximab) had no clinical benefit in COPD (Wollin et al. 2006, European Medicines Agency 
2010). Blocking antibody to IL-8 had a small effect in reducing dyspnoea (Kumar et al. 
2003) and there has been great interest utilizing CXCR2 blocking strategies to modify 
neutrophil recruitment in COPD (Barnes 2005). CXCR2 blockade is associated with a 
reduction in neutrophil migration (Del Rio et al. 2001) with a resulting decrease in 
inflammation in animal models of inflammatory disease (Farooq et al. 2009). Two recent 
clinical trials in humans demonstrated that a CXCR2 antagonist (AZD8309) attenuated 
neutrophil airway recruitment after LPS challenge in healthy humans (Virtala et al. 2011, 
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Leaker et al. 2013). If a similar effect were to be observed in COPD patients, it could 
potentially reduce lung damage caused by neutrophil transmigration and possibly slow the 
emphysematous process. 
Due to the increased bacterial colonisation commonly seen in COPD and the association 
between chronic inflammation and acute exacerbations (Hassett et al. 2014), the use of 
macrolide therapy (such as erythromycin, clarithromycin and azithromycin) as a treatment 
has been investigated. Their antibacterial effects include the inhibition of bacterial protein 
synthesis, impaired bacterial biofilm synthesis and the attenuation of bacterial virulence 
factors and their effectiveness in treating infectious respiratory diseases is well established 
(Woodhead et al. 2011). In addition, it has also been demonstrated that macrolides have a 
number of immunoregulatory effects, including control of mucus hypersecretion, resolution of 
inflammation, and modulation of host defence mechanisms (Lopez-Boado et al. 2008, Altenburg 
et al. 2011a, Altenburg et al. 2011b). Yao et al. have recently published a meta-analysis of 
previous research into the effectiveness of macrolide maintenance therapy in reducing 
exacerbation rate in COPD (Yao et al. 2013). They concluded that treatment with macrolides 
significantly lowered the frequency of acute exacerbations in COPD, although treatment for 
at least 6 months was required to elicit a positive therapeutic effect. 
As mentioned previously (see Section 1.2.3), PI3K activity is intimately involved in 
neutrophil inflammatory functions (Stephens et al. 2002) and has been proposed as a putative 
target for therapeutic interventions in COPD.  In vitro and transgenic animal models with 
increased PI3K activity appear to mimic the COPD neutrophil migratory phenotype: PTEN 
knockout (KO) mouse neutrophils demonstrate increased speed of migration (Sarraj et al. 
2009); SHIP1 KO mice have greater neutrophil accumulation following inflammatory insult 
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(Helgason et al. 1998); and PTEN knockout Dictyostelium demonstrate reduced chemotaxis, 
corrected by reducing PI3K output (Tang et al. 2011). In keeping with this, previous in vitro 
studies by our group demonstrated that incubation of COPD neutrophils with a non-selective 
PI3K inhibitor (LY29004) restored normal migratory behaviour by reducing their speed and 
increasing their accuracy, although LY29004 is not specific to PI3K so its effect could not be 
exclusively attributed to PI3K activity (Sapey et al. 2011). 
However, these are likely to be associated with various side effects as PI3K is associated 
with many cellular functions. However, the γ- and δ-isoforms are the dominant isoforms in 
leukocytes (Ferguson et al. 2007, Martin et al. 2010), so their anti-inflammatory effects may 
target these cells more exclusively. Data on specific isoform inhibition and neutrophil 
migration is limited. One study investigating blockade of PI3Kγ in mouse models of 
rheumatoid arthritis demonstrated that neutrophil recruitment and joint inflammation is 
suppressed in both PI3Kγ knockout mice and those treated with an oral PI3Kγ inhibitor 
(Camps et al. 2005). In contrast, a later murine study demonstrated that GROα-mediated 
recruitment of neutrophils to the lung was only inhibited in PI3Kγ knockout mice when 
treated with a PI3Kδ inhibitor and not by PI3Kγ or PI3Kδ inhibitor in wild type mice (Pinho 
et al. 2007). Another group observed that inhibition of PI3K by LY294002 and PI3Kγ by a 
specific isoform inhibitor, blocked neutrophil recruitment driven by the chemokine regulated 
on activation normal T-cell expressed and secreted (RANTES) in a murine model of 
peritoneal chemotaxis (Ferrandi et al. 2007). Collectively, these data suggest that specific 
PI3K isoform inhibition can modulate neutrophil chemotaxis, although the effects of PI3K 
isoform inhibition in human COPD patients are currently unknown. In addition, PI3Kδ may 
also reverse the corticosteroid resistance in COPD (Hamblin et al. 2008) and its inhibition 
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attenuates neutrophil migration into inflamed tissue by 20-40% in a murine model of acute 
lung injury (Puri et al. 2004). This partial inhibition would be of particular importance if the 
same effect was observed in human subjects with COPD as the desired outcome would be to 
provide a degree of relief to the lung parenchyma from neutrophil influx (thereby reducing 
lung damage and slowing disease progression), while not significantly compromising the 
innate immune defence within the pulmonary airspace. 
There have also been a number of studies investigating the effects of statins in COPD. 
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors that 
are traditionally used to treat hypercholesterolaemia by blocking the mevalonate pathway. In 
addition to blocking cholesterol synthesis, all products downstream of HMG-CoA are 
reduced, including the isoprenoids farnesylpyrophosphate (FPP) and 
geranylgeranylpyrophosphate (GGPP), which regulate Ras and Rho activity respectively. A 
number of studies suggest Ras and Rho inactivation by statins have a number of pleiotropic 
anti-inflammatory and immunomodulatory effects (Fromigue et al. 2006, Dai et al. 2007). 
These effects are shown in Table 1.2 (summarised from Blanco-Colio et al. 2003). 
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Anti-Inflammatory Effects Immunomodulatory Effects 
 Inflammatory Cell activation/recruitment  Proliferation of lymphoid cells 
 Inflammatory Cell proliferation/differentiation  Natural killer cell activity 
 Pro-inflammatory cytokine release  Major histocompatibility class II antigens 
 Adhesion molecule expression  Organ rejection 
 Transcription factors   
 ROS production  
 
Table 1.2: A summary of the potential pleiotropic effects of statins. 
Legend: Statins are thought to have many anti-inflammatory and 
immunomodulatory effects in addition to their effect on cholesterol. Many of these 
arise through the inhibition of GTPase activity. 
 
 
 
There have been a number of studies into the effects of statins on neutrophil 
inflammation and migration, although the majority of these simply investigate overall cell 
recruitment rather than migratory dynamics. It has previously been shown that statins inhibit 
neutrophil influx into the lungs in both human transplant recipients (Maher et al. 2009) and 
murine models of emphysema (Lee et al. 2005). One study in atherosclerosis found that 
simvastatin inhibits neutrophils adhesion to the endothelium under flow (Eccles et al. 2008). 
In addition, a longitudinal study by Guasti et al. showed that a four-week treatment course of 
20 mg simvastatin in high-risk atherosclerosis patients attenuated the pro-inflammatory 
properties of neutrophils by reducing chemotaxis (using a Boyden Chamber) as well as IL-8 
production (Guasti et al. 2006). A similar study in healthy individuals also showed a 
reduction in ex vivo neutrophil chemotaxis following a two-week course of 40 mg 
simvastatin (Kinsella et al. 2011). Animal studies have also shown that statins reduce 
neutrophil recruitment to the lungs of rats following one-lung ventilation and re-expansion 
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(Leite et al. 2013) and mice following inflammatory insult with LPS (Grommes et al. 2012). 
Clinical trials of statin in respiratory disease are limited. One recent trial in COPD found no 
positive effect of 40 mg simvastatin on exacerbation frequency over two years, although no 
assessment of neutrophil function was included (Criner et al. 2014). A similar trial on 
ventilator-acquired pneumonia (VAP) showed no difference in 8-day mortality with 60 mg 
simvastatin (Papazian et al. 2013). At present, the effects of statins on the migratory 
dynamics of COPD neutrophils remains unexplored, although statins could potentially alter 
chemotaxis neutrophils, at least in part, by modulating PI3K activity through GTPase 
prenylation. 
 
1.6   ALPHA 1-ANTITRYPSIN DEFICIENCY 
Alpha 1-Antitrypsin Deficiency (α1-ATD) was first described by Laurell and Eriksson in 
1963 when they found missing α1 bands in electrophoretic patterns of serum samples from 
some patients with emphysema (Laurell et al. 1963). It is a hereditary condition resulting 
from the inheritance of two recessive alleles on the α1-AT gene (Darlington et al. 1982). 
There are over 100 different phenotypes of the α1-AT protein, with “PiZ” being the most 
common deficiency. It causes a mutation the tertiary structure of α1-AT protein, where a 
single substitution of lysine for glutamic acid widens the β-sheet. This results in 
polymerisation of α1-AT that prevents its secretion by hepatocytes (Lomas et al. 1992) and 
leads to severely limited serum concentration. 
In PiZ individuals, there is a proteinase/anti-proteinase imbalance between the 
concentrations of NE (normal) and α1-AT (reduced). Uncontrolled NE activity leads to a 
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greater degree of lung tissue destruction during neutrophil migration and degranulation 
(Campbell et al. 1999). This process is illustrated in Figure 1.12. 
 
 
Figure 1.12: A comparison of collateral damage to the extracellular matrix 
during neutrophil migration in a health and α1-ATD. 
 
Legend: Neutrophil migration through the lung matrix in health (small area of 
destruction due to effective neutralisation of NE by α1-AT) and in α1-ATD (large 
area of destruction due to poor control of NE by low serum levels of α1-AT). 
 
 
The presence of NE further increases the release of pro-inflammatory mediators (such as 
LTB4 by macrophages), thereby increasing the neutrophil influx and indirectly amplifying 
the destructive processes. Over time, these processes can manifest physiologically as 
panaciner emphysema with basal distribution, which may not only occur at a relatively early 
age, but also in non-smokers (Gishen et al. 1982, Brantly et al. 1988). Studies of neutrophil 
migration in α1-ATD are limited but one study suggests migration towards sputum in α1-ATD 
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could be enhanced (Woolhouse et al. 2002). However, this may be explained by the increased 
concentration of chemoattractants in the α1-ATD sputum (such as IL-8 and LTB4) rather than 
altered neutrophil function. 
Patients with α1-ATD provide a useful control group when studying neutrophil 
inflammation and migration in COPD as they can be matched for all elements of lung disease 
and inflammation as well as smoking history and therapeutics. 
 
1.7   SUMMARY 
COPD is chronic inflammatory condition of the lungs. The pathophysiology is complex, 
involving a number of inflammatory cells and a multitude of mediators. It is believed that the 
neutrophil is the key effector cell in the disease pathology and numerous experimental 
models have demonstrated that they can cause all of the pathological features of COPD. 
Furthermore, neutrophil numbers within the lung correlate with disease severity and 
progression. However, the exact role of neutrophils in COPD and the precise mechanisms of 
their dysfunction (particularly migratory behaviour) remain unclear. Further definition of the 
cellular pathways involved in neutrophil chemotaxis and migratory morphology may yield a 
greater understanding of their role in COPD and ultimately lead to the development of much-
needed novel therapeutic interventions. 
 
1.8   AIMS OF THE THESIS 
The experiments in this thesis were designed to investigate different aspects of 
inflammation and migration of COPD neutrophils compared to those from age-matched 
healthy control subjects and patients with α1-ATD. There are many aspects of neutrophil 
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function and their inflammatory environment that could potentially explain their dysfunction 
in COPD, though the experiments of this thesis were designed to investigate five main 
questions; 
 
1. Is the aberrant migration of COPD neutrophils to IL-8, GROα and sputum previously 
described (Sapey et al. 2011) a generic phenomenon and is it inherent to the cell or 
influenced by the local inflammatory environment? (Chapter 3). 
 
To study this, two-dimensional neutrophil migratory dynamics were determined in vitro 
using a specific chamber for direct visualisation of chemotaxis (Muinonen-Martin et al. 
2010) in response to five chemoattractants; IL-8, GROα, fMLP, LTB4 and C5a. These were 
chosen to represent different arms of host immunity (some of which have been shown to be 
increased in COPD BALF) as well as those commonly released by invading bacteria. Initial 
concentration responses for these chemoattractants were performed to determine the most 
effective concentration for the final chemotaxis experiments. 
In separate, follow-on assays, COPD neutrophils were pre-incubated with plasma from a 
healthy donor and vice versa to determine if the inflammatory environment may be 
influencing chemotaxis. Furthermore, expression of surface markers of cell activation 
(CD11b, CD62L), maturity (CD16) and degranulation (CD63) was quantified on neutrophils 
in whole blood by flow cytometry to determine of COPD neutrophils were of a different 
phenotype to those from healthy subjects. 
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2. Does the migratory accuracy of neutrophils worsen with disease severity or relate to other 
factors that comprise the clinical phenotype of COPD patients (Chapter 3). 
 
To study this, migratory data from the current study was collated with data from 
collaborative researchers to generate a large cohort of both healthy individuals and COPD 
patients with GOLD Stages I-IV (GOLD 2007). Chemotaxis in each GOLD Stage was 
compared in a group-wide analysis and linear regression was conducted comparing 
chemotaxis to FEV1 % Predicted and FEV1/FVC. Comparisons of chemotaxis to age, 
smoking status and the presence of emphysema were also made. 
 
3. Can any differences in migratory dynamics be explained by an altered cell surface 
expression of chemokine receptors or differences in their localisation and/or rates of 
recycling and shedding? (Chapter 4). 
 
To study this, surface expression of receptors for the five chemoattractants used in the 
original chemotaxis assay were semi-quantified using immunohistochemistry and flow 
cytometry. This was performed on both quiescent neutrophils (for all five chemoattractants) 
and then for selected receptors over a two-hour time-course following stimulation. Initial 
concentration responses for the fluorescent antibodies and their respective isotype control 
antibodies were performed to determine the most effective concentration for the final 
analysis. 
Receptor shedding at specific time-points throughout the time-course was later 
quantified by Enzyme-linked Immunosorbent Assay (ELISA). Receptor localisation on 
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quiescent and activated, polarised neutrophils from COPD and healthy donors was 
determined by fluorescence microscopy. 
 
4. Can any differences in migratory dynamics be explained by altered intracellular 
signalling? (Chapter 4). 
 
To study this, both PI3K and Akt phosphorylation was determined by western blot. 
Lysates from COPD and healthy neutrophils were compared from both unstimulated 
neutrophils and those stimulated with various chemokines. The length of stimulation time 
was predetermined through time-course assays for each antibody. 
In addition, intracellular calcium signalling was quantified by real-time fluorometric 
measurement of both peak and total calcium ion release following stimulation with IL-8. 
 
5. Can the dysfunctional neutrophil migration in COPD be improved with novel therapeutic 
interventions? (Chapter 5). 
 
To study this, the chemotaxis assays were repeated in selected chemokine gradients after 
pre-incubation in a variety of different pharmaceutical agents. These included CXCR1 and 
CXCR2 agonists, specific PI3K isoform inhibitors (α, β, γ & δ), Erk and p38 inhibitors and 
simvastatin. The concentrations used were either based on those currently used in medical 
prescription (simvastatin), half maximal inhibitory concentration (IC50) (PI3K isoform 
inhibitors) or maximal effect (CXCR1 and CXCR2 agonists) as determined by concentration 
response experiments. 
  
 
 
 
 
 
 
CHAPTER 2 
 
METHODS 
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2.1   HUMAN PARTICIPANTS 
All experiments in the current study were approved by the South Birmingham Health 
Authority ethics committee (Ethics Number: LREC3359A). All subjects included provided 
informed and written consent for the donation of blood samples. 
COPD was defined clinically in accordance with the GOLD guidelines (Pauwels et al. 
2001). All patients with α1-ATD were of the PiZ phenotype. Due to the potential effects of 
ageing on neutrophil function, all subjects were aged-matched within five years. 
 
2.2   PULMONARY FUNCTION TESTING 
All subjects undertook pulmonary function testing in the Lung Investigation Unit, 
University Hospital Birmingham NHS Foundation Trust. Tests were performed by trained 
Respiratory Physiologists in accordance with the national guidelines recommended by the 
British Thoracic Society (BTS) (BTS 1997). As a minimum, all subjects undertook 
Spirometry (including FEV1 and FVC), though COPD and α1-ATD patients often undertook 
Static Lung Volumes and Gas Transfer tests as part of their routine lung function 
assessments. 
 
2.3   PERIPHERAL BLOOD PROCESSING 
Venous blood samples were taken using lithium heparin Vacutainer® tubes (Becton 
Dickinson Vacutainer System, Franklin Lakes, USA) and processed within 30 minutes of 
collection. 
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2.3.1   Plasma Samples 
Plasma samples were obtained by centrifugation of blood at 3000rpm for 10 minutes at 
20°C (Jouan C3i Centrifuge, DJB Labcare, Buckinghamshire, UK). If they were not used on 
the same day, the samples were stored at -80°C until required. 
 
2.3.2   Neutrophil Isolation 
Neutrophils were isolated in accordance with a previously established protocol (Afford 
et al. 1992). Whole blood was first treated with 2% Dextran T500 (500 kDa molecular 
weight) (Pharmacosmos, Holbaek, Denmark) in Phosphate Buffered Saline (PBS) (Sigma-
Aldrich, Poole, UK) at a ratio of 1 ml 2% Dextran to 6 ml whole blood. Once the 
erythrocytes had sedimented, the remaining plasma containing the leukocytes was extracted 
and layered onto a discontinuous Percoll density gradient. 100% Percoll (Sigma-Aldrich, 
Poole, UK) was diluted in a ratio of 9:1 with sterile 10x Saline solution (1.5M NaCl) to give 
90% Percoll, or “100% working Percoll” (wPercoll). 100% wPercoll was further diluted into 
80% wPercoll (by dilution in a ratio of 4:1 with 1x Saline solution (0.15M NaCl)) and 56% 
wPercoll (by dilution in a ratio of 14:11 with 1x Saline solution). The discontinuous gradient 
was prepared by carefully underlaying 5 ml 56% wPercoll with 2.5 ml 80% wPercoll in a    
15 ml Falcon™ Tube (BD Biosciences, Oxford, UK). Up to 6.5 ml the plasma containing 
leukocytes was carefully layered onto the gradient and the tube was then centrifuged at 
1100rpm for 20 minutes at 20°C (Jouan C3i Centrifuge, DJB Labcare). 
Following centrifugation, the plasma and peripheral blood mononuclear cell layer was 
removed using a pasteur pipette and the isolated neutrophil layer was then extracted with a 
fresh pipette and then washed with sterile PBS by centrifugation at 1600rpm for 10 minutes 
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at 20°C (Jouan C3i Centrifuge, DJB Labcare). The cells were then re-suspended in Roswell 
Park Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich) for all experiments except 
calcium signalling, where they were re-suspended in calcium-containing Hanks Buffered 
Saline Solution (HBSS) (Sigma-Aldrich). Neutrophils were counted in a haemocytometer 
and, if necessary, diluted further to achieve the desired concentration (between 1 and 4x10
6
 
neutrophils/ml, depending on the assay). Purity was verified by differential Giemsa staining 
and only viable samples (neither activated nor apoptotic) with a neutrophil purity of >95% 
were used. Neutrophil gradients before and after centrifugation are illustrated in Figure 2.1. 
 
 
 
Figure 2.1: A diagram illustrating the discontinuous Percoll gradient. 
Legend: Before (left) and after (right) centrifugation at 1100rpm for 20 minutes at 
20°C. The PBMC layer is disposed of before the neutrophil layer is removed, 
washed in PBS and re-suspended at the desired concentration in the appropriate 
medium. 
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2.4   SPUTUM COLLECTION AND SOL PHASE PREPARATION 
Spontaneously expectorated sputum samples were collected from COPD patients in 
sterile containers within four hours of waking.  Patients undertook mouth washing procedures 
prior to expectoration to minimise saliva contamination. A large aliquot (1 g minimum 
weight) was ultracentrifuged at 50,000 g for 90 minutes at 4ºC. The supernatant was removed 
and stored at -80ºC until required.  
 
2.5   NEUTROPHIL MIGRATION ASSAYS 
 
2.5.1   Neutrophil Migration to Different Chemoattractants 
Neutrophils were isolated and re-suspended in RPMI-1640 at a concentration of 
2x10
6
/ml. 7.5% Bovine Serum Albumin (BSA) (Sigma-Aldrich) was then added to the 
neutrophil suspension at a volume quantity of 0.15%. Coverslips were prepared by 
submersion in 0.4M sulphuric acid and then twice in fresh distilled water before being coated 
on one side with 7.5% BSA. After 20 minutes, the BSA was tipped off and 300 ml of 
neutrophil suspension at 2x10
6
/ml (equivalent to 6x10
5
 cells) was then added to the coverslip 
and a 20 minute incubation period at room temperature was allocated to allow sufficient time 
for the cells to adhere. 
The assay was performed using an Insall Chamber (Muinonen-Martin et al. 2010) at 
room temperature. The channels were cleaned twice with RPMI-1640 and then re-filled 
before each use. Excess neutrophils were tipped off the coverslip after 20 minutes incubation 
and the coverslip was inverted over the Insall Chamber channels. The RPMI-1640 in the 
loading channels was extracted and replaced by pipette with either the same medium (as a 
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control) or one of the five chemoattractants; IL-8 (R&D Systems, Abingdon, UK), GROα 
(R&D Systems), fMLP (Sigma-Aldrich), LTB4 (Sigma-Aldrich) or C5a (Sigma-Aldrich). 
Phase time-lapse recordings were made using a Zeiss Axiovert 200 Microscope (Zeiss, 
Welwyn Garden City, UK) fitted with a Hammamatsu C4742-95 digital camera 
(Hammamatsu, Welwyn Garden City, UK). Images were captured every 20 seconds for 12 
minutes (this was chosen as previous unpublished data from our group showed that 
migrational behaviour beyond this time did not alter). Figure 2.2 is a diagrammatic 
representation of the Insall Chamber, showing a magnified concentration gradient and 
microscopic image of the viewing field containing migrating neutrophils. 
Images were then analysed to determine cell movement using the Java software ImageJ 
(Wayne Rasband, National Institutes of Health, Bethesda). A total of 10 cells were chosen at 
random and digitally tracked in every other image captured (a total of 18 images spanning 12 
minutes). The resulting neutrophil migratory parameters included four separate indices. 
Firstly, the speed of migration, or “chemokinesis” (the distance travelled between two frames 
in μm/min), which equates to non-specific movement in any direction. Secondly, the 
chemotaxis (migrational speed in a consistent direction towards the chemoattractant source 
measured in μm/minute), which is a measure of the speed of migration towards the 
chemotactic source. The third was the directional persistence (the continuity of cell 
orientation over time, calculated by the cosine of the angle between directions in consecutive 
frames, on a scale of 0 to 1), which is a determinate of how frequently and rapidly the cells 
change direction during migration (the closer to a straight line and the lower the number of 
directional changes, the higher the persistence). Lastly, was the chemotactic index (cosine of 
the angle between the cell’s direction and the orientation of the chemoattractant gradient, on 
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a scale of -1 and 1), which is an overall measure of how accurately and rapidly the cell 
migrates towards the chemotactic source (a higher score indicates more accurate migration). 
 
 
 
 
Figure 2.2: A diagrammatic representation of the Insall Chamber. 
Legend: An overhead view of the chamber (top left) with magnified regions showing the 
chemotactic gradient (top right) with an arrow indicating the expected trajectory of 
neutrophil migration towards the chemoattractant. Further magnification shows a 
microscopic image of migrating neutrophils (bottom right). Examples of the migratory 
tracks are shown in red on the microscopic image with the start point at the cell and the 
endpoint at the arrowhead. 
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2.5.2   Effect of Donor Plasma on Neutrophil Migration 
For this “cross-over” assay, neutrophil migration was assessed in RPMI-1640 and 
chemoattractants that were limited to 100 nM IL-8 (an endogenous cytokine) and 100 nM 
fMLP (a bacterial cytokine). For COPD neutrophils, migration was assessed with cells 
bathed in RPMI-1640 medium, 100% plasma from the same patient and 100% plasma from 
healthy control subject that was closely age-matched. For healthy control neutrophils, 
migration was assessed with cells bathed in RPMI-1640 medium, plasma from the same 
donor and plasma from an age-matched COPD patient. Incubation in the various media was 
done at room temperature for 40 minutes (including 20 minutes in solution and 20 minutes on 
the albumin-coated coverslip). Images were analysed and results reported as described 
previously (Section 2.5.1). 
 
2.5.3   Neutrophil Migration with CXCR1 and CXCR2 Agonists 
COPD neutrophil migration was assessed in RPMI-1640, 100 nM IL-8 and 10 nM 
GROα. Migration in IL-8 and GROα was assessed with and without pre-incubation for 40 
minutes in either 2 µg/ml of CXCR1 inhibitor (Monoclonal Mouse IgG2A Clone # 42705) or 
50 µg/ml of CXCR2 inhibitor (Monoclonal Rat IgG2A Clone # 242216) (both R&D 
Systems). In addition, migration in IL-8 was also assessed following incubation for 40 
minutes with a dual CXCR1/2 inhibitor (SCH527123) (AbMole Bioscience, Kowloon, Hong 
Kong). SCH527123 was diluted initially in DMSO then RPMI-1640 to two different IC50 
concentrations; 3nM (specific to CXCR2) and 42nM (required for concurrent CXCR1 
inhibition). These concentrations were recommended by the manufacturer. Neutrophils that 
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were not incubated with the CXCR1/2 inhibitors were incubated with the equivalent 
concentration of DMSO for the same duration of time as a carrier control. 
 
2.5.4   Neutrophil Migration with PI3K Isoform Inhibitors 
COPD neutrophil migration was assessed in RPMI-1640, 100nM IL-8 alone and 100 nM 
IL-8 following pre-incubation for 40 minutes with PI3Kα, -β, -γ and -δ isoform inhibitors 
(Stratech Scientific Ltd, Newmarket, UK) or a the equivalent concentration of DMSO as a 
carrier control. PI3K inhibitors were used at the IC50 final concentrations (prepared initially 
in DMSO then diluted with RPMI-1640) recommended by the manufacturer, which are 
shown in Table 2.1. 
 
 
Isoform Inhibitor 
 
Product Name 
 
IC50 (nM) 
α PIK-75 7.8 
β TGX-221 8.5 
γ AS-25 33 
δ CAL-101 65 
 
Table 2.1: PI3K isoform inhibitors. 
Legend: The four PI3K isoform inhibitors used in the chemotaxis assay 
together with their IC50 as recommended by the manufacturer. 
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2.5.5   Neutrophil Migration with p38 and ERK Inhibitors 
COPD neutrophil migration was assessed in RPMI-1640, 100nM IL-8 alone and 100 nM 
IL-8 following pre-incubation for 40 minutes with either an ERK inhibitor (UO126) or one of 
two different p38 inhibitors (SCIO469 or VX745) (Tocris Bioscience, Abingdon, UK) or the 
equivalent concentration of DMSO as a carrier control. The ERK and p38 inhibitors were 
diluted initially in DMSO then RPMI-1640 to the IC50 final concentrations recommended by 
the manufacturer, which are shown in Table 2.2. 
 
 
Inhibitor 
 
Product Name 
 
IC50 (μM) 
Erk UO126 0.07 
p38 SCIO469 0.09 
p38 VX745 0.01 
 
Table 2.2: ERK and p38 inhibitors. 
Legend: The ERK and p38 inhibitors used in the chemotaxis assay 
together with their IC50 as recommended by the manufacturer. 
 
 
2.5.6   Neutrophil Migration with Simvastatin 
Neutrophils from COPD patients were incubated for 40 minutes with simvastatin 
(Sigma-Aldrich) before their migratory dynamics in gradients of IL-8 and fMLP were 
assessed. The concentrations of simvastatin used were based on doses used in general 
therapy, with 1 nM equivalent to the minimum therapeutic dose of 20 mg/day and 1 µM 
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equivalent to the maximum therapeutic dose of 80 mg/day. Patients were excluded from this 
experiment if they were currently on statin therapy. 
 
2.6   NEUTROPHIL PHENOTYPE 
To determine if neutrophils from the peripheral blood of COPD patients were of a 
different phenotype to those from healthy controls, the expression of different surface 
markers was quantified by flow cytometry. These included markers of cell activation 
(CD11b, CD62L), neutrophils maturity (CD16) and a marker of degranulation (CD63). 
Active CD11b was used as, only when it dimerises with CD18 to form Mac-1, does it 
become a marker of neutrophil activation. To minimise the risk of activation during the assay 
preparation, neutrophils were not isolated. Instead, whole blood was used and the neutrophil 
population was gated for analysis. 
50 µl of whole blood was added to each FACS tube. 500 µl of 1% PBS-BSA was then 
added to each tube and the cells were then pelleted by centrifugation at 4˚C for 5 minutes at 
250g (Jouan C3i Centrifuge, DJB Labcare). The supernatant was then carefully removed with 
a pasteur pipette and Fluorescein Isothiocyanate Isomer (FITC) conjugated monoclonal 
antibody for 20 µl Active CD11b (Clone CBRM1/5, 400 µg/L), 5 µl CD16 (Clone 3G8,    
400 µg/L) and 20 µl CD63 (Clone H5C6, 200 µg/L) were added into the appropriate FACS 
tubes (all from BioLegend, London, UK). 20 µl Phycoerythrin (PE) conjugated CD62L 
(BioLegend, Clone DREG-56, 25 µg/L) was added into the tube containing the FITC CD16. 
IgG1 isotype-matched irrelevant antibodies were also used at the same concentrations to 
control for non-specific binding.  FITC IgG1 (BioLegend, Clone MOPC-21, 500 µg/L) alone 
was added to one FACS tube of whole blood, and both FITC and PE IgG1 (Clone MOPC-21, 
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200 µg/L) was added to the other. The FACS tubes were then left on ice for 30 minutes in the 
dark to allow for antibody/receptor binding. The cells were then washed twice with 500 µl 
1% PBS-BSA by centrifugation at 4˚C for 5 minutes at 250g (Jouan C3i Centrifuge, DJB 
Labcare), with the supernatant removed and replaced with fresh 1% PBS-BSA between 
washes. After the second spin, the supernatant was removed and replaced with 2 ml of BD 
FACS lysing solution (BD Biosciences, Oxford, UK) (diluted 1:10 with distilled water) to 
remove the erythrocytes. After 10 minutes, the tubes were centrifuged at 4˚C for 5 minutes 
(Jouan C3i Centrifuge, DJB Labcare) and then washed twice more with 500 µl 1% PBS-BSA 
(between washes, the excess fluid was simply tipped off). After the final wash, the cells were 
re-suspended in 300 µl 1% PBS-BSA, placed on ice and analysed immediately with a BD 
Accuri C6 Flow Cytometer (BD Biosciences). 
10,000 cells were analysed in each sample and the neutrophil population was identified 
by assessing forward and sideways light scattering, with forward scatter equating to cell size 
and side scatter to cell granularity. Gating was used to ensure only the signals from the 
neutrophil population were included. Neutrophil fluorescence from those labelled with 
specific receptor antibodies were determined relative to those labelled with the analogous 
non-specific antibody by subtraction of the isotype Median Fluorescence Intensity (MFI) 
value from that of the receptor antibody. A representative image of fluorescent cells 
(showing forward and side scatter) and neutrophil gating is shown in Figure 2.3. 
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Figure 2.3: A graphical display of a typical FACS plot. 
Legend: The neutrophil population was determined by cell size (forward scatter) and 
granularity (side scatter). The neutrophils were gated around in order to exclude debris 
and other cell types in the analysis. Each pixel is one cell and a total of 10,000 
neutrophils were analysed for each sample. 
 
 
2.7   CHEMOKINE RECEPTORS 
 
2.7.1   Receptor Expression on Quiescent Neutrophils 
2x10
5
 isolated neutrophils in 100 μl RPMI-1640 (Sigma-Aldrich) were added to 
appropriate wells of a 96 well plate. An additional 100 μl of cold 1% PBS-BSA was added to 
each well. The plate was then spun in a centrifuge pre-cooled to 4˚C for 5 minutes at 250g 
(Jouan C3i Centrifuge, DJB Labcare). Pelleted cells were then resuspended in 50 μl of cold 
1% PBS-BSA, followed by the addition of appropriate Fluorescein Isothiocyanate Isomer 
(FITC) conjugated monoclonal antibody for CXCR1 2 μg/ml (Clone 42705), CXCR2             
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3 μg/ml (Clone 48311), fMLP receptor (FPR1) 3 μg/ml (Clone 350418), LTB4 receptor 
(LTB4R1) 3 μg/ml (Clone 203/14F11) and C5a receptor (C5aR) 3 μg/ml (Clone 347214)  (all 
from R&D Systems). An IgG2A isotype-matched irrelevant antibody (Dako, Ely, UK, Clone 
DAK-GO5) was used as a control for CXCR1, CXCR2, FPR1 and C5aR antibodies and an 
IgG1 isotype-matched irrelevant antibody (Dako, Clone DAK-GO1) was used as a control 
for LTB4R1 antibody. The suspension was mixed and incubated in the dark at 4˚C for 15 
minutes. 
After incubation, an additional 150 μl of cold 1% PBS-BSA was added to each well and 
the plate was spun again in a centrifuge pre-cooled to 4˚C for 5 minutes at 250g (Jouan C3i 
Centrifuge, DJB Labcare). Following this spin, the pelleted cells were resuspended in 200 μl 
of cold 1% PBS-BSA and transferred to individual tubes (already containing 200 μl of cold 
1% PBS-BSA) for analysis by flow cytometry using a Coulter Epics XL machine (Coulter 
Corp., Florida, USA). 
 
2.7.2   Receptor Expression Following Stimulation 
The change in neutrophil surface receptor expression of CXCR1, CXCR2 and FPR1 was 
measured over a two hour time-course following stimulation with either IL-8 or fMLP at 
various time-points. These chemoattractants were selected based on their potency and the fact 
that they originate from both an endogenous and bacterial source. The assay was performed 
using neutrophils from COPD patients, healthy subjects and patients with α1-ATD. 
The wells of a 96 well U-bottomed FACS plate were pre-coated with heat-inactivated 
Fetal Calf Serum (FCS) (Sigma-Aldrich) to minimise cell adhesion. 50 µl of neutrophil 
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suspension (4x10
6
 neutrophils/ml suspended in RPMI-1640 +10% FCS) was then added to 
each well of the FACS plate required for the time-course. Stimulants used were IL-8 and 
fMLP at final concentrations of 100 nM, which were added to specific wells at the 
appropriate time-points. The FACS plate was incubated at 37°C for the duration of the time-
course to allow receptor internalisation, shedding and re-expression to occur. The cells were 
kept in suspension by gently tapping the FACS plate every 30 minutes. 
At the end of the time-course, the FACS plate was removed from the incubator and 
immediately placed on ice while specific anti-human antibodies were added to the 
appropriate wells. These included CXCR1 PE conjugated (at 2 µg/ml), CXCR2 FITC 
conjugated (at 3 µg/ml) and FPR1 FITC conjugated at (3 µg/ml). The isotype-matched 
irrelevant antibody, IgG2A (R&D Systems, Clone MOPC-21) was used at the same 
concentration to each of the respective anti-receptor antibodies. 
The FACS plate was then left on ice in the dark for 15 minutes to allow surface binding 
of the antibodies to occur. Each well was then topped up with 150 µl of cold 2% PBS with 
Bovine Serum Albumin (PBS-BSA) (Sigma-Aldrich) and centrifuged at 250g for 5 minutes 
in a pre-cooled centrifuge at 4°C (Jouan C3i Centrifuge, DJB Labcare). Following 
centrifugation, the supernatant was carefully collected (ensuring the pellet was not disturbed) 
from each time-point and placed in labelled eppendorf tubes. These were stored at -80°C for 
future quantification of receptor shedding by ELISA (see Section 2.6.4). Neutrophils were 
then re-suspended in 200 µl of 2% cold PBS-BSA and placed into labelled FACS tubes 
already containing 200 µl of cold 2% PBS-BSA and kept on ice for immediate analysis with 
a BD Accuri C6 Flow Cytometer (BD Biosciences). 
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2.7.3   Chemokine Receptor Recycling 
It has previously been demonstrated that chemokine receptor re-expression occurs on the 
cell surface once the stimulus is removed (Chuntharapai et al. 1995). To assess this 
mechanism, 100 µl of neutrophil suspension (2 x 10
6
/ml) in FACS tubes was treated with 
either 100 nM IL-8 or 100 nM fMLP at 37°C for 30 minutes. Cells were then washed with 
RPMI-1640 containing 10% FCS and the cells re-suspended in 100 µl RPMI-1640+ 10% 
FCS. 50 µl of the neutrophil suspension was then placed in corresponding wells on the FACS 
plate for 90 minutes at 37°C in an incubator. The cells were then stained for CXCR1, 
CXCR2 and FPR1 described in Section 2.7.1. 
 
2.7.4   Chemokine Receptor Shedding 
 
CXCR1 
A commercial CXCR1 ELISA kit (Cusabio Biotech Co. Ltd, East Sussex, UK) was used 
to quantify CXCR1 shedding during the two hour time-course. All reagents were removed 
from 4°C storage and allowed to warm to room temperature for 30 minutes prior to use. All 
vials were vortexed before use to ensure the contents were mixed well. The working wash 
buffer was prepared by diluting 20 ml of the wash buffer concentrate into 480 ml of 
deionised water. The Biotin-antibody working solution was made by diluting the Biotin-
antibody 100-fold using the Biotin-antibody diluent. Working HRP-Avidin was made by 
diluting HRP-Avidin 100-fold using the HRP-Avidin diluent. 
Supernatants collected from COPD patients and healthy control subjects at the 30 and 
120 minute time-points during the time-course (as described in Section 2.7.2) were removed 
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from -80°C storage and allowed to warm to room temperature. 100 µl of the standard, blank 
or patient sample were added in duplicate to corresponding wells on a 96 well ELISA plate. 
50 µl of conjugate was then added to each well and mixed thoroughly. The plate was then 
sealed with an adhesive strip and left to incubate for 2 hours at 37°C. Following this, the 
liquid from each well was carefully removed with a pipette and the remaining drops were 
removed by patting the plate on a paper towel. 100 µl of the Biotin-antibody working 
solution was then added to each well and left to incubate for 1 hour at 37°C. The wells were 
then washed with an automated microplate washer (Asys Atlantis 4, Biochrom, Cambridge, 
UK) with 200 µl of working wash buffer and left to stand for 150 seconds. This was repeated 
3 times, after which the remaining liquid was removed by patting the plate on a paper towel. 
100 µl of HRP-Avidin working solution was then added to each well and the microtitre plate 
was then left to incubate for 1 hour at 37°C. The same aspirating and wash cycle was then 
repeated 5 times. Following this, 90 µl of 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate 
was added to each well and left to incubate in the dark 37°C. Once the wells containing the 
highly concentrated standards (S7-S6) turned blue, 50 µl of the stop solution was added to 
each well. The optical density was then determined immediately using a microplate reader 
(BioTek EL808, Potton, UK) set at 450nm. 
 
CXCR2 
A commercial CXCR2 ELISA kit (Novateinbio, Massachusetts, USA) was used to 
quantify CXCR2 shedding during the two hour time-course. The assay procedure was very 
similar to the CXCR1 kit, although there were slight differences. As before, all reagents were 
removed from 4°C storage and allowed to warm to room temperature for 30 minutes prior to 
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use and all vials were vortexed before use to ensure the contents were well mixed. All 
standards and solutions were provided pre-prepared in the kit apart from the 10 ml of wash 
solution, which had to be diluted with 990 ml distilled water to form 1 litre. The 
concentrations of the standards were as follows; S7 = 50 ng/ml, S6 = 25 ng/ml, S5 = 12.5 
ng/ml, S4 = 6.25 ng/ml, S3 = 3.125 ng/ml, S2 = 1.563 ng/ml and S1 = 0.781 ng/ml. 
100 µl of the standard, blank or patient sample were added in duplicate to corresponding 
wells on a 96 well ELISA plate. 50 µl of conjugate was then added to each well and mixed 
thoroughly. The plate was then sealed with an adhesive strip and left to incubate for 1 hour at 
37°C. The plate was then washed five times with an automated microplate washer 
(Biochrom) with 400 µl of working wash buffer with a soaking time of 10 seconds and a 
shaking time of 5 seconds in between washes. 50 μl Chromogenic Substrate A and then 50 μl 
Chromogenic Substrate B was added to each well. The plate was then covered and incubated 
for 10 minutes at room temperature away from sunlight. 50 µl of the stop solution was then 
added to each well and mixed thoroughly. The optical density was then determined 
immediately using a microplate reader (BioTek) set at 450nm. 
 
2.7.5   Chemokine Receptor Localisation 
Chemokine receptor localisation was assessed by fluorescence microscopy following 
binding of conjugated monoclonal antibodies for CXCR1 and CXCR2. This was done with 
quiescent and polarised neutrophils from both healthy and COPD donors. 
Coverslips were prepared by submersion in 0.4M sulphuric acid and then twice in fresh 
distilled water before being coated on one side with 80 µg/ml of fibronectin (Sigma-Aldrich), 
after which they were left for 45 minutes at room temperature. The fibronectin was then 
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removed and the coverslip immersed in PBS to rinse. 300 µl of neutrophil suspension 
(2x10
6
/ml in RPMI-1640) was immediately layered onto the fibronectin and 15 minutes were 
allowed for the cells to adhere. The excess RPMI (including any neutrophils that had not 
adhered) was then removed and replaced with either 100 nM fMLP (to induce polarisation 
without affecting the receptors of interest) or RPMI-1640. After 5 minutes, the fMLP or 
RPMI-1640 was replaced with 4% Paraformaldehyde (PFA) and the coverslips were left for 
30 minutes to fix the neutrophils. The PFA was then replaced with either 2 µg/ml CXCR1 PE 
conjugated or 3 µg/ml CXCR2 FITC conjugated. The coverslips were then left in the dark for 
15 minutes to allow sufficient time for antibody/receptor binding to occur. 
The FITC-stained neutrophils showed weak fluorescence. Therefore, these cells were 
subsequently bathed in 300 µl of Anti-FITC Alexa Fluor 488 (Life Technologies Ltd., 
Paisley, UK) (diluted from stock 1:100 with PBS) in the dark for 20 minutes. Excess solution 
was then removed and the coverslips were inverted and fixed to labelled microscope slides 
with one drop of Fluoromount (Sigma-Aldrich) and left to dry for 10 minutes before 
observation under a fluorescence microscope (Leica Microsystems, Milton Keynes, UK) 
using a x40 objective lens. Cells were selected at random starting at the bottom left corner 
and gradually moving upwards (by traversing the viewing field left to right then right to left) 
until the first clearly visible population of neutrophils was found. 
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2.8   PI3K & AKT PHOSPHORYLATION BY WESTERN BLOT 
 
2.8.1   Neutrophil Stimulation and Lysis 
Once isolated, neutrophils were suspended at 4x10
6
 cells/ml in RPMI-1640. 1 ml (4x10
6
 
cells) was added to each of four eppendorf tubes, which were then centrifuged at 4000 rpm 
for 5 minutes in a Micro Centaur (Sanyo, UK). Excess RMPI-1640 was discarded and the 
cells were resuspended in 90 µl of RPMI-1640. 10 µl of stimulant (to give final 
concentrations of 100 nM IL-8, 100 nM fMLP and 10 nM GROα) or RPMI-1640 (control) 
were added to appropriate eppendorf tubes. For both pPI3KT458 and pAktS473, neutrophils 
were stimulated at room temperature for 3 minutes whereas, for pAktT308, they were 
stimulated at room temperature for 20 seconds (see Section 4.4.1 for stimulation time-
courses). After this time, 900 µl of cold PBS was added to each eppendorf and the samples 
were quickly transferred (in an ice tray) to a centrifuge (Jouan C3i Centrifuge, DJB Labcare, 
Buckinghamshire, UK) and spun at 4000 rpm for 3 minutes at 4°C. Following this spin, 
excess PBS was removed and the neutrophils were resuspended in 64 µl of MOPS-based 
lysis buffer (8 µl per 0.5 x 10
6
 cells). The components of the MOPS-based lysis buffer are 
shown in Table 2.3. 
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Chemical Function 
20mM 3-[N-Morpholino] Propanesulfonic Acid (MOPS) 
(Sigma-Aldrich) 
Buffer 
50mM Sodium Fluoride (Sigma-Aldrich) 
Phosphatase 
Inhibitor 
50mM -glycerophosphate (Sigma-Aldrich) 
Phosphatase 
Inhibitor 
10mM Sodium Orthovanadate (Sigma-Aldrich) 
Phosphatase 
Inhibitor 
1% Triton X-100 (Sigma-Aldrich) Detergent 
7.3ml dH2O 
 
1mM 4-(2-Aminoethyl) Benzenesulfonyl Fluoride 
Hydrochloride (AEBSF) (Sigma-Aldrich) 
Protease inhibitor 
1mM Dithiothreitol (DTT) (Sigma) Reducing agent 
1:100 Calbiochem Protease inhibitor Set III (Millipore, 
Watford, UK) 
Protease inhibitor 
1:100 Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich) 
Phosphatase 
Inhibitor 
1:100 Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich) 
Phosphatase 
Inhibitor 
 
Table 2.3: Components of the MOPS-Based Lysis Buffer 
Legend: A solution containing the first 6 components was made up in advance and 
stored at 4°C. The other components were added just before use. 
 
 
 
The eppendorf tubes were then vortexed and left on ice for 5 minutes. This step was 
repeated twice more. 64 µl of hot 2X SDS lysis buffer was then added to each eppendorf 
tube, which were then transferred into a heating block and boiled for 10 minutes at 100°C. 
The samples were then stored at -80°C until required for western blotting. The components of 
the SDS-lysis buffer are shown in Table 2.4. 
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2X Sodium Dodecyl Sulfate (SDS) Lysis Buffer 
4% SDS (Sigma-Aldrich) 
0.1M DTT (Sigma-Aldrich) 
20% Glycerol (Sigma-Aldrich) 
0.0625M Tris-HCL (pH 6.8) 
0.004% Bromophenol Blue (Sigma-Aldrich) 
 
Table 2.4: Components of the 2x SDS Lysis Buffer 
Legend: The buffer solution was made up in advance, stored at         
-20°C and heated before use. 
 
 
2.8.2   Running Samples by Western Blot 
Subject samples (COPD and healthy control) were removed from -80°C storage, allowed 
to warm to room temperature and subsequently boiled at 100°C for 5 minutes. Samples were 
then centrifuged at 13,000 rpm for 5 minutes to pellet any debris and 20 µl of each sample 
were added to corresponding lane in a Criterion TGX Precast Gel (Bio-Rad, Hemel 
Hempstead, UK). The first lane was allocated for 20 µl of protein marker (Bio-Rad) and 
samples from a COPD patient and a healthy control were run in parallel. 
Gels were run for 3½ hours at 100 volts in a running buffer comprising 1X 
Tris/Glycine/SDS (Sigma-Aldrich) and 9X distilled H2O (dH2O). Once the gel had run, 
proteins were transferred to a nitrocellulose membrane (Geneflow, Lichfield, UK) in a 
blotting buffer (1X Tris/Glycine (Sigma-Aldrich), 1X Methanol and 8X dH2O) using the Bio-
Rad transfer kit, standing in ice to minimise the formation of large bubbles between the gel 
and blotting membrane. The membrane was then blocked with 1X Tris-Buffered Saline 
(TBS)-1%Tween-20 containing 5% BSA under agitation for one hour at room temperature. 
Anti-phospho-AktS473 or anti-phospho-AktT308 (both New England Biolabs, Hitchin, UK) was 
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then added at the recommended concentration of 1:1000 and the membrane was left under 
agitation overnight at 4°C. The following morning, the membrane was washed for 15 minutes 
in 1X TBS-1%Tween-20 three times before the addition of Anti-Rabbit IgG Horseradish 
Peroxidase-Linked secondary antibody (GE Healthcare, Chalfont St Giles, UK) at a 
concentration of 1:2000. After one hour incubation under agitation at room temperature, the 
membrane was once again washed three times with 1X TBS-1%Tween-20. It was then 
covered in Enhanced Chemiluminescence (ECL) solution (Geneflow) for 5 minutes before 
analysis in a Bio-Rad Chemidoc system. 
To determine the cellular loading of each lane, the membrane was subsequently stripped 
with a mild stripping buffer (15 g glycine, 1 g SDS, 10 ml Tween20, adjusted to pH to 2.2 
and brought to 1 L with ultrapure water (all from Sigma-Aldrich)), re-blocked with 1X TBS-
1%Tween-20 containing 5% BSA under agitation for one hour at room temperature. Total 
(pan)-Akt (New England Biolabs, Hitchin, UK) was then added at the recommended 
concentration of 1:1000 and the membrane was left under agitation overnight at 4°C. The 
following morning, the same protocol was followed for washing, probing with Anti-Rabbit 
IgG Horseradish Peroxidase-Linked secondary antibody, ECL exposure and analysis. 
For phospho-PI3KT458 analysis, the same methods were used with an anti-phospho 
PI3KT458 antibody (New England Biolabs) with equal loading checked using an anti-β-Actin 
antibody (Sigma-Aldrich) at a 1:5000 dilution with an Anti-Mouse IgG Horseradish 
Peroxidase-Linked secondary antibody (GE Healthcare). 
Optical density of phospho-Akt, phospho-PI3K and their respective loading controls 
were analysed using the Image J freeware Version 1.43u (National Institute of Health, USA). 
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2.9   INTRACELLULAR CALCIUM SIGNALLING 
Neutrophils were isolated as described previously but re-suspended at 1x10
6
 cells/ml in 
RPMI-1640 + 0.5% BSA. One vial of the a UV light-excitable, ratiometric Ca
2+
 indicator, 
Indo-1 AM (Life Technologies Ltd, Paisley, UK) was reconstituted with 110 µl of anhydrous 
Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich). This was then added to the neutrophil 
suspension in the ratio of 7 µl per 1 ml of suspension, mixed well and incubated in the dark 
(in a foil-wrapped 50 ml Falcon Tube) at room temperature. Following this, the cell 
suspension was increased to 50 ml with additional RPMI-1640 + 0.5% BSA and then 
centrifuged at 1600 rpm for 10 minutes (Jouan C3i). The neutrophils were then re-suspended 
in fresh RPMI-1640 + 0.5% BSA and left in the dark for a further 30 minutes. They were 
then centrifuged again at 1600 rpm for 10 minutes and then re-suspended in calcium-
containing HBSS (Sigma-Aldrich) at 1 x 10
6
/ml. 
For real-time analysis of Ca
2+
 release following stimulation, 2 ml of neutrophils 
suspension was transferred into a cuvette and placed in a pre-warmed water bath at 37°C for 
5 minutes. The cuvette was then transferred to the fluorimeter (Perkin Elmer LS50B 
Luminscence Spectrometer, Beakonsfield, UK) and a magnetic stirrer was added to ensure 
the neutrophils remained in suspension. Once a stable baseline had established 
(approximately 1 minute), the neutrophils were stimulated with 100 nM IL-8 to induce 
intracellular Ca
2+
 release. Once the signal had returned to baseline (indicating that Ca
2+
 
release had ceased), the neutrophils were stimulated with 2.7 mM ionomycin (a positive 
control stimulant) was added. Once Ca
2+
 release had peaked and plateaued, ethylene glycol 
tetra-acetic acid (EGTA) (1mM final concentration) was added to return the signal to 
baseline. This process is illustrated in Figure 2.4. 
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Figure 2.4: The process of Ca
2+
 signal measurement. 
Legend: A graphical representation of real-time Ca
2+
 analysis. 2 x 10
6
 neutrophils 
were stimulated with IL-8 to induce Ca
2+
 release from intracellular stores. Once Ca
2+
 
release had ceased, ionomycin was added as a positive control and, at its peak, Ca
2+
 
release was halted with the addition of EGTA. 
 
Fluorescence measurements were then converted into Ca
2+
 concentration by comparison 
of the maximum and minimum fluorescence at two emission wavelengths in relation to the 
positive control (ionomycin). From these data, both peak (increase from baseline) and total 
(area under the curve) calcium release were determined and compared between neutrophils 
from healthy, COPD and α1-ATD subjects. 
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2.10   STATISTICAL ANALYSIS 
Statistical analyses were performed using either the SPSS statistical program (version 
16.0, Chicago, USA) or GraphPad Prism (version 5.03, La Jolla, USA). Initially, a 
Kolmogorov-Smirnov test was used to determine if data sets were normally distributed. The 
distribution of data then dictated whether parametric tests (for normally distributed data) or 
non-parametric tests (for data not normally distributed) were used. For group comparisons, 
the specific test was then dependent on; (i) the number of data groups that were to be 
compared and (ii) whether or not the data groups were from different patients (unpaired) or 
separate data from the same patients (paired; e.g. pre- and post-therapeutic intervention). 
Lastly, the application of a one-tailed or two-tailed test depended on the expected outcome. 
For example, if results from one group were expected to be higher or expected to be lower 
(e.g. an increase from baseline following the application of a validated intervention such as a 
functional inhibitor) the test was one-tailed. In instances where the outcome could not be 
predicted, a two-tailed test was used, where the “p” value was twice that of a one-tailed test 
(meaning the probability of the outcome occurring by chance was essentially doubled). 
Therefore, for data that were normally distributed, either a t-test (unpaired for 
comparisons of two separate cohorts or paired for comparisons of two data sets from the 
same patients) or a one-way Analysis of Variance (ANOVA) (for comparisons between 3 
cohorts) with subsequent Tukey’s test (to determine which comparisons were significantly 
different from each other) were performed to compare the results. When the data were not 
normally distributed, either a Mann-Whitney U test (unpaired for comparisons of two 
separate cohorts or paired for comparisons of two data sets from the same patients) or a 
Kruskal-Wallis test (for comparisons between 3 cohorts) with subsequent Dunn’s test (to 
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determine which comparisons were significantly different from each other) were conducted. 
For linear regression, a Pearson’s correlation was used for data that were normally distributed 
and a Spearman’s Rank correlation was used for data that were not normally distributed. In 
this thesis, a p value of 0.05 or less (p ≤ 0.05) was classified as statistically significant. 
To ensure the experiments were adequately powered, power calculations for sample size 
were performed using the following formula; 
   
n = 1+2C x (s / D) 
 
D is the smallest difference detected, s represents the standard deviation of the 
observations and C = 7.85 to provide an 80% power of detecting a difference at the 5% level 
of significance (Snedecor and Cochran 1989). 
  
 
 
 
 
 
 
CHAPTER 3 
 
ABERRANT NEUTROPHIL 
MIGRATION IN COPD 
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3.1   BRIEF INTRODUCTION 
COPD is a chronic inflammatory disease and there is a wealth of evidence implicating 
the neutrophil as a key effector cell in its pathogenesis. Neutrophils migrate towards the 
lung along a series of chemotactic gradients that are established through the secretion of 
pro-inflammatory cytokines by the endothelium, host inflammatory cells and invading 
pathogens. 
Previous work investigating neutrophil migration in COPD has yielded conflicting 
results. An early study (Burnett et al. 1987) suggested that neutrophils from COPD patients 
migrate more efficiently than neutrophils from healthy donors, whereas a later study 
described a reduced chemotaxis of COPD neutrophils (Yoshikawa et al. 2007). More 
recently, a study looking specifically at how the neutrophils migrate by two-dimensional 
tracking has demonstrated that neutrophils from the peripheral blood of COPD patients 
migrate with increased speed but impaired accuracy in comparison to those from healthy 
subjects (Sapey et al. 2011). Although this study provided far more insight into how the 
cells were migrating rather than how many moved from one location to another, only IL-8 
and GROα were used to generate chemotactic gradients. Therefore, it is unclear whether 
the aberrant neutrophil migration in COPD is a general phenomenon or simply related to 
IL-8, GROα and their respective receptors (CXCR1 and CXCR2). 
The studies described in this chapter were conducted to initially investigate whether 
the aberrant migration of COPD neutrophils occurs in gradients of other endogenous 
chemoattractants as well as those of bacterial origin. Further studies were then conducted to 
determine if any differences in migration between neutrophils from COPD and healthy 
donors were due to intrinsic cell defects or a result of systemic inflammation. 
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3.2   SUBJECT DEMOGRAPHICS 
Demographic data for the COPD patients, healthy age-matched control subjects and 
patients with α1-ATD included in this chapter are shown in Table 3.1.  
 
  COPD Healthy Control α1-ATD 
        
Number 71 70 10 
        
Age (years) 66 (41 - 85) 58 (35 - 87) 61 (47 - 71) 
Sex (% Male) 65 64 60 
Smoking status  31 CS, 50 XS 6 NS, 14 CS, 21 XS 5 NS, 5 XS 
Pack years 60 (4.8) 5 (1.1) 13 (4.6) 
     
FEV1 % predicted 49.5 (2.1) 101.2 (2.0) 40.6 
FEV1 /FVC % 42.9 (1.5) 73.6 (0.9) 30.0 (2.3) 
        
 
Table 3.1: Subject Demographics. 
Legend: A table showing the demographic data for all subjects included in this chapter. 
Data are normally distributed and presented as the mean and SEM, except the age which 
is mean (range). NS = Never-smokers, CS = Current smokers, XS = Ex-smokers. 
 
 
 
3.3   NEUTROPHIL MIGRATION 
 
3.3.1   Validation: Selection of Chemoattractant Concentrations 
To determine the most appropriate concentration of each chemoattractant (IL-8, 
GROα, fMLP, LTB4 and C5a), neutrophil chemotaxis was assessed in response to a range 
of concentrations using neutrophils from healthy donors (n=5). The chemotactic index 
(migratory accuracy) data for the concentration responses of each chemoattractant are 
shown in Figure 3.1. 
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Figure 3.1: Chemoattractant concentration 
response curves. 
 
Legend: Chemotactic Index (accuracy of 
migration) in gradients of IL-8, GROα, 
fMLP, LTB4 and C5a. Chemotactic Index 
ranges from -1 to 1 and the optimal 
concentrations were determined from the 
highest chemotactic index value. Results are 
reported as the mean and the standard error of 
the mean (SEM) (n=5). 
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From these assays, the optimal concentration of each chemoattractant was determined 
from the highest chemotactic index value, which equates to the most accurate neutrophil 
migration. IL-8, fMLP and C5a displayed a typical “bell-shaped” concentration response 
curve, though this was less obvious for LTB4 (though 10 nM seemed most effective) and 
absent for GROα, which also displayed high variability. The optimal concentrations of the 
five chemoattractants were as follows; IL-8: 100nM, GROα: 10nM, fMLP: 100nM, LTB4: 
10nM, C5a: 1nM. Henceforth, subsequent assays were performed using the 
chemoattractants at these concentrations. 
 
3.3.2   Neutrophil Migration in COPD, Health and α1-ATD 
Neutrophil migration was assessed using the Insall Chamber in the presence of 
medium alone (RPMI), IL-8, GROα, fMLP, LTB4 and C5a (as described in Section 2.5.1) 
in a total of 10 subjects in each group. 
 
Chemokinesis 
The random speed of migration (chemokinesis) of COPD neutrophils was significantly 
higher in comparison to healthy control subjects for each of the five chemoattractants; IL-8 
(p = 0.01), GROα (p = 0.009), fMLP (p = 0.004), LTB4 (p = 0.008) and C5a (p = 0.02). 
The same phenomenon was also observed when comparing the COPD to the α1-ATD 
group, where COPD neutrophils moved at greater speed than those from α1-ATD patients; 
IL-8 (p = 0.001), GROα (p = 0.006), fMLP (p = 0.01), LTB4 (p = 0.01) and C5a (p = 
0.009). No differences were observed in neutrophil chemokinesis between healthy subjects 
and α1-ATD patients. These data are summarised in Figure 3.2. 
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Figure 3.2: Neutrophil chemokinesis in health, COPD and α1-ATD. 
Legend: Chemokinesis (speed of movement) in the presence of medium alone (RPMI), IL-
8, GROα, fMLP, LTB4 and C5a. Results are shown as the mean and SEM (n=10). * 
indicates p ≤ 0.05 for COPD compared to Healthy Control (HC) and ** indicates p ≤ 0.05 
for COPD compared to α1-ATD patients. (Analysed by one-way ANOVA). 
 
 
Chemotaxis 
Significant differences were also observed in neutrophil chemotaxis (speed of 
migration towards the chemoattractant source), for all chemoattractants. COPD neutrophils 
moved with markedly reduced chemotaxis compared to neutrophils from healthy subjects; 
IL-8 (p = 0.001), GROα (p = 0.04), fMLP (p = 0.007), LTB4 (p = 0.02) and C5a (p = 0.03). 
The same reductions in chemotaxis were observed when comparing COPD neutrophils to 
those from α1-ATD patients; IL-8 (p = 0.006), GROα (p = 0.04), fMLP (p = 0.01), LTB4 (p 
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= 0.01) and C5a (p = 0.02). Interestingly, neutrophils from α1-ATD patients showed a 
tendency to move with greater chemotaxis than those from healthy control subjects and, in 
the presence of IL-8 and fMLP, these differences were significant; IL-8 (p = 0.04), fMLP 
(p = 0.05). The neutrophil migratory chemotaxis data are summarised in Figure 3.3. 
 
 
 
Figure 3.3: Neutrophil chemotaxis in health, COPD and α1-ATD. 
Legend: Chemotaxis (directed cell movement) towards medium alone (RPMI), IL-8, 
GROα, fMLP, LTB4 and C5a. Results are shown as the mean and SEM (n=10). * indicates 
p ≤ 0.05 for COPD compared to HC and ** indicates p ≤ 0.05 for COPD compared to α1-
ATD patients. ψ indicates ≤ 0.05 for α1-ATD patients compared to HC. (Analysed by one-
way ANOVA). 
 
 
111 
 
Persistence 
 No significant differences were observed in neutrophil persistence for any of the 
five chemoattractants in comparisons between any group. These results are summarised in 
Figure 3.4. 
 
 
Figure 3.4: Neutrophil persistence in health, COPD and α1-ATD. 
Legend: Persistence in the presence of medium alone (RPMI), IL-8, GROα, fMLP, LTB4 
and C5a. Results are shown as the mean and SEM (n=10). No significant differences were 
observed in comparisons between groups for any of the chemoattractants. (Analysed by 
one-way ANOVA). 
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Chemotactic Index 
 Significant differences in the chemotactic index (accuracy of migration) were 
observed for all chemoattractants. COPD neutrophils moved less accurately compared to 
those from healthy subjects; IL-8 (p = 0.004), GROα (p = 0.003), fMLP (p = 0.002), LTB4 
(p = 0.03) and C5a (p = 0.01). Even greater differences in migratory accuracy were 
observed when comparing the α1-ATD group to the COPD; IL-8 (p = 0.004), GROα (p = 
0.002), fMLP (p < 0.001), LTB4 (p = 0.01) and C5a (p = 0.005). Although neutrophils from 
α1-ATD donors appeared to be moving with greater accuracy in some instances than those 
from healthy donors, the comparisons did not achieve statistical significance. The 
migratory accuracy data are summarised in Figure 3.5. 
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Figure 3.5: Chemotactic Index in health, COPD and α1-ATD. 
Legend: Chemotactic index (overall migratory accuracy) in the presence of RPMI, IL-8, 
GROα, fMLP, LTB4 and C5a. Results are shown as the mean and SEM (n=10). * indicates 
p ≤ 0.05 for COPD compared to HC and ** indicates p ≤ 0.05 for COPD compared to α1-
ATD patients. (Analysed by one-way ANOVA). 
 
 
 
3.3.3   Effect of Donor Plasma on Neutrophil Migration 
To determine if the local inflammatory environment could be influencing neutrophil 
migration through a systemic effect, migratory dynamics of COPD neutrophils were re-
assessed following pre-incubation in healthy plasma and vice versa in shallow gradients of 
IL-8 and fMLP. Cells were also incubated in autologous plasma or RPMI-1640 for control 
comparisons. Since migration was aberrant to all chemoattractants studied, IL-8 and fMLP 
were chosen in order to replicate chronic inflammation and bacterial infections, 
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respectively. Furthermore, previous work on neutrophil chemotaxis in COPD had also 
predominantly focussed on these two chemokines. 
When the migratory dynamics of neutrophils from COPD donors was assessed 
following incubation in RPMI-1640, autologous plasma or plasma from an age-matched 
healthy control subject, no significant differences were observed in their chemokinesis in 
the presence of either IL-8 or fMLP (Figure 3.6). Pre-incubation in the different media also 
had no effect on the chemotaxis of COPD neutrophils (Figure 3.7). 
 
 
 
Figure 3.6: The effect of healthy plasma on the chemokinesis of COPD neutrophils. 
Legend: The chemokinesis of COPD neutrophils in the presence of IL-8 and fMLP 
following pre-incubation in RPMI, plasma from the same donor and plasma from an age-
matched healthy donor. Results are displayed as the mean and SEM (n=5). (Analysed by 
one-way ANOVA). 
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Figure 3.7: The effect of healthy plasma on the chemotaxis of COPD neutrophils. 
Legend: The chemotaxis of COPD neutrophils in the presence of IL-8 and fMLP following 
pre-incubation in RPMI, plasma from the same donor and plasma from an age-matched 
healthy donor. Results are displayed as the mean and SEM (n=5). (Analysed by one-way 
ANOVA). 
 
 
 
When the migratory dynamics of neutrophils from healthy control subjects was 
assessed in the presence of either IL-8 or fMLP, neither chemokinesis (Figure 3.8) nor 
chemotaxis (Figure 3.9) was altered by pre-incubation in plasma from an age-matched 
COPD patient compared to autologous plasma or RPMI-1640. 
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Figure 3.8: The effect of COPD plasma on the chemokinesis of healthy neutrophils. 
Legend: The chemokinesis of healthy neutrophils in the presence of IL-8 and fMLP 
following pre-incubation in RPMI, plasma from the same donor and plasma from an age-
matched COPD patient. Results are displayed as the mean and SEM (n=5). (Analysed by 
one-way ANOVA). 
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Figure 3.9: The effect of COPD plasma on the chemotaxis of healthy neutrophils. 
Legend: The chemotaxis of healthy neutrophils in the presence of IL-8 and fMLP 
following pre-incubation in RPMI, plasma from the same donor and plasma from an age-
matched COPD patient. Results are displayed as the mean and SEM (n=5). (Analysed by 
one-way ANOVA). 
 
 
3.4   NEUTROPHIL PHENOTYPING 
Due to the inflammatory nature of COPD, it is possible that neutrophils from the 
peripheral blood of COPD patients may adopt a different phenotype compared to those 
from healthy subjects and this may, in turn, affect cellar functions such as migration. This 
could potentially occur either through a systemic inflammatory effect or be due to early 
release of immature neutrophils from the bone marrow to compensate for the increased 
neutrophil influx from the circulatory system into the lungs.  To determine if neutrophils 
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from COPD patients were of a different phenotype, expression of surface markers of cell 
activation (active CD11b, CD62L), degranulation (CD63) and maturity (CD16) were 
measured in whole blood samples.  
 
3.4.1   Validation: Selection of Antibody Titre 
To determine the most appropriate concentration of each receptor antibody, 
immunostaining was quantified by flow cytometry using a range of concentrations with 
whole blood from 2 healthy donors. The concentrations recommended by the manufacturer 
were 20 μl for CD11b and CD62L and 5 μl for CD16 and CD63 into cells isolated from      
50 μl of whole blood (following centrifugation and removal of the supernatant). Therefore, 
concentration responses were performed for all antibodies using volumes of 5 μl, 10 μl and 
20 μl. Neutrophils were gated relative to the isotype control so that only cells positive for 
each antibody were included in the analysis. This gating strategy is shown in Figure 3.10. 
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Figure 3.10: A representative FACS plot of isotype control and FITC/PE positive 
neutrophils. 
 
Legend: The gating strategy (left) was designed to account for non-specific FITC or PE 
binding. Gates were positioned around neutrophils stained with the isotype control antibody 
IgG1 (example population indicated by the blue box), so that only neutrophils positive for 
FITC- and/or PE-stained receptor expression (outside the lower left quadrant) were included 
in the final analysis (example population indicated by the green box). An example of the cell 
count display is shown on the right for IgG1 vs. CD16 (FITC
+
). 
 
 
 
The MFI data for each antibody are shown in Figure 3.11. From these concentration 
response assays, the optimal concentration of each antibody was determined from the 
highest MFI value. The optimal volumes of the four antibodies per 50 μl of whole blood 
were as follows; CD11b (active) (400 µg/L): 20 μl, CD16 (400 µg/L): 5 μl, CD62L (25 
µg/L): 20 μl and CD63 (200 µg/L) 20 μl. Henceforth, the subsequent assay was performed 
using these volumes of the antibodies. 
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Figure 3.11: Antibody concentration response curves for neutrophil markers of 
activation and maturity. 
 
Legend: Neutrophil surface expression of CD11b (active) (400 µg/L), CD16 (400 
µg/L), CD62L (25 µg/L) and CD63 (200 µg/L) in whole blood from healthy donors. 
The optimal concentrations were determined from the highest MFI value. Results are 
reported as the mean and SEM (n=2). 
 
 
3.4.2   Markers of Neutrophil Activation and Maturity 
The surface expression of active CD11b, CD16, CD62L and CD63 on neutrophils in 
whole blood was compared between 15 COPD patients and 15 healthy control subjects. No 
differences were observed between comparisons of COPD and healthy neutrophils for the 
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MFI of active CD11b, CD16 or CD62L. However, a modest but significantly higher 
expression of CD63 was observed in COPD neutrophils. These data are summarised in 
Figure 3.12. 
In addition, the percentage of neutrophils with a positive expression of each of the four 
markers was determined. As expected, virtually all neutrophils from every subject were 
highly positive for CD16 (Healthy control = 99.7%, COPD 99.4%) and CD62L (Healthy 
control = 99.8%, COPD 99.8%) expression but there were no differences between COPD 
and health. Unexpectedly, a few subjects had a small percentage of neutrophils that were 
positive for active CD11b. This was observed more frequently in COPD than health 
(Healthy control = 3.5%, COPD 5.1%), although there was no statistically significant 
difference. This phenomenon was more pronounced for CD63 expression (Healthy control 
= 5.2%, COPD 11.4%) but, again, this did not reach statistical significance. These data are 
summarised in Figure 3.13. 
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Figure 3.12: Surface expression of active CD11b, CD16, CD62L and 
CD63. 
Legend: Surface expression was semi-quantified in populations of neutrophils in 
whole blood from 15 HC subjects and 15 COPD patients by flow cytometry. Mean 
MFI values for each patient group are indicated by the horizontal line. (Analysed by 
unpaired Mann-Whitney U test). 
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Figure 3.13: The percentage of CD11b
+
, CD16
+
, CD62L
+
 and CD63
+
 neutrophils. 
Legend: The percentage of neutrophils positive for these markers was determined by 
a gating strategy whereby only neutrophils that fell outside the gate of the isotype-
matched irrelevant antibodies (IgG1). Results are displayed as the median with 
standard deviation (data within 95% confidence intervals). (Analysed by unpaired 
Mann-Whitney U test). 
 
 
3.5   NEUTROPHIL MIGRATION AND CLINICAL PHENOTYPE 
Currently, it is unknown whether or not the aberrant neutrophil migration in COPD is a 
genetically predetermined phenomenon or caused by other factors that relate to the disease, 
such as smoking status, the presence of emphysema and age. It is also unknown if 
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migratory accuracy of neutrophils changes with the severity of COPD. This is important as 
it may help clarify whether the aberrant neutrophil migration in COPD is a secondary effect 
of chronic inflammation or, in fact, a hereditary condition, where neutrophils always 
migrate with poor accuracy in susceptible individuals due to altered gene expression, but 
COPD only manifests as a result of increased transmigration in response to chronic toxin 
inhalation. 
Although the initial chemotaxis data was sufficiently powered to discern differences in 
the migratory dynamics of neutrophils in COPD as a whole, it was not sufficiently powered 
to allow for the analysis of individual stages of disease severity or other factors that 
contribute to the clinical phenotype of COPD, such as smoking status, the presence of 
emphysema and age. Therefore, a much larger cohort of both COPD patients with varying 
disease severity (n = 52) and healthy individuals (n = 55) was generated through the 
addition of chemotaxis data (in 100nM IL-8) from collaborative researchers within our 
group. 
 
3.5.1   Neutrophil Chemotaxis and COPD Severity 
Group comparison of migratory data in COPD Stages I-IV revealed no significant 
differences between neutrophil chemotaxis in IL-8 in any group. When a large healthy 
cohort was included in a subsequent comparison, chemotaxis was only significantly 
different in COPD Stages II-IV compared to health. However, the fact that chemotaxis was 
not different in COPD Stage I compared to health was most likely due to a large 
discrepancy in patient numbers (n = 55 for healthy controls compared to n = 8 in COPD 
Stage I).  These data are summarised in Figure 3.14. 
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Figure 3.14: Neutrophil chemotaxis in health and COPD Stages I-IV. 
Legend: Chemotaxis data to 100nM IL-8 was collated healthy controls (n=55) and for 
COPD GOLD Stage I (n=8), Stage II (n=19), Stage III (n=14) and Stage IV (n=11). Data 
are presented as a Box and Whisker Plot with the median, quartiles and range. * p ≤ 0.05 
compared to health. (Analysed by Kruskal-Wallis test). 
 
COPD Gold Stages I-IV are defined by the presence of airflow obstruction (FEV1/FVC 
less than 70%) and further classified by FEV1 % Predicted. A linear regression plot of 
chemotaxis and FEV1 % Predicted for all COPD patients (n = 52) was used to determine if 
126 
 
there was a relationship between chemotaxis and the severity of COPD. There was no 
significant correlation between chemotaxis and FEV1 % Predicted (r
2
 = -0.042, p = 0.144). 
These data are summarised graphically in Figure 3.15. 
 
 
 
Figure 3.15: Linear regression of neutrophil chemotaxis and FEV1 % Predicted in 
COPD. 
Legend: Chemotaxis data (to 100nM IL-8) from a large cohort of COPD patients with 
varying degrees in severity was compared to FEV1 % Predicted by linear regression. 
Statistically, there was no significant relationship  (r
2
 = -0.042, p = 0.144). (Analysed by 
Spearman’s Rank). 
 
 
Although the severity of airflow obstruction in COPD is defined by the FEV1 % 
Predicted, the FEV1/FVC ratio is perhaps a better measure of airflow obstruction. Indeed, it 
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is possible for a COPD patient to have “mild” COPD (FEV1 > 80% predicted) but with a 
markedly reduced FEV1/FVC. Therefore, a linear regression plot of chemotaxis and 
FEV1/FVC for all COPD patients was used to determine if there was a relationship between 
chemotaxis and the degree of airflow obstruction. There was no significant correlation 
between chemotaxis and FEV1/FVC (r
2
 = 0.016, p = 0.430). These data are summarised in 
Figure 3.16. 
 
 
Figure 3.16: Linear regression of neutrophil chemotaxis and FEV1/FVC in COPD. 
Legend: Chemotaxis data (to 100nM IL-8) from a large cohort of COPD patients with 
varying degrees in severity was compared to FEV1/FVC by linear regression. Statistically, 
there was no significant relationship (r
2
 = 0.016, p = 0.430). (Analysed by Spearman’s 
Rank). 
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3.5.2   Neutrophil Chemotaxis and Smoking Status 
To determine if smoking status influenced neutrophil migration, the healthy and COPD 
cohorts were divided into groups related to their smoking status. These included never 
smokers (NS; healthy cohort only), current smokers (CS) and ex-smokers (XS). In 
agreement with the previous data (Section 3.3.2), neutrophils from COPD patients moved 
with significantly increased chemokinesis and decreased chemotaxis when compared to 
those from healthy control subjects. However, no differences in either chemokinesis 
(Figure 3.17) or chemotaxis (Figure 3.18) were observed between never smokers, current 
or ex-smokers in either health or COPD.  
 
3.5.3   Neutrophil Chemotaxis and the Presence of Emphysema 
As COPD is a disorder of different disease pathologies and clinical syndromes 
(emphysema, chronic bronchitis and bronchiolitis) (Saetta et al. 2001), the next analysis 
sought to determine if the presence of emphysema (which seems to be related to neutrophil 
transmigration (Woolhouse et al. 2005)) had any relationship to aberrant neutrophil 
migration in COPD. Patients within the COPD cohort were divided into those with or 
without emphysema in accordance with a previously validated HRCT Scan protocol, where 
a Voxel Index below -910 Hounsfield Units (HU) defines the presence of emphysema (Parr 
et al. 2008). Comparisons of chemokinesis (Figure 3.19A) and chemotaxis (Figure 3.19B) 
showed no difference in these COPD sub-groups. 
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Figure 3.17: The effect of smoking status on neutrophil chemokinesis in health 
and COPD. 
Legend: Chemokinesis data (to 100nM IL-8) from the large cohorts of healthy subjects 
and COPD patients split by their smoking status. Neutrophils from both COPD current 
smokers (CS) and ex-smokers (XS) migrated with increased chemokinesis when 
compared to those from healthy never smokers (NS), CS and XS (p<0.05). No 
differences were observed between COPD CS and XS or between healthy NS, CS and 
XS. Results are displayed as the median with standard deviation (data within 95% 
confidence intervals). (Analysed by Kruskal-Wallis test). 
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Figure 3.18: The effect of smoking status on neutrophil chemotaxis in health 
and COPD. 
Legend: Chemotaxis data (to 100nM IL-8) from the large cohorts of healthy subjects 
and COPD patients split by their smoking status. Neutrophils from both COPD current 
smokers (CS) and ex-smokers (XS) migrated with decreased chemotaxis when 
compared to those from healthy never smokers (NS), CS and XS (p<0.05). No 
differences were observed between COPD CS and XS or between healthy NS, CS and 
XS. Results are displayed as the median with standard deviation (data within 95% 
confidence intervals). (Analysed by Kruskal-Wallis test). 
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Figure 3.19: The relationship between emphysema and neutrophil migration 
in COPD. 
Legend: Chemotaxis data (to 100nM IL-8) from COPD patients was divided into 
those patients with or without emphysema (confirmed by HRCT Scan). There was 
no significant difference in either chemokinesis (A) or chemotaxis (B) between 
groups. Data are displayed as the mean and SEM (n=18). (Analysed by 2-tailed 
unpaired t-test). 
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3.5.4   Neutrophil Chemotaxis and Age 
Linear regressions were performed for both neutrophil chemokinesis and chemotaxis 
versus age in healthy control subjects and patients with COPD. There was no correlation 
between chemokinesis and age in either group (Figure 3.20). There was a significant 
negative correlation between chemotaxis and age in the healthy control cohort (r
2
 = -0.4, 
p=0.003), although a similar relationship was not observed in COPD (Figure 3.21). 
 
 
Figure 3.20: Linear regression of neutrophil chemokinesis and age in health 
and COPD. 
 
Legend: Chemokinesis data (to 100nM IL-8) from large cohorts of Healthy 
Control (HC) subjects and COPD patients was compared to subject age by linear 
regression. There was no statistical correlation. (Analysed by Spearman’s Rank). 
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Figure 3.21: Linear regression of neutrophil chemotaxis and age in health 
and COPD. 
 
Legend: Chemotaxis data (to 100nM IL-8) from large cohorts of Healthy Control 
(HC) subjects and COPD patients was compared to subject age by linear 
regression. There was a significant negative correlation between neutrophil 
chemotaxis and age in health (r
2
 = -0.4, p=0.003), but this relationship was not 
observed in COPD. (Analysed by Spearman’s Rank). 
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3.6   DISCUSSION 
 
3.6.1   Aberrant Neutrophil Chemotaxis in COPD 
The ability of neutrophils to migrate accurately from the circulation, through the 
extracellular matrix and onwards to an inflammatory source is paramount for a rapid innate 
immune response. Moreover, once at the site of migration, their ability to locate and 
destroy invading pathogens is also essential for the resolution of bacterial infection. 
Neutrophils migrate in response to a series of chemokine gradients produced by both host 
cells and pathogens themselves. 
Previous work by our group demonstrated that neutrophils from COPD patients 
migrated with increased speed but reduced accuracy in vitro compared to those from age-
matched healthy donors and patients with α1-ATD in shallow gradients of IL-8 and GROα 
(Sapey et al. 2011). However, whether this effect was a general phenomenon or exclusively 
related to the IL-8 and GROα receptors, CXCR1 and CXCR2 could not be determined. 
Therefore, the first aim of the current study was to assess the migratory dynamics of 
neutrophils from patients with COPD, age-matched healthy control subjects and patients 
with α1-ATD not only in the in the presence of IL-8 and GROα, but also three other 
chemoattractants, C5a, fMLP and LTB4. Although there are a vast number of 
chemoattractive stimuli produced by both host inflammatory cells and invading pathogens, 
C5a, fMLP and LTB4 each have different, specific receptors on the cell surface of 
neutrophils and we believe that these, together with IL-8 and GROα represent a good 
variety of host and bacterial chemokines that signal through different receptors. 
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In the current study, COPD neutrophils consistently demonstrated clear differences in 
migratory behaviour to all five chemoattractants when compared to those from age-
matched healthy donors and patients with α1-ATD, migrating with increased speed 
(chemokinesis) but impaired accuracy (chemotaxis and chemotactic index). This suggests 
that the aberrant migration of COPD neutrophils in vitro is a generic phenomenon and not 
specific to particular chemokines and their respective receptors.  
Previous studies of neutrophil migration in COPD have yielded conflicting results. 
One group (Burnett et al. 1987) used a Boyden Chamber to assess neutrophil migration in 
the presence of an fMLP gradient. In this assay, cells migrate from an upper well through 
two membranes to a lower well that contains a chemoattractive source. This study 
demonstrated an increased migration of neutrophils from COPD patients compared to those 
from healthy controls and patients with bronchiectasis (another lung disease involving 
neutrophil inflammation). More recently, a similar study described a reduced chemotaxis to 
IL-8 and fMLP in neutrophils from patients with Stage II-IV COPD (though not Stage I 
COPD) compared to healthy neutrophils (Yoshikawa et al. 2007). 
The differences in results from these studies and those reported here may be reflective 
of the assay used. The basic mechanism behind the Boyden chamber is to calculate the 
proportion of leukocytes migrating into a chemoattractant filled chamber through a porous 
membrane (Chen 2005). The migration of cells through the membrane of the Boyden 
chamber relies on the formation of a chemical gradient between the chambers which is 
determined by pore size and pore spacing. However, Burnett et al. used a small pore double 
membrane, whereas Yoshikawa et al. used a large pore single membrane. These variations 
in pore size can change the decay rates of chemical gradients, which could result in an 
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altered neutrophil migratory response. Also, in the absence of a non-standardised Boyden 
assay membrane, it is suggested that sample sizes should be large (n=50) to reduce the 
effects of artefact. However, both Yoshikawa et al. and Burnett et al. used study groups of 
less than 20 subjects. Therefore, it is difficult to determine whether differing results 
between studies using non-homogenous membranes are real. Furthermore, these assays 
provide limited information on neutrophil migration, as they only assess the overall number 
of neutrophils that have migrated from the upper to lower well. The Insall chamber used 
here provides more insight into how the neutrophils are moving during two-dimensional 
migration in a chemotactic gradient. Although computer tracking is capable of providing 
information on four migratory parameters (chemokinesis, chemotaxis, persistence and 
chemotactic index), there was no difference in persistence between COPD, health and α1-
ATD. As a result, the chemotaxis and chemotactic index were almost exact mirrors of one 
another. Therefore, the subsequent assays of neutrophil migration focussed solely on 
chemokinesis and chemotaxis for simpler interpretation. 
The Insall chamber is not without limitations. Firstly, it is possible that the neutrophils 
that adhere to the albumin-coated coverslip are of a different phenotype to those that do not 
adhere (for instance their quiescent expression of adhesion molecules, such as integrins, 
could be higher). Secondly, it is an in vitro assay that only measures two-dimensional 
migration. Migration of cells on albumin-coated glass predominantly relies on β2 integrins 
(Sixt et al. 2001), which also are important in mediating adhesion to many extracellular 
matrix molecules (Hansell et al. 1994, Kubes et al. 1995, Frieser et al. 1996). In contrast, 
migration through the basement membrane appears to rely on β1 and β3 integrins (Frieser 
et al. 1996). This means that, although the in vitro data from the current study may reflect 
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neutrophil migration along the endothelium and within pulmonary airspaces, it may not 
necessarily reflect migration through the extracellular matrix (which could potentially 
involve different processes). 
Another limitation is that the chemotaxis assays were performed at room temperature 
and not 37ºC, which would be more representative of an in vivo environment. Lower 
temperatures could potentially influence neutrophil function, particularly integrin-
dependent adhesion (Nash et al. 2001). Ambient temperature is also subject to variation 
(particularly winter to summer months), although the migration assays using healthy and 
COPD neutrophils were performed at the same time of year and would, therefore, have 
been subject the same variations in temperature. Importantly, neutrophils from both healthy 
and COPD neutrophils were migrating and clear differences in their migratory dynamics 
were observed. However, preliminary chemotaxis assays at 37ºC from our group suggest 
the differences in chemotaxis between healthy and COPD neutrophils are maintained 
(unpublished data from G. Walton). 
Inaccurate neutrophil migration may have implications in the pathogenesis of COPD 
as, if neutrophils are migrating less directly through the lung parenchyma to the airways, 
the area of collateral damage resulting from the release of destructive enzymes (such as 
NE) would be increased. Interestingly, neutrophils from patients with α1-ATD seem to 
migrate more accurately in the presence of certain chemoattractants (IL-8 and fMLP), 
which cannot be accounted for by an age effect (as there is no age difference between 
groups). One previous study has suggests that α1-AT actually inhibits neutrophil 
chemotaxis (Lomas et al. 1995). Therefore, it is possible that low serum α1-AT has had a 
residual effect on the neutrophils of α1-ATD patients and improves their chemotaxis. 
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Incubation of AATD neutrophils or (even those from healthy or COPD neutrophils) in α1-
AT prior to the chemotaxis assay may help confirm or refute this effect. As no impairment 
was demonstrated in the migration of α1-ATD neutrophils, it can be inferred that the 
analogous emphysematous pathology in COPD and α1-ATD occur via different 
mechanisms. As COPD neutrophils migrate, the area of residual proteolytic damage along 
their migratory track is comparable to healthy neutrophils (as it is sufficiently controlled by 
anti-proteinases). However, the tracks may be much longer as the cells seem to move more 
randomly, which would result in a net increase in the area of damage. In α1-ATD, the cells 
migrate normally along a more direct path but the area of tissue destruction is amplified 
due to a proteinase/anti-proteinase imbalance. These theoretical effects are illustrated in 
Figure 3.22. 
Assessment of neutrophil migration through artificial matrices (such as collagen) may 
clarify whether or not COPD neutrophils migrate with the same impaired accuracy within a 
three-dimensional environment. 
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Figure 3.22: A theoretical model of neutrophil transmigration in health, COPD and  
α1-ATD. 
 
Legend: Healthy neutrophil transmigration is accurate with sufficient antiproteinase levels 
to minimise collateral damage to the surrounding tissue. COPD neutrophils migrate less 
accurately, leading to longer migratory tracks and increased tissue damage. α1-ATD 
neutrophils migrate accurately but, due to reduced levels of α1-AT, their migratory tracks 
are wider and the resulting tissue damage is also increased. 
 
 
In addition, the inability of COPD neutrophils to migrate accurately along two-
dimensional chemoattractive gradients (particularly fMLP) could result in an impaired 
“hunting” ability when tracking invading pathogens. Ultimately, this could lead to an 
increased bacterial presence within the lungs, although unpublished data by our group 
suggests that neutrophil migration does not relate to exacerbation frequency. The fact that 
there is an increased neutrophil presence within the pulmonary airways of COPD patients 
(Martin et al. 1985, Stanescu et al. 1996, Rutgers et al. 2000, Pilette et al. 2007) could 
mean that, although they may be less able to locate bacteria, their increased numbers 
140 
 
(Stanescu et al. 1996, Rutgers et al. 2000) and phagocytic capacity (Burnett et al. 1987) 
may balance this effect. 
 
3.6.2   Effect of Donor Plasma on Neutrophil Chemotaxis 
As mentioned previously (Section 1.5.7), inflammation in COPD not only occurs 
within the lungs, but also systemically. It has previously been shown that the pro-
inflammatory cytokine, TNFα, is increased in the plasma (Takabatake et al. 2000, 
Broekhuizen 2005) and serum (Karadag et al. 2008) of COPD patients. Furthermore, serum 
levels of TNFα correlate with disease severity (von Haehling et al. 2009). Therefore, it was 
hypothesised that soluble factors in the circulation (such as increased levels of 
inflammatory mediators) could potentially alter the neutrophil phenotype in COPD and 
possibly lead to impaired migration. 
Comparisons of migratory dynamics were performed following incubation of COPD 
neutrophils in their own plasma and plasma from an age-matched healthy control. In the 
presence of an IL-8 chemotactic gradient, no significant differences in migration were 
observed and in fMLP, COPD neutrophils appeared to move more accurately in their own 
plasma than in healthy plasma or medium alone. This demonstrates that a COPD phenotype 
cannot be induced in healthy neutrophils by incubation in COPD plasma and, also, that 
dysfunctional COPD neutrophil migration cannot be normalised or even improved by 
transferring the cells into healthy plasma. These data suggest that the immediate systemic 
inflammatory environment may not influence neutrophil migration in COPD and the 
aberrant migration observed in COPD neutrophils could be due to an intrinsic cell defect. 
The null effect of donor plasma incubation is further supported by the fact that incubation 
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in 100% plasma did not affect the ability of healthy or COPD neutrophil to adhere to the 
albumin-coated coverslips or their ability to initiate migration. However, the effect of 
chronic exposure in the bone marrow during neutrophil development cannot be 
extrapolated from these data, which only reflects acute exposure in the plasma. 
On reflection, it may also have been useful to measure plasma concentration of pro-
inflammatory cytokines (such as TNFα, IL-1β, IL-6 and IL-8) as well as other soluble 
inflammatory markers (such as CRP) in the plasma of each subject included in this 
experiment to confirm the presence or absence of systemic inflammation. 
 
3.6.3   Neutrophil Phenotype 
Despite of the null effect of incubating healthy neutrophils with COPD plasma and 
vice versa on migratory dynamics, previous work has provided evidence that at least a 
proportion of circulating neutrophils in patients with stable COPD may be activated. In 
earlier studies, one group consistently showed an increase in surface expression of Mac-1 
(an integrin dimer comprising active CD11b and CD18) on neutrophils isolated from 
COPD patients compared to those from healthy controls. In their first study, this was true 
under both basal conditions and following stimulation with TNFα and, importantly, 
expression of healthy non-smokers and healthy smokers was no different (Noguera et al. 
1998). In a subsequent study, basal expression of Mac-1 was higher in stable COPD 
compared to health but, surprisingly, decreased to levels comparative to health during 
exacerbations of COPD (Noguera et al. 2001). In both of these studies, the neutrophil 
surface expression of other adhesion molecules, namely L-Selectin (CD62L) and 
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Lymphocyte Function-Associated Antigen (CD11a/CD18) was the same in health and 
COPD. A later study by a different group also found increased expression of CD11b on 
isolated COPD neutrophils compared to health, although CD18 was not differentially 
expressed (Yamagata et al. 2007). The most recent study analysed various activation 
markers on isolated neutrophils from patients with COPD as well as healthy smokers at 
baseline and post-rhinovirus infection (Mallia et al. 2013). These markers included CD62L 
and CD163 (P-Selectin) (involved in rolling and capture), CD11a and CD11b (required for 
firm adhesion), CD31 and CD54 (ICAM-1) (involved in transmigration) and CD63 and 
CD66b (activation markers). In contrast to the previous studies, this group reported no 
difference in any of these neutrophil activation markers at baseline between COPD and 
healthy smokers. Although CD11a was reduced in both cohorts and CD11b, CD62L and 
CD162 expression significantly reduced in COPD following rhinoviral infection, no 
differences were observed between healthy smokers and COPD. 
In the current study, no difference in either CD11b or CD62L surface expression on 
quiescent neutrophils from patients with COPD compared to those from healthy subjects. 
While none of the previous studies have found a difference in CD62L expression, the data 
on CD11b is at variance with the majority of previous studies that found an increased 
expression on COPD neutrophils (Noguera et al. 1998, Noguera et al. 2001, Yamagata et 
al. 2007) and only in agreement with one study (Mallia et al. 2013). This could potentially 
be due to differences in methodology as, in all previous studies, neutrophils have been 
isolated from whole blood. In order to minimise the risk and the number of neutrophils that 
could become activated, the analysis was conducted using neutrophil populations in whole 
blood. It is possible that COPD neutrophils are more susceptible to activation in COPD 
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(particularly if they are primed with increased plasma levels of TNFα), and the proportion 
of neutrophils that express CD11b following isolation may, therefore, be increased in 
COPD compared to health. 
In contrast, the data reported here indicate that the surface expression of CD63 is 
higher on circulating neutrophils from COPD patients compared to those from healthy 
individuals, although the difference was only modest. CD63 is a membrane marker of 
azurophile granules and its translocation to the plasma membrane is associated with PMN 
stimulation and azurophilic granule exocytosis (Mahmudi-Azer et al. 2003). For this 
reason, upregulation of CD63 on the surface of neutrophils is considered a cogent marker 
of azurophilic degranulation and, by inference, neutrophil activation (Kuijpers et al. 1991). 
One study has investigated CD63 expression in isolated neutrophils from COPD 
patients compared to healthy controls (Zhang et al. 2007). In addition to surface expression, 
they also measured total CD63 content of permeabilised neutrophils and found an increased 
expression on the surface of COPD neutrophils compared to health but a lower overall 
content. The data in this chapter are in agreement with Zhang et al., although they are at 
variance with a later study by Malia et al. that did not show difference (Mallia et al. 2013). 
A trend towards a higher percentage of cells with a CD63 positive phenotype was also 
found but this did not reach statistical significance. Whether or not the increase in CD63 
expression is a true reflection of increased neutrophil activation in COPD is difficult to 
determine, as other markers of activation were not different when compared to health. If 
the higher CD63 surface expression is a genuine phenomenon, it is unlikely to be related to 
overall neutrophil migration, as only a modest difference was observed. However, it could 
influence the pathology of COPD because, as CD63 is a marker of azurophilic 
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degranulation, there is potential for an increased collateral damage during migration 
through the parenchyma as well as during the respiratory burst if granular exocytosis is also 
increased. However, as Zhang et al. actually found a lower overall CD63 content in COPD 
neutrophils compared to those from healthy subjects (Zhang et al. 2007), this may not be 
the case. CD63 interacts with a number of molecules, including MHC Class II molecules 
(found on antigen presenting cells and monocytes) (Hammond et al. 1998), integrins 
(Berditchevski et al. 2001) and Phosphatidylinositol 4-kinase (Berditchevski et al. 1997, 
Yauch et al. 2000) (which is involved in intracellular membrane trafficking). Therefore, 
increased expression on the cell surface (particularly in fully activated neutrophils) could 
affect cell adhesion as well as the interaction with other inflammatory cells (such as 
dendritic cells), which may augment chronic inflammation in COPD. 
Measurement of the surface expression of CD63 on activated neutrophils in COPD and 
health may provide further insight, though the precise mechanisms by which CD63 is 
involved in granule mobilisation and release have yet to be established. Furthermore, it 
would important to assess CD63 expression on adhered and fixed cells by confocal 
microscopy to determine if this phenotype is robustly present during migration. It was 
surprising to see an increased expression of CD63 on COPD neutrophils when more 
sensitive markers of neutrophil activation, CD62L and CD11b, were not different. To 
confirm this phenomenon, it would be logical to repeat this experiment and include other 
markers of the azurophile granule (such as NE, MPO and lysozyme). 
Two recent studies by a group in the Netherlands have identified sub-populations of 
neutrophils with differential expression of CD16 and CD62L. Firstly, Pillay et al. identified 
a population of CD16
bright
/CD62L
dim
 neutrophils in humans in vivo during acute systemic 
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inflammation induced by either LPS challenge or severe injury. These were considered a 
unique population of myeloid cells with a functional difference in that they were able to 
suppress human T cell proliferation (Pillay et al. 2012). In the follow-on study, Kamp et al. 
further classified sub-populations of circulating neutrophils into CD16
bright
/CD62L
dim
, 
CD16
dim
/CD62L
bright
 (immature, banded phenotype), and CD16
bright
/CD62L
bright
 
(phenotypically mature) (Kamp et al. 2012). When various aspects of neutrophil migration 
(including endothelial capture, integrin binding and chemotaxis) were assessed, functional 
differences were recorded. Of note, the immature, CD16
dim
/CD62L
bright
 population had 
impaired Mac-1 binding in fMLP and IL-8 but increased chemotaxis in fMLP (though not 
in IL-8 or C5a) compared to the more mature (CD16
bright
) sub-populations. However, 
chemotaxis was assessed using a Boyden Chamber, and information on migratory 
dynamics was not determined. 
As COPD is a chronic inflammatory disorder and is associated with persistent 
neutrophil migration from the circulation into the lungs, it was hypothesised that, under this 
burden, immature neutrophils may be released from the bone marrow to balance the 
number of neutrophils that have left the circulation. If the neutrophils in the circulation of 
COPD patients are less mature than those of healthy subjects, they may not have developed 
the capacity to direct themselves accurately along a chemotactic gradient. However, no 
difference was found in either CD16 or CD62L expression on the surface of neutrophils 
from COPD patients and healthy subjects and the percentage of CD16
+
 and CD62L
+
 was 
virtually 100% in every subject (with negative cells most likely artefact). Furthermore, 
there did not seem to be any “double populations” of CD16dim and CD16bright neutrophils 
that were observed by the aforementioned studies (Pillay et al. 2012, Kamp et al. 2012). 
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Therefore, it can be concluded that, regardless of the potential differences in migratory 
accuracy between immature and mature neutrophils, there seems to be no difference in the 
neutrophil CD16/CD62L phenotype between COPD and health. 
 
3.6.4   Clinical Phenotype 
COPD is a complex, heterogeneous disorder, which presents clinical and functionally 
with large variability in patients with comparable airflow obstruction (Wedzicha 2000, 
Agusti 2005, GOLD 2009). This study sought to determine if factors relating to the clinical 
phenotype of COPD were related to the degree of chemotactic impairment. 
It seems logical to hypothesise that, as COPD is a progressive disease, neutrophil 
function may become worse as the disease becomes more severe. However, no statistically 
significant differences were observed in chemotaxis between COPD GOLD Stages I-IV. 
Moreover, there was no correlation between chemotaxis and FEV1 % Predicted (the 
severity of COPD) or FEV1/FVC (degree of airflow obstruction). This suggests that 
neutrophil chemotaxis may be equally impaired at any stage of the disease and could even 
be a congenital disorder, where COPD only manifests due to a chronic inflammatory insult 
(such as tobacco smoke inhalation). Despite no observed statistical differences between 
neutrophil chemotaxis and either GOLD Stage or FEV1 % Predicted in COPD, a visual 
trend for decreasing chemotaxis with disease severity was observed (both through COPD 
Stages I-IV and with decreasing FEV1 % Predicted). Although this potential relationship is 
biologically plausible, it is purely speculative (as the groups were clearly underpowered) 
and a further investigation with a much larger study is needed to confirm or refute this 
hypothesis.  
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This theory is partly supported by the fact that no differences in neutrophil migratory 
dynamics were observed between current and ex-smokers with COPD. In ex-smokers with 
more severe COPD, the degree of lung damage may be extensive enough for the 
inflammation to become self-perpetuating, which may continually influence neutrophil 
function. From the data in the current study, it is not possible to accurately describe the 
effects of smoking in mild COPD as, although this group included both current and ex-
smokers, it was not highly powered. In addition, the negative correlation between age and 
chemotaxis observed in healthy ageing was not observed in COPD. This suggests that the 
same degree of chemotactic impairment is present in all COPD patients regardless of their 
age (as young as 31). The data are rather widespread and markedly reduced neutrophil 
chemotaxis was even observed in a small proportion of younger healthy adults. The data 
from these healthy subjects are most likely outliers. However, if the hypothesis that COPD 
susceptibility is hereditary is correct, they could be individuals that would develop COPD 
if they had a longer smoking history. 
In patients with COPD (even in severe disease), airflow obstruction can result from 
inflammation and a gradual thickening of the small airways (< 2mm diameter) (Hogg et al, 
1668). Furthermore, in a proportion of these patients, the small airways disease can occur 
in the absence of emphysema. It is plausible that different pathophysiological phenotypes 
of COPD may have different degrees of inflammatory cell functional impairment. 
However, no differences in neutrophil migration in COPD patients were seen between 
patients with emphysema compared to those without. This suggests that neutrophil 
chemotaxis impaired to the same degree in different “forms” of COPD and that it does not 
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matter where in the pulmonary environment the inflammatory signal originates from, 
neutrophils may always migrate to it with poor accuracy. 
Although the data are collated from a number of experiments conducted by different 
individuals, the current author either performed or supervised the majority. Moreover, each 
individual performed the assays according to standardised protocol although, admittedly, 
there may be slight methodological differences between researchers that could account for 
some of the variability in the data. However, the fact that every separate set of experiments 
observed the same reduced chemotaxis of COPD neutrophils compared to health strongly 
supports our initial observations. Importantly, the large variability in chemotaxis data in the 
healthy cohort as a whole (as seen in Figure 3.14) can be accounted for by the large age 
range and the fact that there is a progressive loss of neutrophil migratory accuracy with 
age. Therefore, the inclusion of younger healthy individuals in the comparison to separate 
COPD GOLD Stages actually introduces a degree of bias. A more statistically robust 
assessment would age match separate healthy cohorts to each COPD Gold Stage, which 
would be a consideration for similar future investigations. 
Altogether, these data strongly suggest that none of the clinical features of COPD 
significantly influence the migratory dynamics of neutrophils. It is possible that migratory 
accuracy may worsen with disease severity, but the data cannot confirm this theory. It is 
also possible that aberrant neutrophil migration is a congenital disorder that only causes 
COPD in individuals who chronically inhale tobacco smoke or other airborne particles. 
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3.6.5   Summary 
In conclusion, this chapter has demonstrated clear differences in the migratory 
accuracy of neutrophils from COPD (which migrated with increased speed but reduced 
accuracy) compared to those from healthy subjects and patients with α1-ATD. This appears 
to be an intrinsic cell defect as incubation of healthy neutrophils in COPD plasma did not 
induce a COPD phenotype. Furthermore, it appears to be unrelated to the clinical features 
of COPD or the activation status and maturity of COPD neutrophils. Therefore, it seems 
logical to assume that the migratory dysfunction of COPD neutrophils is related to 
chemokine receptor function and/or downstream intracellular signalling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 4 
 
MECHANISMS UNDERLYING ABERRANT 
NEUTROPHIL MIGRATION IN COPD 
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4.1   BRIEF INTRODUCTION 
The studies described in Chapter 3 revealed clear differences in the migratory dynamics 
of neutrophils from COPD patients compared to those from both healthy donors and patients 
with α1-ATD. These included an increased migratory speed but a decreased migratory 
accuracy. This was a generic phenomenon that occurred in the presence of a number of 
different chemoattractants. Furthermore, it appears to be to an intrinsic cell defect and is not 
the result of a higher level of neutrophil activation in COPD. 
As described previously, the initiation of intracellular signalling that ultimately leads to 
migration occurs when chemotactic ligands bind to their respective receptors on the cell 
surface. Many endogenous and exogenous molecules can act as neutrophil chemoattractants 
and neutrophils have at least five different types of receptor for these stimuli, which include 
unique receptors for C5a, LTB4, PAF and fMLP, as well as a number of CC and CXC 
receptors that bind other chemokines such as IL-8 and GROα. 
Previous work on neutrophil chemokine receptor expression has only included studies on 
CXCR1 and CXCR2 with sole focus on IL-8 as a chemoattractant. The evidence for differing 
expression of these receptors in COPD is conflicting, where one group reported no difference 
between expression of CXCR1 in COPD compared to health but a decrease in CXCR2 
expression (Pignatti et al. 2005) and, in contrast, another group reported no difference in 
CXCR2 expression but an overexpression of CXCR1 in COPD (Yamagata et al. 2007). 
Therefore, the roles of CXCR1 and CXCR2 in neutrophil migration, particularly in COPD, 
remain unclear and no previous work has been conducted to investigate the expression of 
other chemokine receptors. Furthermore, previous studies have only looked at chemokine 
expression on quiescent cells. This yields limited information, as migrating neutrophils are 
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not quiescent and surface receptor expression is likely to change due to internalisation, 
shedding and mobilisation to the plasma membrane from internal stores. This is important as 
it seems logical that the number of receptors available on the cell surface and their location 
relative to the leading edge at any one time would govern neutrophil migration, not simply 
their expression in a quiescent state. Rates of receptor recycling (internalisation and re-
expression) and, potentially, receptor shedding both dictate the degree of surface expression 
following stimulation and during migration. In turn, this could influence how effectively the 
cell responds to a chemotactic stimulus and how accurately it migrates along the gradient. 
The aberrant neutrophil migration observed in this study could also be a result of altered 
downstream signalling. Following chemokine/GPCR binding, the βγ-subunit activates a 
variety of cellular mediators and signalling pathways. Of particular interest is the PI3K 
signalling pathway, which has been heavily implicated in neutrophil chemotaxis and 
directionality (Stephens et al. 2002, Hannigan et al. 2002, Wang et al. 2002, Wu 2005, Sapey 
et al. 2011). Importantly, evidence suggests that, although components of the PI3K pathway 
(particularly PIP3) influence cell migration, they are not essential for chemotaxis. 
Dictyostelium lacking PI3K are still able to migrate accurately in steep chemotactic gradients, 
though their speed of movement is reduced (Loovers et al. 2006, Hoeller et al. 2007). In 
shallow chemotactic gradients, inhibition of PI3K in Dictyostelium affects the rate at which 
pseudopods are generated which, in turn influences migration (Andrew et al. 2007). Although 
not essential for cell migration, the PI3K signalling pathway may be preferential and 
differences in the activity of PI3K itself and/or other key components could be a potential 
mechanism for the aberrant neutrophil migration in COPD. 
153 
 
Calcium is a diverse second messenger that also has an important role in many 
physiological functions (Meshulam et al. 1986, Marks et al. 1990), though its role in 
neutrophil chemotaxis is less well defined. Neutrophil polarisation is an essential precursor to 
accurate cell migration (O’Donnell et al. 1992, Onsum et al. 2007) and local calcium signals 
have been shown to occur at the leading edge migrating neutrophils (Evans et al. 2007, Wei 
et al. 2011). Therefore, dysfunctional calcium signalling could also provide a reason for the 
impaired migratory accuracy of COPD neutrophils. 
The studies described in this chapter were conducted firstly to investigate expression of 
CXCR1, CXCR2, FPR1, LTB4R1 and the C5aR receptor on quiescent neutrophils. Following 
this, CXCR1, CXCR2 and FPR1 expression was measured on neutrophils that had been 
stimulated with either IL-8 or fMLP over a two hour time-course. Receptor shedding 
throughout the time-course was quantified by ELISA and receptor localisation was 
determined by fluorescent labelling of stimulated neutrophils and microscopy. Secondly, 
intracellular signalling was investigated; PI3K and Akt phosphorylation was determined by 
Western Blot and real-time intracellular calcium ion release following stimulation was 
quantified by fluorimetry. 
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4.2   SUBJECT DEMOGRAPHICS 
Demographic data for the COPD patients, healthy age-matched control subjects and 
patients with α1-ATD included in this chapter are shown in Table 4.1.  
 
 
  COPD Healthy Control α1-ATD 
        
Number 51 49 23 
        
Age (years) 68 (49 - 85) 60 (41 - 87) 61 (47 - 71) 
Sex (% Male) 53 47 48 
Smoking status  18 CS, 33 XS 38 NS, 3 CS, 8 XS 16 NS, 7 XS 
Pack years 49 (4.4) 2 (1.1) 9 (3.0) 
     
FEV1 % predicted 44.7 (3.1) 101.0 (1.3) 57.5 (6.2) 
FEV1 /FVC % 38.8 (2.1) 73.2 (0.5) 37.5 (3.7) 
        
 
 
Table 4.1: Subject Demographics. 
Legend: A table showing the demographic data for all subjects included in this chapter. Data 
are normally distributed and presented as the mean and SEM, except the age which is mean 
(range). NS = Never-smokers, CS = Current smokers, XS = Ex-smokers. 
 
 
 
4.3   CHEMOKINE RECEPTOR EXPRESSION 
 
4.3.1   Validation: Receptor Antibody Titrations 
To determine the most appropriate concentration of each chemokine receptor antibody 
(CXCR1, CXCR2, FPR1, LTB4R1 and C5aR), receptor expression was assessed over a range 
of concentrations using neutrophils from 3 healthy donors. Data for the median fluorescence 
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intensity (MFI = level of receptor expression) for each antibody at each concentration are 
shown in Figure 4.1. Neutrophils were gated relative to the isotype control so that only cells 
positive for each antibody were included in the analysis. 
From these data, the optimal concentration of each receptor antibody was determined 
from the highest MFI value. With some of the antibodies (such as FPR1 and C5aR), a 
maximal binding was not achieved by 3μg/ml. The optimal concentrations of the five 
receptor antibodies were as follows; CXCR1: 2μg/ml, CXCR2: 3μg/ml, FPR1: 3μg/ml, 
LTB4R1:  3μg/ml, C5aR: 3μg/ml. Henceforth, subsequent assays were performed using the 
antibodies at these concentrations. 
Isotype-matched irrelevant antibodies (IgG1 and IgG2A) did not demonstrate a 
concentration response and were therefore used at the same concentration to each of the 
respective anti-receptor antibodies. 
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Figure 4.1: Staining optimisation for 
CXCR1, CXCR2, and fMLP, LTB4 and 
C5a receptor antibodies. 
 
Legend: Results are reported as the Median 
Fluorescence Intensity (MFI) of all subjects 
with standard deviation. The optimal 
concentration is determined by the highest 
MFI. Data are mean and SEM (n=5). 
 
Titration for CXCR2 Antibody 
 
Titration for CXCR1 Antibody 
 
Titration for fMLP Receptor Antibody 
 
Titration for LTB4 Receptor Antibody 
 
Titration for C5a Receptor Antibody 
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4.3.2   Quiescent Chemokine Receptor Expression in COPD, Health and α1-ATD 
Quiescent neutrophil receptor expression was measured for CXCR1, CXCR2, and FPR1, 
LTB4R1 and C5aR in 20 age-matched subjects from each cohort. Surface expression of 
CXCR1 was significantly lower in COPD neutrophils compared to those from healthy 
control subjects (p = 0.02) and a trend towards a similar reduction in CXCR2 expression was 
also observed in COPD, although this did not achieve statistical significance (p = 0.06). No 
significant differences were observed between healthy and α1-ATD neutrophils for 
expression of either CXCR1 or CXCR2. When comparing neutrophils from α1-ATD to 
COPD patients, no differences were observed in CXCR1 expression, although there was a 
lower expression of CXCR2 in COPD (p = 0.04). These data shown in Figure 4.2. 
 
 
    
Figure 4.2: Quiescent neutrophil surface expression of CXCR1 and CXCR2. 
Legend: CXCR1 and CXCR2 expression was semi-quantified in populations of isolated, 
quiescent neutrophils from 20 Healthy Control (HC) subjects, α1-ATD patients and COPD 
patients by immunostaining and flow cytometry. Median MFI values for each patient group 
are indicated by the red horizontal line. (Analysed by Kruskal-Wallis test). 
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No significant differences were observed between any group comparison for surface 
expression of FPR1 or LTB4R1. Expression of C5aR was significantly lower in COPD 
neutrophils compared to healthy controls (p = 0.04), although no significant differences were 
observed for C5aR expression in α1-ATD compared to healthy controls or the COPD patients 
(Figure 4.3). 
 
 
          
 
Figure 4.3: Quiescent neutrophil surface 
expression of fMLP, LTB4 and C5a 
receptors. 
 
Legend: Surface expression of the FPR1, 
LTB4R1 and C5aR was semi-quantified in 
populations of isolated, quiescent neutrophils 
from 20 Healthy Control (HC) subjects, α1-
ATD patients and COPD patients by 
immunostaining and flow cytometry. Median 
MFI values for each patient group are indicated 
by the red horizontal line. (Analysed by 
Kruskal-Wallis test). 
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4.3.3   Chemokine Receptor Expression Following Neutrophil Stimulation 
Although differences in chemokine receptor expression on quiescent neutrophils may be 
indicative of a mechanism of aberrant migration, when neutrophils migrate down 
chemotactic gradients they are not in a quiescent state. Following stimulation by chemokines, 
surface expression their respective receptors may potentially increase due to mobilisation 
from intracellular stores or decrease due to internalisation and/or shedding. Furthermore, it is 
unclear whether or not surface expression fluctuates with time. 
To determine if the differences observed in chemokine receptor expression between 
COPD and healthy neutrophils persist following stimulation, CXCR1, CXCR2 and FPR1 
expression was measured at various time-points throughout a two hour stimulation with IL-8 
or fMLP (n=13). CXCR1 and CXCR2 shedding was also measured in neutrophils from 
COPD and healthy donors at various time-points by ELISA (n=11). 
 
Quiescent Expression 
In agreement with the previous results (Section 4.3.2), CXCR1 expression was 
significantly lower in quiescent COPD neutrophils when compared to those from healthy 
controls. Interestingly, CXCR1 expression was also significantly lower in neutrophils from 
COPD patients when compared to those from patients with α1-ATD. This difference was not 
observed in the previous experiment. No differences were observed between CXCR2, which 
is also at variance with the previous data, where a significantly lower expression of CXCR2 
on COPD neutrophils compared to those from α1-ATD patients was reported. There were no 
differences in FPR1 expression, which is in agreement with the previous results. 
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 Kinetics of Receptor Loss Upon Stimulation 
Surface expression of both CXCR1 decreased continually in all cohorts following 
stimulation with IL-8 throughout the time-course. Although there was still a trend towards 
lower expression of CXCR1 in COPD neutrophils compared to healthy controls, the 
significant difference observed in quiescent neutrophils was rapidly abolished (within 5 
minutes). CXCR1 expression remained significantly lower in COPD neutrophils compared to 
those from patients with α1-ATD at the 10 minute time-point but was no longer present 15 
minutes after stimulation. These data are summarised in Figure 4.4. 
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Figure 4.4: CXCR1 expression following stimulation with IL-8. 
Legend: CXCR1 surface expression was measured following stimulation with 100nM 
IL-8. The difference in expression in unstimulated (US) neutrophils between Healthy 
Controls (HC) and COPD (*) (p ≤ 0.05) was abolished within 5 minutes. The difference 
between α1-ATD and COPD (ұ) (p ≤ 0.05) remained for longer but was not present after 
15 minutes. Results are median and IQR (n=13). (Analysed by Kruskal-Wallis test). 
 
 
 
CXCR2 expression decreased more rapidly following stimulation in all cohorts 
(compared to CXCR1) and remained the same throughout the time-course for all patient 
groups. These data are summarised in Figure 4.5. 
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HC 
 
COPD 
 
α1-ATD 
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Figure 4.5: CXCR2 expression following stimulation with IL-8. 
Legend: CXCR2 surface expression was measured upon stimulation with 100nM IL-8. 
Expression declined rapidly in all cohorts following stimulation. No differences were 
observed in surface expression at any time-point. Results are median and IQR (n=13). 
(Analysed by Kruskal-Wallis test). 
 
 
 
FPR1 surface expression was initially relatively low in all cohorts and remained so 
throughout the time-course. No differences in FPR1 expression were observed between any 
patient group at any time-point. These are summarised in Figure 4.6. 
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Figure 4.6: FPR1 expression following stimulation with fMLP. 
Legend: FPR1 expression was measured after stimulation with 100nM fMLP. Expression 
was initially low in unstimulated neutrophils in all cohorts (n=13). Expression did not 
increase or decrease following stimulation with fMLP and no differences in expression 
were observed between cohorts at any time-point. Results are median and IQR (n=13). 
(Analysed by Kruskal-Wallis test). 
 
4.3.4   Chemokine Receptor Recycling 
In order to verify that receptor recycling was occurring, CXCR1 and CXCR2 expression 
on neutrophils from selected healthy and COPD donors was measured 90 minutes after the 
IL-8 stimulus was removed. Surface expression of both CXCR1 and CXCR2 had increased 
from expression at 30 minutes post-stimulation in both healthy and COPD subjects. Although 
the surface expression in each case had not returned to baseline levels observed in quiescent 
neutrophils, a clear trend for surface re-expression was observed in each instance (Figure 
4.7). 
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Figure 4.7: CXCR1 recycling following removal of IL-8 stimulus. 
Legend: Surface expression of CXCR1 (A) and CXCR2 (B) was quantified on unstimulated cells, 
30 minutes after stimulation with 100 nM IL-8 and, finally, 90 minutes after the IL-8 stimulus was 
removed. This was done with neutrophils from COPD patients (n=8) and healthy subjects (n=5). 
Data are median and IQR. (Analysed by unpaired Mann-Whitney U test). 
A 
B 
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4.3.5   Chemokine Receptor Shedding 
The degree of CXCR1 and CXCR2 shedding was assessed by ELISA using supernatants 
collected at the 30 and 120 minute time-points. These time-points were chosen as receptor 
expression had decreased dramatically by 30 minutes (and had plateaued in COPD patients) 
and by 120 minutes receptor expression had plateaued in all groups. Therefore, if any 
shedding had occurred, it would most likely be detected at these times. The standard curve, 
which indicates the optical density of known CXCR1 concentration-dependent manor, is 
shown in Figure 4.8. 
 
 
Figure 4.8: CXCR1 ELISA Standard Curve. 
Legend: The Log concentration of the standard samples (S1 to S7) were plotted 
against the mean Log optical density of duplicate samples to produce a standard 
curve. As expected, the relationship was linear. This graph was then used to 
determine the concentrations of CXCR1 in the neutrophil supernatants from healthy 
and COPD donors following stimulation. 
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For CXCR1, the concentration in the supernatant of healthy controls was 8.6 pg/ml after 
30 minute stimulation and 9.5 pg/ml after 120 minutes. For COPD patients it was 7.6 pg/ml 
at 30 minute stimulation and 8.3 pg/ml at 120 minutes. These values were actually less than 
the blank reference value (15.6 pg/ml), essentially indicating that no CXCR1 was detectable 
in supernatants from either COPD neutrophils suspension or those from healthy controls. 
In contrast, CXCR2 was detected in the majority of supernatants for both COPD and 
healthy controls, though the results were still relatively low and rather variable. The 
concentration in the supernatant of healthy controls was 2.1 ng/ml after 30 minute 
stimulation and 1.6 ng/ml after 120 minutes. For COPD patients it was 1.1 ng/ml at 30 
minute stimulation and 1.4 ng/ml at 120 minutes. No differences were observed between 
COPD and health at either time-point. These data are summarised in Figure 4.9. 
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Figure 4.9: CXCR2 shedding following stimulation with IL-8. 
Legend: Supernatants were collected from stimulated neutrophils over a two-hour time-
course. CXCR1 shedding was quantified at 30 and 120 minutes by ELISA. Results are 
reported as the median and IQR (n=11). (Analysed by unpaired Mann-Whitney U test). 
 
 
 
 
4.3.6   Chemokine Receptor Localisation 
As expected, CXCR1 and CXCR2 were uniformly distributed across the cell surface in 
quiescent neutrophils in health and COPD. After polarisation, both CXCR1 and CXCR2 
were highly expressed at the leading edge on neutrophils from healthy donors. Neutrophils 
from COPD donors also appeared to localise CXCR1 and CXCR2 to the leading edge to the 
same degree as those from healthy subjects. Microscopic images showing CXCR1 and 
CXCR2 localisation on quiescent and polarised neutrophils are shown in Figure 4.10 and 
Figure 4.11, respectively and results are representative of separate experiments for four 
individual COPD patients and healthy subjects. 
168 
 
 
 
              
 
 
              
 
 
 
Figure 4.10: CXCR1 localisation on quiescent and polarised neutrophils. 
Legend: Microscopic images showing the distribution of PE-labelled CXCR1 across the 
surface of neutrophils in quiescent (left) and polarised (right) neutrophils from COPD 
patients (top) and healthy control subjects (bottom). Images were taken using a Leica 
Microsystems fluorescence microscope using a x40 objective lens and are representative 
of experiments from 4 separate individuals for each cohort. 
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Figure 4.11: CXCR2 localisation on quiescent and polarised neutrophils. 
Legend: Microscopic images showing the distribution of FITC-labelled CXCR2 across 
the surface of neutrophils in quiescent (left) and polarised (right) neutrophils from COPD 
patients (top) and healthy control subjects (bottom). Images were taken using a Leica 
Microsystems fluorescence microscope using a x40 objective lens and are representative 
of experiments from 4 separate individuals for each cohort. 
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4.4   PI3K & AKT PHOSPHORYLATION 
 
4.4.1   Stimulation time-courses 
Expression of the phosphorylated, active form of both PI3K at tyrosine 458 (T458) and 
Akt (at both phosphorylation sites; serine 473 (S473) and threonine 308 (T308)) was 
determined by western blotting. Initial time-course experiments were conducted to establish 
the optimal length of chemokine stimulation for PI3K and Akt phosphorylation. For PI3KT458 
and AktS473, time-points included 1, 2, 3, 5, 10, 15 and 30 minutes. These experiments 
indicated a good degree of phosphorylation in stimulated cells by 1 minute, with optimal 
expression occurring at 3 minutes for both phospho(p)-PI3KT458 and pAktS473. Therefore, 
neutrophils were stimulated for 3 minutes on every subsequent assay with these antibodies. 
An example blot from a time-course for pAktS473 is shown in Figure 4.12. 
 
 
  
                   
                   
 
 
Figure 4.12: Akt phosphorylation at S473 over a time-course of IL-8 stimulation. 
Legend: A western blot of pAktS473 and total Akt from neutrophil lysates from 
unstimulated neutrophils and those stimulated with 100 nM IL-8 over a 30 minute 
time-course (stimulation time in minutes is indicated at the top. US = Unstimulated). 
The image is representative of 3 separate experiments. 
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From a personal communication from Dr. Philip Hawkins in The Babraham Institute, 
Cambridge, it was indicated that phosphorylation of Akt at T308 occurs far more rapidly and 
transiently than at S473. Therefore, the time-course for pAktT308 was adjusted accordingly to 
include 0, 10, 20, 30, 40, 50 and 60 second stimulations (with “0 seconds” being where IL-8 
was added immediately before washing by centrifugation). The time-courses were of lower 
quality than pPI3K or pAktT308 but optimal expression occurring at 20 seconds. Therefore, 
neutrophils were stimulated for 20 seconds on subsequent assays with pAktT308. An example 
blot from a time-course for pAktT308 is shown in Figure 4.13. 
 
           
      
 
 
           
 
 
Figure 4.13: Akt phosphorylation at T308 over a time-course of IL-8 stimulation. 
Legend: A western blot of pAktT308 and total Akt from neutrophil lysates from 
unstimulated neutrophils and those stimulated with 100 nM IL-8 over a 60 second 
time-course (stimulation time in seconds is indicated at the top. US = Unstimulated). 
The image is representative of 3 separate experiments. 
 
 
Initial western blots, including the time-courses were unreliable and often of very poor 
quality. Therefore, a number of modifications were made to the lysis protocol, most 
importantly the rapid cooling of neutrophil suspensions post-stimulation with ice-cold PBS 
(to halt cellular processes) and the addition of MOPS-based lysis buffer (with additional 
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phosphatase inhibitors that further prevent the breakdown of the enzymes of interest) before 
boiling with the SDS buffer. Following these modifications, results were far more reliable 
and reproducible. 
 
4.4.2   PI3KT458 Phosphorylation 
Baseline PI3KT458 phosphorylation was relatively high in unstimulated (RPMI control) 
neutrophils for both healthy control subjects and COPD patients. There was a trend towards 
higher phosphorylation in COPD patients under all stimulatory conditions, though it was only 
significantly higher in COPD following stimulation with GROα. A typical pPI3KT458 western 
blot is shown in Figure 4.14 and the collated data for 6 COPD patients and 6 age-matched 
healthy control subjects are summarised graphically in Figure 4.15. 
 
 
  
 
 
 
 
 
 
Figure 4.14: A representative western blot for pPI3KT458. 
Legend: A western blot from phospho-PI3K in lysates of unstimulated neutrophils (RPMI 
control) and those stimulated with fMLP, GROα and IL-8 from a Healthy Control (HC) 
subject and a patient with COPD. The blot is representative of 6 separate experiments. 
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Figure 4.15: PI3KT458 phosphorylation in neutrophils from healthy and COPD subjects. 
Legend: COPD and healthy neutrophils were either unstimulated (RPMI control) or 
stimulated for 3 minutes with fMLP (100 nM), GROα (10 nM) and IL-8 (100 nM). Density 
ratio was calculated by dividing the optical density of pPI3KT458 by that of the loading 
control, β-Actin. Data are mean and SEM (* indicates phosphorylation is significantly 
higher in COPD compared to Healthy Control (HC) with the same stimulus (p ≤ 0.05)). 
(Analysed by unpaired Mann-Whitney U test). 
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4.4.3   AktS473 Phosphorylation 
Baseline AktS473 phosphorylation was relatively low in unstimulated (RPMI control) 
neutrophils for both healthy control subjects and COPD patients. AktS473 phosphorylation 
increased significantly with fMLP, GROα and IL-8 stimulation in healthy control neutrophils 
and with fMLP and IL-8 stimulation in COPD neutrophils. However, there was no difference 
in AktS473 phosphorylation between COPD and healthy control neutrophils under any 
experimental condition. A typical pAktS473 western blot is shown in Figure 4.16 and the 
collated data for 6 healthy and 6 COPD subjects are summarised graphically in Figure 4.17. 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: A representative western blot for pAktS473. 
Legend: A western blot of pAktS473 from lysates of unstimulated neutrophils (RPMI control) 
and those stimulated with fMLP, GROα and IL-8 from a Healthy Control (HC) subject and a 
patient with COPD. The blot is representative of 6 separate experiments. 
 
 
 
Phospho-Akt 
p60 (Ser473) 
Pan-Akt 
   HC       COPD        HC        COPD       HC        COPD        HC         COPD 
RPMI                       fMLP                     GROα                       IL-8 
  
175 
 
 
 
Figure 4.17: Akt phosphorylation at S473 in neutrophils from healthy and COPD 
subjects. 
Legend: COPD and healthy control (HC) neutrophils were either unstimulated (RPMI) 
or stimulated for 3 minutes with fMLP (100 nM), GROα (10 nM) and IL-8 (100 nM). 
Density ratio was calculated by dividing the optical density of phospho-Akt by that of 
the loading control, Pan-Akt. Data are displayed as median and IQR (# indicates 
phosphorylation is significantly higher in stimulated cells compared to unstimulated 
cells of the same cohort (p ≤ 0.05)). (Analysed by unpaired Mann-Whitney U test). 
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4.4.5   AktT308 Phosphorylation 
Baseline AktT308 phosphorylation was comparatively high in unstimulated (RPMI 
control) neutrophils for both healthy control subjects and COPD patients. This did not 
increase significantly when neutrophils were stimulated with fMLP, GROα or IL-8 in health 
or COPD. Furthermore, no significant differences in AktT308 phosphorylation were observed 
when comparing health to COPD. A typical pAktT308 western blot is shown in Figure 4.18 
and the collated data for 3 healthy and 3 COPD subjects are summarised graphically in 
Figure 4.19. 
 
 
 
 
 
 
 
Figure 4.18: A representative western blot for pAktT308. 
Legend: A western blot of pAktT308 from lysates of unstimulated neutrophils (RPMI) and 
those stimulated with fMLP, GROα and IL-8 from a healthy control (HC) subject and a 
patient with COPD. The blot is representative of 3 separate experiments. 
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Figure 4.19: Akt phosphorylation at T308 in neutrophils from healthy and COPD 
subjects. 
Legend: COPD and healthy neutrophils were either unstimulated (RPMI) or stimulated for 
3 minutes with fMLP (100 nM), GROα (10 nM) and IL-8 (100 nM). Density ratio was 
calculated by dividing the optical density of phospho-Akt by that of the loading control, 
Pan-Akt. Data are displayed as median and IQR. No significant differences were observed 
between comparisons of AktT308 phosphorylation between COPD and health. (Analysed by 
unpaired Mann-Whitney U test). 
 
 
4.5   INTRACELLULAR CALCIUM SIGNALLING 
Intracellular calcium release following stimulation with IL-8 was measured by 
fluorimetry in neutrophils from age-matched healthy subjects, patients with COPD and 
patients with α1-ATD (n=10). Both peak calcium release (increase from baseline) and total 
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calcium release (area under the curve) were calculated for each patient. As expected, the 
addition of IL-8 caused a rapid increase in neutrophil intracellular calcium in every subject 
and there was only modest variability in the initial surge of calcium release and the length of 
time it took for the intracellular calcium to return to basal levels. There was no significant 
difference in the peak calcium release between the three cohorts (Figure 4.20). Furthermore, 
the total calcium release was also comparable between groups (Figure 4.21). 
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Figure 4.20: Peak Intracellular calcium release following stimulation with IL-8. 
Legend: Neutrophils from healthy, COPD and α1-ATD subjects were stimulated with 
100 nM IL-8 to induce calcium release from intracellular stores. Peak calcium release 
was taken as the highest value achieved. Data are mean and SEM (n=10). (Analysed by 
one-way ANOVA). 
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Figure 4.21: Total Intracellular calcium release following stimulation with IL-8. 
Legend: Neutrophils from healthy, COPD and α1-ATD subjects were stimulated with 
100 nM IL-8 to induce calcium release from intracellular stores. Total calcium release 
was derived from the area under the curve. Data are mean and SEM (n=10). (Analysed 
by one-way ANOVA). 
 
 
 
4.6   DISCUSSION 
 
4.6.1   Quiescent Chemokine Receptor Expression 
To date, there have been a number of studies into the function of CXCR1- and CXCR2-
mediated neutrophil migration, although the specific role of these receptors in chemotaxis is 
still not clearly defined. In addition, there have been a few studies into the role of CXCR1 
and CXCR2 in neutrophil migration toward IL-8 but results are also conflicting and 
definitive conclusions cannot be drawn. Some studies suggest CXCR2 is not necessary for 
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IL-8 mediated migration (Loetscher et al. 1994, Godaly et al 2000) while others conclude 
that CXCR2 is important (Chuntharapai et al. 1995, Ben-Barach et al. 1997). One recent 
review (Stillie et al. 2009) proposed that both receptors may be capable of stimulating 
chemotaxis but, as CXCR2 responds to lower concentrations of IL-8 (as well as other 
chemoattractants) and is internalised/recycled more quickly than CXCR1, it may play a more 
significant role in migration at further distances from the chemoattractive source. In contrast, 
CXCR1 is not as sensitive to IL-8 and internalised more slowly but ultimately produces a 
broader range of physiological responses (such as ROS production) and may be more 
important nearer the site of inflammation for antimicrobial defence. Moreover, 
desensitisation of CXCR2 by CXCR1 at the site of inflammation may slow neutrophil 
migration (Stillie et al. 2009), which could theoretically facilitate more efficient bacterial 
killing.  Currently, there have been no studies investigating neutrophil expression of LTB4, 
fMLP or C5a receptors expression in COPD. 
Initially, this chapter compared surface expression of CXCR1, CXCR2, FPR1, LTB4R 
and C5aR on quiescent neutrophils from healthy subjects, patients with COPD and patients 
with α1-ATD.  A significant reduction in the surface expression of CXCR1 and C5aR on the 
neutrophils of COPD patients was seen compared to those from healthy controls. There was 
also a trend towards reduced expression of CXCR2 in COPD. No differences were observed 
between chemokine receptor expression in health and α1-ATD.  
During the stimulatory time-course experiments, surface expression of CXCR1, CXCR2 
and FPR1 on quiescent neutrophils was also compared. In agreement with the initial data, 
CXCR1 expression was significantly lower on COPD neutrophils compared to those from 
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healthy controls. CXCR1 was also significantly lower on COPD neutrophils compared to 
those from patients with α1-ATD, which was not observed in the previous experiments. No 
differences were observed in CXCR2 expression between subject groups, which is again at 
variance with the previous experiments, where expression was significantly lower on COPD 
neutrophils compared to α1-ATD. No significant differences in FPR1 expression were 
observed, which is in accordance with the previous work. 
The discrepancies between these data and the first set of experiments conducted 
highlight the fact that there is a large variability in published results. There have been a 
number of studies comparing expression of CXCR1 and CXCR2 on quiescent neutrophils 
from COPD and healthy subjects, although this is the first study to include patients with α1-
ATD. One recent study reported no difference in either CXCR1 or CXCR2 quiescent surface 
expression in COPD (Sapey et al. 2011). Pignatti et al. reported no difference between 
surface expression of CXCR1 in COPD neutrophils compared to those from healthy controls 
but a decrease in CXCR2 expression (Pignatti et al. 2005). In contrast, Yamagata et al. 
reported no difference in CXCR2 expression but an increased expression of CXCR1 in 
COPD neutrophils (Yamagata et al. 2007). It is also important to note that the processes 
involved in neutrophil isolation may also activate a proportion of neutrophils within the 
studied population (although cytospin images suggest this was minimal). In retrospect, it may 
have been better to perform this assay using whole blood and gating around the neutrophil 
population. 
The conflicting results of these studies make it difficult to draw definitive conclusions, 
though it is reassuring that a lower expression in CXCR1 on COPD neutrophils compared to 
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those from healthy subjects but similar expression of CXCR2 and FPR1 was observed in two 
independent experiments. Unfortunately, it was not possible to pool these data as the two 
experiments were conducted on different flow cytometers following laboratory relocation. 
 
4.6.2   Chemokine Receptor Expression Following Stimulation 
Studies into chemokine receptor expression to date have only investigated expression on 
quiescent neutrophils. While lower quiescent receptor expression may indicate a possible 
mechanism for aberrant neutrophil migration in COPD, it is impossible to draw conclusions 
based on this, as migrating neutrophils are not quiescent. Surface receptor expression in 
activated neutrophils is governed by rates of internalisation and recycling as well as any 
receptor shedding that may occur. Therefore, it is important to know whether or not these 
differences in quiescent CXCR1 expression endure following cell activation and whether 
new differences (for instance in CXCR2 and FPR1) may arise. 
Neutrophils were stimulated neutrophils over a 2 hour time-course with fMLP and IL-8 
and surface expression of CXCR1, CXCR2 and FPR1 was measured during cell activation. 
These two chemokines and their respective receptors were chosen over the other chemokines 
initially investigated (C5a, GROα and LTB4) as assessment of receptor recycling with all five 
chemokines was not feasible. Also, IL-8 is a potent endogenous chemoattractant and the 
majority of previous work in this area has included CXCR1 and CXCR2. fMLP is a bacterial 
peptide and also a potent activator of neutrophils. Like many chemokines, its levels are 
elevated during COPD exacerbations (Saetta et al. 2001). 
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Both CXCR1 and CXCR2 surface expression decreased over time in all patient groups, 
indicating that either receptor internalisation or shedding was most likely occurring. CXCR1 
expression decreased in a more linear fashion than CXCR2, which decreased very rapidly in 
all patient groups and plateaued after 15 minutes. The only other mechanism by which 
surface receptor expression can decrease is by shedding. Therefore, CXCR1 and CXCR2 
shedding was quantified by ELISA. CXCR1 shedding was negligible at 30 and 120 minutes 
post-stimulation in both health and COPD, suggesting that the dominant process of CXCR1 
removal from the cell surface following IL-8 stimulation was internalisation. A modest 
amount of CXCR2 shedding was detected but was comparable in both cohorts. It has 
previously been demonstrated that stimulation of neutrophils with other inflammatory 
cytokines (such as TNFα) can induce CXCR2 shedding (Asagoe et al. 1998). The data in this 
chapter suggest that CXCR2 is shed more readily than CXCR1 following stimulation with 
IL-8. Receptor recycling was confirmed by removal of the IL-8 stimulus and quantification 
CXCR1 and CXCR2 expression 90 minutes later. Surface expression of both receptors 
increased on COPD and healthy neutrophils, albeit not back to baseline levels observed on 
quiescent cells, suggesting recycling and re-expression was occurring at a relatively slow 
rate. 
The initial difference observed in CXCR1 expression on quiescent neutrophils between 
COPD and healthy controls was rapidly abolished (within 5 minutes) following stimulation 
with IL-8. CXCR1 expression remained significantly higher in α1-ATD than COPD for 
slightly longer (15 minutes), which could potentially explain why more accurate chemotaxis 
was observed with α1-ATD neutrophils in the presence of IL-8. CXCR2 expression decreased 
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at the same rate in all patient groups and no significant differences in surface expression were 
observed at any time-point. 
FPR1 surface expression was relatively low on quiescent neutrophils from COPD 
patients, healthy controls and patients with α1-ATD. Activation supposedly induces a 
dramatic and rapid increase in FPR1 expression via the mobilisation of internal secretory 
vesicles (Sengelov et al. 1994, Kitchen et al. 1996, Borregard et al. 1997). Therefore, it was 
surprising to see that FPR1 surface expression did not increase at any stage of the time-
course in any patient group. It could be that a large number of internal FPR1 receptors are 
mobilised to the cell surface before 5 minutes, bind rapidly to fMLP before becoming 
internalised once more, which may be demonstrated by including additional time points 
before 5 minutes. Alternatively, a more steady supply of FPR1 receptors may be expressed 
from internal stores and, again, internalise very rapidly after binding to fMLP. Both 
mechanisms would account for a relatively constant but low expression of FPR1 on the 
neutrophils surface during stimulation with fMLP. The latter is less likely based on 
previously published data showing upregulation of fMLP receptors following stimulation, 
although the authors used PAF as a stimulant rather than fMLP (Sengelov et al. 1994, 
Kitchen et al. 1996). The fact that expression (albeit low) was detected in quiescent 
neutrophils (in two independent assays using two different supplies of FPR1 antibody) 
suggests that the antibody was most likely reliable. However, it is possible that the fMLP was 
unreliable or could have degraded in storage, meaning the ability to sufficiently stimulate 
neutrophils could have been compromised. Therefore, it would be logical to repeat this 
experiment with fresh fMLP, fresh FPR1 antibody additional and time points before 5 
minutes to confirm or refute our observation. 
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To our knowledge, no previous studies have compared the difference in surface 
chemokine receptor expression on neutrophils from COPD patients and healthy controls in 
the presence of a stimulus. One study (Pignatti et al. 2005) compared CXCR1 and CXCR2 
expression on neutrophils in the peripheral blood and sputum of COPD patients. They 
identified a significantly lower expression in sputum neutrophils compared to those in the 
peripheral blood. In effect, this is somewhat of a similar comparison between quiescent 
neutrophils (in the blood) and activated neutrophils (that have migrated to the airway) that 
seems to support findings in this study. It is plausible that down-regulation of surface 
receptors for endogenous chemokines during migration to an inflammatory site (such as the 
lungs in COPD) may be important for the sensing of and ability to follow gradients of 
bacterial chemokines such as fMLP at the site of inflammation. It would be interesting to 
determine whether or not surface expression of FPR1 is up-regulated on neutrophils 
following stimulation with IL-8 alone. 
 
4.6.3   Receptor Localisation 
The final question this chapter sought to answer regarding chemokine receptors was 
whether or not these receptors were localising to the leading edge of COPD neutrophils as 
effectively as would be expected for healthy neutrophils. Therefore, CXCR1 and CXCR2 
localisation was investigated on adhered neutrophils following stimulation with fMLP in an 
assay adapted from a recent study by Mondal et al. (Mondal et al. 2012). Initially, the FITC-
stained neutrophils did not fluoresce to a large degree but the addition of Anti-FITC Alexa 
Fluor 488 resulted in markedly higher fluorescence and clearer images. Although the         
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PE-labelled neutrophils were relatively clear, it may also have been useful to use an Anti-PE 
Alexa Fluor to increase the PE fluorescence further. 
Unfortunately, densitometric quantification of the receptor expression by pixilation 
brightness did not seem applicable due to the high variability of CXCR1 and CXCR2 
expression observed in the initial flow cytometry assays (between individuals within the 
same cohort as well as differential expression between COPD and health). Therefore, this 
method is perhaps a relatively crude means of assessing receptor localisation. However, clear 
differences in receptor localisation were observed between quiescent neutrophils (where 
receptors were more uniformly distributed) and stimulated, polarised neutrophils (where 
receptors localised to one side of the cell) for both COPD and healthy neutrophils. Moreover, 
the results demonstrate that CXCR1 and CXCR2 appeared to localise to the leading edge of 
stimulated neutrophils as effectively in COPD as they do in health. 
 
4.6.4   PI3K and Akt Phosphorylation 
The PI3K pathway has been implicated in a number of neutrophil inflammatory 
functions, including cell migration (Knall et al. 1997, Sasaki et al. 2000, Sadhu et al. 2003). 
Therefore, it was hypothesised that increased activation of key effector proteins such as PI3K 
and Akt, detected by protein phosphorylation, may account for the aberrant migration of 
COPD neutrophils. 
Ideally, investigation into PI3K phosphorylation and activation in relation to GPCR-
mediated neutrophil migration would have included the assessment of the p84/p101 
regulatory subunits and, more importantly, the p110 catalytic subunit of PI3Kγ. However, at 
the time of experimentation, there were no validated phosphospecific antibodies for these 
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subunits and the only robustly validated antibody was for the Class 1a regulatory subunit, 
p85 at tyrosine 458 (PI3KT458). The biological significance of Tyr458 phosphorylation on 
PI3K function is currently unknown, although phosphorylation of p85 at serine 83 (by 
Protein Kinase A) has been shown to influence the interaction of the SH3 domain with 
binding partners (Cosentino et al. 2007) and it is possible that similar functional 
modifications could occur through Tyr458 phosphorylation. Therefore, it is important to note 
that the assessment of pPI3KT458 was a pilot study that may be indicative of potential 
differences in the function of this family of kinases in COPD neutrophils. 
A relatively high PI3KT458 phosphorylation was detected in unstimulated neutrophils 
from both healthy controls and COPD patients. Phosphorylation did not increase in either 
subject group following stimulation by fMLP, GROα or IL-8. While this may seem 
surprising, published data from our group support these results. Young healthy subjects had 
low PI3KT458 phosphorylation in unstimulated neutrophils, which increased significantly 
upon stimulation with IL-8, whereas PI3KT458 phosphorylation was elevated in unstimulated 
neutrophils from old healthy subjects and did not increase upon stimulation (Sapey et al. 
2014). This suggests that hypothetical neutrophil PI3K over-activity in the elderly may be an 
independent phenomenon which, once again, highlights the importance of age-matching 
healthy control groups to COPD patients. In addition, there was a trend towards even higher 
PI3KT458 phosphorylation in both unstimulated and stimulated COPD neutrophils, although 
the majority of these comparisons failed to reach statistical significance. With greater power, 
it is possible that all of these comparisons between COPD and health may achieve statistical 
significance. As the regulatory subunits can influence the stability, localisation and function 
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of the catalytic subunits, it is possible that dysregulation of the phosphorylation state of 
different p85 subunits may influence the overall function of Class 1a PI3Ks. Indeed, there 
have been two studies that have described splice mutations of the PIKR31 gene (that encodes 
p85α) in lymphocytes that lead to over-activity of PI3K, alterations in lymphocyte 
structure/function and immunodeficiency (Deau et al. 2014, Lucas et al. 2014). It is possible 
that this phenomenon could be mirrored in neutrophils, although it is highly speculative to 
infer that a similar effect may be occurring in the Class 1b PI3Kγ (which signals through the 
GPCRs involved in chemokine-mediated neutrophil migration). However, the pPI3KTYR458 
data presented in this thesis suggest that there could be some differences in the 
phosphorylation and activity of the PI3K family of kinases in COPD and certainly warrants 
further investigation. Future studies should include assessment of the phosphorylation of the 
p84/p101 regulatory and p110 catalytic subunits of PI3Kγ. If increased phosphorylation of 
one or more of these subunits is observed, it could provide a possible reason for the 
dysfunctional neutrophil migration observed in COPD. Further to this, potential mutations in 
the genes that encode these subunits could be investigated with whole-exome sequencing, 
which may identify a genetic cause behind any PI3K over-activity in COPD neutrophils. 
The improvement in migratory accuracy with the non-selective PI3K inhibitor LY29004 
previously observed (Sapey et al. 2011) infers that PI3K activity could potentially be 
increased in COPD. Our pilot PI3KT485 data demonstrating increased phosphorylation at p85 
support this hypothesis, although the information is limited. Increased phosphorylation of 
PI3K regulatory subunits in quiescent neutrophils could result in a more pronounced 
association with the plasma membrane and, potentially, augment PIP3 formation once the 
catalytic subunits are also phosphorylated upon stimulation. However, this is speculative and 
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the fact that phosphorylation of the catalytic subunits of Class 1a PI3Ks and, most 
importantly, the catalytic/regulatory subunits of Class 1b PI3Kγ were not investigated means 
that the potential alteration of PI3Kγ phosphorylation during GPCR-mediated neutrophil 
migration could not be truly evaluated. Although our data suggest the phosphorylation of the 
p85 regulatory subunit is maintained in COPD, it may have been useful to determine if there 
was a differential expression of the PI3Kδ and, particularly, the PI3Kγ isoforms between 
health and COPD, as lower PI3Kγ (with either p84 or p101 regulatory subunits) expression 
may explain why COPD neutrophils were migrating with poor accuracy in chemokines that 
signal through GPCRs. 
In contrast, Akt phosphorylation at the serine 473 site was low in unstimulated 
neutrophils from both healthy subjects and COPD patients and increased significantly 
following stimulation with fMLP and IL-8 in both subject groups. A small, but significant 
increase was seen in healthy neutrophils following stimulation with GROα but this was not 
seen in COPD. These data help also validate the results for pPI3K, as identical methods were 
used for stimulation, freezing and western blotting, indicating that the absence of increased 
PI3K phosphorylation post-stimulation does not seem to be due to methodological 
limitations. The western blots for Akt phosphorylation at threonine 308 were of poorer 
quality, which made analysis more difficult and interpretation less clear. This was most likely 
due to an unreliable primary antibody, which resulted in a high degree of irrelevant binding 
and made densitometric analysis of the pAktT308 protein bands difficult. It may be expected 
that a hypothetical loss of p85-mediated catalytic subunit activity of PI3K may increase the 
downstream signalling of Akt. However, our data suggest that differences in PI3KT458 
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phosphorylation do not appear to relate to Akt phosphorylation (particularly basal levels) 
and, although Akt is important in cell migration, its activity may not explain the aberrant 
neutrophil migration observed in COPD. However, with low power (and poor quality western 
blots for AktT308), it is difficult to draw definitive conclusions and western blots with larger 
cohorts and more reliable pAkt antibodies seem warranted. Unfortunately, this experiment 
was conducted at the end of the thesis and we were unable to repeat it with a different 
pAktT308 antibody within the timeframe. 
Achieving good quality western blots with neutrophils has proved somewhat difficult. 
Initially, no reliable results were obtained although, with methodological adjustments, clearer 
blots were ultimately achieved for the majority of the antibodies. Following these 
amendments, protein bands were clear (with no evidence of proteolysis) but they were still 
often faint, which may have resulted from a number of factors. Firstly, neutrophils contain 
high levels of proteinases, which may not be adequately controlled during the lysis protocol 
(despite the use of protease inhibitors), giving a weaker signal. Secondly, protein 
phosphorylation could be more transient than the time-courses suggest (particularly in the 
case of Akt) and the peak phosphorylation time may also be variable between subjects. 
However, for pPI3KT458 and pAktS473, phosphorylation was detected at the majority of time-
points throughout the time-course. Lastly, the primary antibodies may not be particularly 
reliable. Although irrelevant binding was minimal for pPI3KT458, this was not the case for 
pAkt (particularly for T308), which made densitometric quantification of Akt 
phosphorylation difficult. Stimulation at room temperature could have been a contributing 
factor to some of the poor responses observed and 37ºC may have been more suitable and 
enhanced phosphorylation. Other studies have observed clear phosphorylation response to 
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fMLP with both AktS437 and AktT308 at 37ºC (Yagi et al. 2007). However, a clear 
phosphorylation of AktS437 as observed at room temperature and increased phosphorylation 
of PI3KT458 following stimulation has been observed in young neutrophils at room 
temperature (Sapey et al. 2014). Nevertheless, repeating these assays at 37ºC may be 
important for future experiments. 
It is also important to note that these assays were all performed on neutrophils in 
suspension, which is unlikely to fully replicate the conditions of migration. In hind sight, it 
may have been more suitable to perform these assays on adhered neutrophils that had been 
stimulated with a gradient of chemoattractant, rather than non-adhered neutrophils that had 
chemoattractant simply added to the medium. 
In summary, the data shown here suggest that PI3K (but not Akt) phosphorylation may 
be increased in COPD neutrophils compared to those from healthy controls. Although pPI3K 
activity cannot be deduced from western blots, this could potentially be a mechanism of 
aberrant neutrophil migration in COPD. 
 
4.6.5   Intracellular Calcium Signalling 
As previously mentioned (Section 1.2.3), current evidence suggests that intracellular 
calcium signalling may be critical for cell polarisation and/or chemotaxis. However, the 
precise mechanisms by which calcium is involved in migration have yet to be elucidated. 
Studies also suggest that calcium transients are only required for neutrophil migration in vitro 
on certain substrates. On fibronectin and vitronectin, which is β1- and β3 integrin-dependant, 
increases in calcium seem to be required for the detachment of these integrins from the 
uropod so they may be recycled back to the leading edge (Marks et al. 1990). In contrast, 
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neutrophil migration on albumin coated glass seems to rely predominantly on β2 integrins 
(Sixt et al. 2001) and may not require calcium (Marks et al. 1991, Mandeville et al. 1996). 
However, if the aberrant neutrophil migration observed in COPD is a general phenomenon 
that occurs during all types of migration in vivo, calcium signalling may still be involved. 
Here real-time Ca
2+
 release from intracellular stores following stimulation with IL-8 was 
analysed in COPD patients, healthy control subjects and patients with α1-ATD. Initially, this 
assay was very unreliable, primarily due to unstable fluorescence signals (even at baseline). 
However, by resuspending the neutrophils in calcium-containing HBSS (rather than HBSS 
alone), signals were far more stable and consistent results were obtained. The disadvantage of 
suspending neutrophils in calcium-containing HBSS is that they could absorb small amounts 
of calcium from the medium. This resulted in a very slight increase in the fluorescence at the 
end of the experiment (following ionomycin and subsequent EGTA administration) 
compared to baseline. To compensate, the value at the end of the test was taken as the 
“baseline” value and applied this to the calculation of peak and total calcium release. 
Although not ideal, the difference in values was minimal and total calcium release (area 
under the curve) could not be calculated without this modification. 
There were no differences in either peak (initial “burst”) or total calcium release, 
indicating that IL-8-induced calcium signalling is unaltered in COPD in vitro. To our 
knowledge, there have been no comparisons between calcium signalling in neutrophils from 
COPD patients and healthy control subjects. However, regardless of its potential involvement 
in cell migration, the data here suggest that altered calcium signalling cannot be implicated in 
the aberrant neutrophil migration in COPD. 
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4.6.6   Summary 
The data in this chapter indicate that the aberrant neutrophil migration in COPD seems 
unrelated to chemokine receptor expression and localisation on activated neutrophils, 
regardless of differential expression on quiescent cells. This suggests that downstream 
signalling is the most likely cause of the chemotactic dysfunction of COPD neutrophils. 
Intracellular calcium signalling was unaltered, but a clear trend towards increased PI3K 
(though not Akt) phosphorylation was observed. This suggests that the PI3K pathway may be 
a suitable target for pharmacological correction of the aberrant neutrophil migration in 
COPD. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 5 
 
PHARMACOLOGICAL CORRECTION OF 
ABERRANT NEUTROPHIL MIGRATION 
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5.1   BRIEF INTRODUCTION 
The studies described previously have demonstrated that COPD neutrophils migrate with 
increased speed but reduced accuracy. This is likely to have implications in the 
pathophysiology of COPD as, if neutrophils migrate inaccurately through the extracellular 
matrix, their migratory tracks will be much longer, leading to an amplification of 
parenchymal destruction by the proteinases released during neutrophil transmigration (Sapey 
et al. 2014). It is also possible that the ability of neutrophils within the airspaces to locate and 
kill invading pathogens may also be impaired, which could lead to increased bacterial 
colonisation and, ultimately, an increase in exacerbation frequency. Current therapies for the 
treatment of COPD are limited and are predominantly aimed at the short-term relief of 
symptoms through the improvement of pulmonary ventilation and a reduction of the work of 
breathing by bronchodilation (Gold 2007). The search for novel anti-inflammatory therapies 
is ongoing but has, to date, been largely unsuccessful. Theoretically, dysfunctional neutrophil 
migration may account for part of the pathogenesis of COPD. Therefore, correction of this 
phenomenon could potentially slow the disease and reduce mortality. 
With any medical research, the ultimate goal should be to further the understanding of 
pathological processes so that novel treatments may be developed. The data presented here 
indicate that the aberrant neutrophil migration in COPD appears to be an intrinsic cell defect. 
Therefore, its pharmacological correction should ideally be aimed specifically at neutrophil 
function rather than a more systemic anti-inflammatory approach. The migratory dysfunction 
in COPD does not seem to be related to chemokine receptor availability or localisation, in 
spite of lower surface expression of some receptors on quiescent neutrophils (although this 
does not necessarily mean that manipulation of chemokine receptor function could not 
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improve chemotaxis). Therefore, it seems logical to infer that it must be due to a dysfunction 
in downstream signalling. 
Intracellular calcium signalling was unaltered in COPD. However, a trend towards 
overexpression of pPI3K (but not pAkt) was observed in neutrophils from COPD patients. 
These data, together with previous work that demonstrated an improvement in migratory 
accuracy of COPD neutrophils with non-specific PI3K inhibitors (Sapey et al. 2011), 
highlight the PI3K pathway as an attractive target for therapeutic intervention. Furthermore, 
the accumulation of PIP3 at the leading edge of migrating neutrophils provides additional 
evidence for the involvement of PI3K in neutrophil chemotaxis. However, PI3K is associated 
with numerous cellular functions, including growth, proliferation, differentiation, motility 
and survival, meaning non-specific inhibition in vivo may result in undesirable side-effects. 
The γ- and δ-isoforms are more specific to leukocytes, and PI3Kγ in particular is known to be 
intimately associated with cell migration following stimulation by a number of chemokines 
and evidence suggests it is necessary for directionality during migration (Hannigan et al. 
2002). PI3Kδ involvement is less well described, though it may aid in the sustainment of a 
chemokine-mediated response (Condliffe et al. 2005). Therefore, it seemed logical that 
PI3Kγ and/or δ isoform inhibition could prove more therapeutically advantageous than broad 
range PI3K inhibitors in COPD, where neutrophil directionality is poor. 
There has been a growing interest in the potential of PI3Kδ- and/or PI3Kγ-specific 
inhibitors, which have shown promise in general neutrophil inflammatory responses (Sadhu 
et al. 2003, Williams et al. 2010) as well as various disease models (Barber et al. 2005, 
Doukas et al. 2006). Furthermore, the use of these inhibitors in the treatment of respiratory 
disease such as asthma and COPD has also shown therapeutic potential (Finan et al. 2004, 
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Adcock et al. 2006, Lee et al. 2006, Ito et al. 2007, Krymskaya 2007), with one group 
showing that an aerosolised PI3Kγ/δ inhibitor had notable anti-inflammatory effects in a 
murine model of COPD (Doukas et al. 2010). Importantly, increased PI3Kδ activity as a 
result of gene mutation has been associated with many adverse physiological effects, 
including recurrent respiratory infections and progressive airway damage (Angulo et al. 
2013). Therefore, if COPD is associated with a general increase in PI3K activity, selective 
isoform inhibition could potentially have a broader anti-inflammatory effect and even reduce 
exacerbation frequency. However, further work is required to understand how PI3Kγ and -δ 
inhibition affects neutrophil function in human COPD. 
As mentioned previously (Section 1.2.3), PI3K is not the only kinase involved in 
neutrophil migration. The MAPKs, including Erk and p38, are involved in migration (Heit et 
al. 2007), the latter of which is indirectly involved in directionality by phosphorylation of 
MAPK-activated protein kinase 2/3 (Huang et al. 2004). However, it is currently unknown 
whether inhibition of these other kinases would also alter the migratory dynamics of 
neutrophils. 
Although chemokine receptor expression may not be altered in migrating COPD 
neutrophils, it does not necessarily mean that their blockade could not influence neutrophil 
migration. Indeed, recent clinical trials in healthy subjects have shown that a CXCR2 
antagonist (AZD8309) attenuated neutrophil airway recruitment following LPS challenge 
(Virtala et al. 2011, Leaker et al. 2013). Similarly, a dual CXCR1/2 antagonist has also been 
shown to inhibit neutrophil recruitment and also reduce mucus production and goblet cell 
hyperplasia in animal models of pulmonary inflammation (Chapman et al. 2007). However, 
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the precise effects of chemokine receptor inhibitors such as AZD8309 on the migratory 
dynamics of COPD neutrophils are currently unknown. 
Another therapy that could potentially improve the migratory accuracy of COPD 
neutrophils is statin, which regulate small GTPase (Ras and Rho) activity further downstream 
of the PI3K pathway (Fromigue et al. 2006, Dai et al. 2007). As discussed previously 
(Section 1.5.9), studies into the effects of statins on neutrophil migration are contrasting, 
although reduced neutrophil influx into the lungs has been demonstrated in both mice and 
humans following statin treatment (Lee et al. 2005, Maher et al. 2009). 
The studies in this chapter were designed to determine if pre-incubation with various 
pharmacological agents, including CXCR1/2 agonists, specific PI3K isoform inhibitors (α, β, 
δ, and γ), Erk and p38 inhibitors, or simvastatin could improve the migratory accuracy of 
neutrophils isolated from the peripheral blood of COPD patients. As the inhibition of 
CXCR1/2 does not block a generic pathway that can be activated by other chemoattractants, 
neutrophils could still transmigrate effectively in vivo towards other chemoattractants (such 
as LTB4) in the sputum. Therefore, the inclusion of Sputum Sol in the CXCR1/ inhibitor 
assay was deemed essential. Importantly, we have previously shown that COPD neutrophils 
migrate with comparably poor accuracy in sputum gradients as they do in isolated 
chemoattractants (Sapey et al. 2011).  Neutrophil migration was assessed using the Insall 
chamber as described previously in Section 2.5.1. 
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5.2   SUBJECT DEMOGRAPHICS 
Demographic data for the COPD patients included in this chapter are shown in Table 
5.1.  
 
5.3   CXCR1 AND CXCR2 INHIBITION 
Migratory dynamics were measured in neutrophils from 10 COPD patients in medium 
(RPMI-1640) and shallow gradients of 100 nM IL-8, 10 nM GROα and sputum sol phase 
(Sol). Migration was re-assessed in IL-8, GROα and Sol following incubation with a CXCR1 
inhibitor (2 μg/ml), a CXCR2 inhibitor (50 μg/ml) or a dual CXCR1/2 inhibitor 
(SCH527123). SCH527123 was used at two concentrations; 3 nM (specific to CXCR2) and 
42 nM (required for additional inhibition of CXCR1). 
 
  COPD 
    
N 35 
    
Age (years) 63 (48 - 80) 
Gender (Male:Female) 54 
Smoking status  12 CS, 23 XS 
Pack years 51 (3.5)  
    
FEV1 % predicted 48.3 (4.5)  
FEV1 /FVC % 48.3 (3.7)  
    
 
 
Table 5.1: Subject Demographics. 
Legend: A table showing the demographic data for all COPD patients 
included in this chapter. Data are normally distributed and presented as 
the mean and SEM, except the age which is mean (range). CS = Current 
smokers, XS = Ex-smokers. 
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5.3.1   CXCR1 Inhibition 
Chemokinesis was relatively low in RPMI-1640 medium and increased significantly in 
gradients of IL-8, GROα and Sol. Pre-incubation with the CXCR1 inhibitor caused a 
significant reduction in chemokinesis in a gradient of IL-8 (p<0.0001) and a modest but 
significant reduction in chemokinesis in GROα (p=0.029). Chemokinesis was also 
significantly reduced when the COPD neutrophils were migrating towards Sol (p<0.001). 
These data are summarised in Figure 5.1. 
Chemotaxis was negligible in medium alone and increased significantly in IL-8, GROα 
and Sol. However, the CXCR1 inhibitor had no effect on chemotaxis in any of these 
chemotactic gradients (Figure 5.2). 
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Figure 5.1: Chemokinesis of COPD neutrophils in the presence of a CXCR1 inhibitor. 
Legend: The chemokinesis of neutrophils from COPD patients was significantly higher in 
IL-8, GROα and Sol compared to RPMI (*p < 0.0001). Chemokinesis was attenuated with 
the CXCR1 inhibitor in cells migrating in IL-8, GROα and Sol. Data are median and IQR 
(n=10).  (Analysed by Kruskal-Wallis test). 
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Figure 5.2: Chemotaxis of COPD neutrophils in the presence of a CXCR1 inhibitor. 
Legend: The chemotaxis of neutrophils from COPD patients was significantly higher in IL-
8, GROα and Sol compared to RPMI (*p < 0.0001). However, chemotaxis was unaltered 
with the CXCR1 inhibitor in any chemotactic gradient. Data are median and IQR (n=10). 
(Analysed by Kruskal-Wallis test). 
 
 
 
 
5.3.2   CXCR2 Inhibition 
Chemokinesis increased significantly in gradients of IL-8, GROα and Sol compared to 
RPMI-1640. Pre-incubation with the CXCR2 inhibitor caused a significant reduction in 
chemokinesis in IL-8, GROα and Sol (p<0.0001 for all) (Figure 5.3). 
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Figure 5.3: Chemokinesis of COPD neutrophils in the presence of a CXCR2 inhibitor. 
Legend: The chemokinesis of neutrophils from COPD patients was significantly higher in 
IL-8, GROα and Sol compared to RPMI (*p < 0.0001). Chemokinesis was attenuated with 
the CXCR2 inhibitor in all chemotactic gradients. Data are median and IQR (n=10). 
(Analysed by Kruskal-Wallis test). 
 
 
 
Chemotaxis was negligible in RPMI-1640 and increased significantly in gradients of IL-
8 and Sol but not GROα. The CXCR2 inhibitor had no effect on chemotaxis in any 
chemotactic gradient (Figure 5.4). 
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Figure 5.4: Chemotaxis of COPD neutrophils in the presence of a CXCR2 inhibitor. 
Legend: The chemotaxis of neutrophils from COPD patients was significantly higher in IL-
8 and Sol (not GROα) compared to RPMI (*p < 0.0001). The CXCR2 antibody had no 
effect on chemotaxis in any chemotactic gradient. Data are median and IQR (n=10). 
(Analysed by Kruskal-Wallis test). 
 
 
 
5.3.3   Dual CXCR1/2 Inhibition 
Pre-incubation with the dual CXCR1/2 inhibitor (SCH527123) at both concentrations (3 
nM and 42 nM) caused a significant reduction in chemokinesis in gradients of both IL-8 and 
GROα, but only 3 nM caused a significant reduction of chemokinesis in Sol (Figure 5.5). 
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Figure 5.5: Chemokinesis of COPD neutrophils the presence of a CXCR1/2 inhibitor. 
Legend: The chemokinesis of neutrophils from COPD patients was significantly higher in 
IL-8, GROα and Sol compared to RPMI (*p < 0.0001). Chemokinesis was attenuated with 
both 3 nM and 42 nM of the CXCR1/2 inhibitor (SHC527123) in gradients of IL-8 and 
GROα but only at 3nM in Sol. Data are median and IQR (n=10). (Analysed by Kruskal-
Wallis test). 
 
 
 
SCH527123 had no effect at 3 nM on chemotaxis in IL-8, although there was a trend for 
reduced chemotaxis in 42 nM (p = 0.052). In GROα, 3 nM SCH527123 caused a modest but 
significant reduction in chemotaxis, but 42 nM had no effect. Neither concentration of 
SCH527123 affected neutrophil chemotaxis in Sol (Figure 5.6). 
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Figure 5.6: Chemotaxis of COPD neutrophils in the presence of a CXCR1/2 inhibitor. 
Legend: The chemotaxis of neutrophils from COPD patients was significantly higher in IL-
8, GROα and Sol compared to RPMI (*p < 0.0001). The CXCR1/2 inhibitor (SHC527123) 
did not have any effect on chemotaxis in IL-8 or Sol. In contrast, 3 nM SHC527123 
significantly reduced chemotaxis in GROα. Data are median and IQR (n=10). (Analysed by 
Kruskal-Wallis test). 
 
 
 
5.4   PI3K ISOFORM INHIBITION 
Migratory dynamics were measured in neutrophils from 5 COPD patients in either 
medium alone, a shallow gradient of 100nM IL-8 alone or IL-8 following incubation in either 
α, β, δ, or γ PI3K isoform inhibitors. As expected, chemokinesis was relatively low in RPMI-
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1640 and this increased significantly in gradients of IL-8 in all patients. However, 
chemokinesis was unaltered by incubation in any of the PI3K isoform inhibitors compared to 
IL-8 alone (Figure 5.7). 
 
 
Figure 5.7: Chemokinesis of COPD neutrophils in the presence of PI3K isoform 
inhibitors. 
 
Legend: The chemokinesis of neutrophils from COPD patients was unaltered following pre-
incubation with any of the four PI3K isoform inhibitors. Data are mean and SEM (n=5). 
(Analysed by one-way ANOVA). 
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Chemotaxis was negligible in RPMI-1640 and also increased significantly when an IL-8 
gradient was applied. This did not improve any further when the neutrophils were pre-
incubated with PI3Kα or -β isoform. However, in contrast to chemokinesis, the PI3Kδ and -γ 
inhibitors significantly improved the chemotaxis of COPD neutrophils (Figure 5.8). 
 
 
Figure 5.8: Chemotaxis of COPD neutrophils the presence of PI3K isoform inhibitors. 
Legend: The chemotaxis of neutrophils from COPD patients was unaltered following pre-
incubation with PI3Kα or -β isoform inhibitors. In contrast, both the PI3Kγ and -δ 
inhibitors significantly improved chemotaxis (* p<0.05). Data are mean and SEM (n=5). 
(Analysed by one-way ANOVA). 
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5.5   Erk INHIBITION 
Migratory dynamics were measured in neutrophils from COPD patients in either medium 
alone or a shallow gradient of 100nM IL-8 with or without pre-incubation in an Erk inhibitor 
(UO126). Chemokinesis was unaltered by incubation in the Erk inhibitor (Figure 5.9). 
 
 
 
Figure 5.9: Chemokinesis of COPD neutrophils in the presence of an Erk inhibitor. 
Legend: The chemokinesis of neutrophils from COPD patients was unaltered following 
pre-incubation with the Erk inhibitor. Data are mean and SEM (n=6). (*p < 0.05 
compared to IL-8 ± UO126). (Analysed by one-way ANOVA). 
 
 
 
 
* 
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Chemotaxis was negligible in median alone and increased significantly when an IL-8 
gradient was applied. This did not alter significantly when the neutrophils were pre-incubated 
with the Erk inhibitor (Figure 5.10). 
 
 
 
Figure 5.10: Chemotaxis of COPD neutrophils in the presence of an Erk inhibitor. 
Legend: The chemotaxis of neutrophils from COPD patients was unaltered following 
pre-incubation with the Erk inhibitor. Data are mean and SEM (n=6). (*p < 0.05 
compared to IL-8 ± UO126). (Analysed by one-way ANOVA). 
 
 
 
 
* 
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5.6   p38 INHIBITION 
Migratory dynamics were measured in neutrophils from COPD patients in either medium 
(RPMI-1640) or a shallow gradient of 100nM IL-8 with or without pre-incubation in one of 
two p38 inhibitors (VX745 or SCIO469). As expected, chemokinesis was relatively low in 
RPMI-1640 and this increased significantly in gradients of IL-8 in all patients. However, 
chemokinesis was unaltered by incubation in either p38 inhibitor (Figure 5.11). 
 
 
 
Figure 5.11: Chemokinesis of COPD neutrophils in the presence of p38 inhibitors. 
Legend: The chemokinesis of neutrophils from COPD patients was unaltered following 
pre-incubation with either p38 inhibitor. Data are mean and SEM (n=6). (*p < 0.05 
compared to IL-8 ± Erk p38 inhibitors). (Analysed by one-way ANOVA). 
 
 
* 
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Chemotaxis was negligible in RPMI-1640 and also increased significantly when an IL-8 
gradient was applied. However, it did not alter significantly when the neutrophils were pre-
incubated with either p38 inhibitor (Figure 5.12). 
 
 
 
 
Figure 5.12: Chemotaxis of COPD neutrophils in medium and IL-8 +/- p38 
inhibitors. 
Legend: The chemotaxis of neutrophils from COPD patients was unaltered following pre-
incubation with either p38 inhibitor. Data are mean and SEM (n=6). (*p < 0.05 compared 
to IL-8 ± Erk p38 inhibitors). (Analysed by one-way ANOVA). 
 
 
 
 
* 
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5.7   SIMVASTATIN 
 
5.7.1   Validation: Simvastatin Concentration Titration 
Chemotaxis was initially assessed using a range of simvastatin concentrations to 
determine which would yield the highest values for the proposed investigation. 
Concentrations of simvastatin spanning the normal therapeutic dose range were tested to 
assess for a concentration response relationship (1nM, 10nM, 100nM, 1µM) using 
neutrophils from 3 healthy donors. Migration was also measured in RPMI-1640 medium and 
IL-8 alone as negative controls. Chemotaxis with simvastatin did not show a true 
concentration response, though migratory accuracy did improve with 1 nM and 10 nM. This 
returned to values comparable to baseline with 100 nM simvastatin and improved a little (but 
not significantly) beyond this with 1 µM. These data are summarised graphically in Figure 
5.13. 
With the increasing concentrations of simvastatin, we obeserved a traditional 
concentration response, with the peak chemotactic response occuring with 10 nM 
simvastatin. However, as there as no difference between 1 nM and 10 nM simvastatin, 1 nM 
(equivalent to 20 mg/day) was used in the final investigation to reflect the minimum 
therapeutic dose. In addition, 1 µM (equivalent to 80 mg/day) was also used to reflect the 
maximum therapeutic dose. 
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Figure 5.13: Chemotactic concentration response to simvastatin of healthy 
neutrophils in IL-8. 
Legend: Chemotaxis of helathy neutrophils migrating in a shallow gradient of 100 
nM   IL-8 following pre-incubation with increasing concentrations of simvastatin. 
Data are mean and SEM (n=3). 
 
 
 
 
5.7.2   Neutrophil Migration Following Treatment with Simvastatin 
The migratory dynamics of neutrophils from both COPD patients were assessed in 
RPMI-1640 medium (control) as well as gradients of 100 nM IL-8 and fMLP with and 
without a 40 minute pre-incubation with simvastatin (1 nM and 1 µM). 
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Chemokinesis 
As expected, chemokinesis was higher in the presence of IL-8 and fMLP compared to 
RPMI-1640 medium alone. Pre-incubation with simvastatin (at either 1 nM or 1 μM) did not 
alter chemokinesis in IL-8. However, there was a significant but modest increase in 
chemokinesis in fMLP following pre-incubation with 1 nM simvastatin (p = 0.02). These 
data are summarised in Figure 5.14. 
 
 
Figure 5.14: The effects of simvastatin on chemokinesis of COPD neutrophils. 
Legend: Chemokinesis of COPD and neutrophils migrating in a shallow gradients of 100 
nM IL-8 and fMLP following pre-incubation with increasing concentrations of 
simvastatin. Data are mean and SEM (n=8) (*p < 0.05 compared to IL-8 and fMLP). 
(Analysed by one-way ANOVA). 
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Chemotaxis 
Chemotaxis was significantly higher (although still low) in IL-8 and fMLP alone 
compared to RPMI-1640 medium. Significant improvements in IL-8 were observed followng 
incubation with both 1 nM (p = 0.03) and 1 µM (p = 0.04) simvastatin. In addition, a 
significant improvement in chemotaxis was observed in fMLP with 1 nM simvastatin (p = 
0.03), although a statistically significant improvement was not observed with 1 uM simvastatin 
(p = 0.09). These results are summarised in Figure 5.15. 
 
 
Figure 5.15: The effects of simvastatin on chemotaxis of COPD neutrophils. 
Legend: Chemotaxis of COPD migrating in a shallow gradients of 100 nM IL-8 and fMLP 
following pre-incubation with increasing concentrations of simvastatin. Data are mean and 
SEM (n=8) (*p < 0.05 compared to IL-8 and fMLP). (Analysed by one-way ANOVA). 
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5.8   DISCUSSION 
 
5.8.1   CXCR1/2 Inhibition 
There has been growing interest into the potential use of CXCR1 and, particularly, 
CXCR2 antagonists in the treatment of chronic inflammatory diseases such as COPD. The 
data here suggest that the dominant effect on isolated CXCR1 or CXCR2 inhibition on 
COPD neutrophils is a reduction in the overall speed of migration with no significant effect 
on their accuracy. Importantly, the effects seen in IL-8 and GROα were generally mirrored in 
sputum, a complex physiological secretion more reflective of the in vivo environment. 
With the dual inhibitor, SHC527123, it would be expected that 3 nM (which favours 
CXCR2 inhibition) should inhibit migration to GROα and, perhaps to a lesser degree, IL-8 
(which can also signal through CXCR1). In contrast, 42 nM (which inhibits both CXCR1 and 
CXCR) would likely provide comparable inhibition in both GROα and IL-8. On average, 
chemokinesis in both GROα and IL-8 in both was reduced by approximately half by 3 nM 
and 42 nM, which seems logical as these were both IC50 concentrations. The fact that the 
effect of SHC527123 on chemokinesis in Sol (although significant) was approximately half 
when compared to chemokinesis in isolated IL-8 and GROα and accuracy was unaltered in 
Sol may be due to a migratory response to other chemokines when both CXCR1 and CXCR2 
are inhibited. Although chemotaxis appeared to be reduced by SHC527123 in GROα and IL-
8, only 3 nM in GROα as significantly lower than it’s respective control. 
The majority chemotaxis data in the CXCR1/2 inhibitor assays appear highly variable. 
The reasons for this may be two-fold; firstly the chemotaxis values (in μm/min) are low and, 
secondly, the data are not normally distributed and, therefore, presented as median with 3
rd
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quartile error bars (not mean and SEM). The general lack of change in chemotaxis with all 
CXCR1/2 inhibitors is most likely because these inhibitors seem to slow neutrophil migration 
and, as the baseline chemotaxis is so poor, it remains unaffected by slower migration. 
Importantly, the CXCR1/2 inhibitors are certainly not improving chemotaxis, which is 
perhaps more clinically pertinent. 
In summary, it appears that COPD neutrophils were simply migrating more slowly 
following treatment with CXCR1/2 inhibitors. This may explain why previous studies 
observed a decrease in airway infiltration following LPS insult (Virtala et al. 2011, Leaker et 
al. 2013), where the neutrophils may have simply been transmigrating more slowly. In COPD 
however, this could potentially be detrimental as slower transmigration would logically 
increase the amount of time that the lung tissue is exposed to the digestive proteinases from 
each neutrophil (if the rate of degranulation is the same). In theory, this could actually 
increase collateral tissue damage and accelerate emphysematous change. Furthermore, one 
recent study that assessed the effects of a CXCR2 antagonist (SB-656933) in patients with 
cystic fibrosis reported an increase in plasma levels of CRP and IL-8 (Moss et al. 2013). This 
potentially detrimental physiological response could also be seen in COPD with CXCR2 
inhibition, although the implications for general and pulmonary inflammation remain to be 
determined. 
 
5.8.2   Kinase Inhibition 
A previous study by our group demonstrated a significant improvement in the migratory 
accuracy of neutrophils from COPD patients in vitro following treatment with the non-
specific PI3K inhibition with LY29004 (Sapey et al. 2011). However, due to the broad 
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association of PI3K with various functions of numerous cell types, the treatment of COPD 
with non-specific PI3K inhibitors could result in undesirable side-effects. By this rationale, 
the experiments in this chapter sought to determine if the advantageous effect of PI3K 
inhibition on neutrophil migration in COPD could be attributed to specific PI3K isoforms 
that could potentially be a more specific and suitable therapeutic target. 
The data demonstrate that inhibition of both the δ- and γ-isoforms at the recommended 
IC50 significantly improved the chemotaxis of neutrophils from COPD patients. In contrast, 
inhibition of the α- and β-isoforms had no effect on the migratory accuracy. It was surprising 
to observe that, in contrast to the initial chemotaxis experiments (Section 3.2.2), the 
chemokinesis of COPD neutrophils was not significantly greater in IL-8 or fMLP alone than 
those from healthy control subjects. This could potentially be due to a smaller number of 
subjects included in this experiment (n = 5) compared to the original experiment (n = 10). On 
reflection, it may also have been useful to determine whether or not the combination of both 
the δ- and γ-isoform inhibitors improved the chemotaxis of COPD neutrophils beyond the 
level achieved when used in isolation. 
Importantly, the inhibition of other kinases involved in neutrophil migration (Erk and 
p38) had no effect on chemokinesis or chemotaxis. This, together with the effects of PI3K 
inhibition, supports the hypothesis that exclusive dysfunction of the PI3K signalling pathway 
may be responsible for the aberrant migration of COPD neutrophils. 
 
5.8.3   Simvastatin 
Statins have been shown to have beneficial immunomodulatory effects in a variety of 
diseases. One study demonstrated a reduction the hospitalisation rates of severe COPD 
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patients with statin treatment (Dobler et al. 2009) and similar effects have been observed in 
patients with sepsis (Falgas et al. 2008). In addition, statins have been shown to reduce 
chemokine production (Inoue et al. 2000) and immune cell endothelial capture, which are 
both important in the excessive inflammatory response that characterises COPD. As it has 
previously been shown that statins exhibit their immunomodulatory effects through 
modulation of GTPase activity (which controls many aspects of cell behaviour including 
migration (Li et al. 2005, Van Keymeulen et al. 2006)), it was hypothesised that the treatment 
of COPD neutrophils with simvastatin could potentially improve their migratory accuracy. 
The data indicated that, while neither 1 nM or 1 μM simvastatin had any major influence 
on migratory speed, both concentrations improved the migratory accuracy of COPD 
neutrophils in IL-8 and fMLP, with the greatest benefit achieved with 1 μM (equivalent to  
80 mg/day) in IL-8. Moreover, the chemotaxis of COPD neutrophils with simvastatin was 
comparable to that of the healthy subjects in the initial chemotaxis experiments (Section 
3.2.2). This suggests that treatment of COPD neutrophils with simvastatin in vitro can 
improve their migratory accuracy to that observed in healthy ageing. Unpublished data from 
our group (H. Greenwood personal communication) show that chemotaxis improves in the 
healthy elderly subjects following treatment with simvastatin, suggesting that neutrophil 
chemotaxis may not be optimal in healthy ageing. This concept is supported by other data 
from our group that indicate chemotaxis of neutrophils from healthy elderly subjects is 
reduced when compared to those from healthy young subjects (Sapey et al. 2014). Once 
again, this highlights the importance of age-matching healthy control subjects and COPD 
patients. 
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The concentration response that we initially observed indicates that the beneficial effects 
of simvastatin (particularly on neutrophil chemotaxis) may not be achieved if the dose is too 
high or too low. Therefore, the null effect of simvastatin in previous studies on inflammation 
and neutrophil function may be because the dose was too low and, perhaps, the assay used 
and the type of patients studied. For instance, Guasti et al reported a reduction in chemotaxis 
with 20 mg simvastatin but they used a Boyden Chamber, which does not provide specific 
information on migratory dynamics and they did not study COPD patients (Guasti et al. 
2006). In addition, the large clinical trials of simvastatin also used doses lower than             
80 mg/day and, importantly, did not investigate effects on neutrophil function (Papazian et al. 
2013, Criner et al. 2014). Recent data from our group has also demonstrated that simvastatin 
has no effect on neutrophil function during pneumonia with severe sepsis (unpublished data 
from J. Patel). This suggests that if the host response to infection or injury is too severe, 
improvements in neutrophil function and, potentially, other anti-inflammatory effects of 
simvastatin may be lost. Collectively, these data suggest that there may be a tight window of 
opportunity for statin therapy in respiratory disease, where a high dose is required when 
patients are not severely ill and clinically stable. This may explain why two other recent 
clinical trials in Adult Respiratory Distress Syndrome (where the dose was 80 mg/day but 
patients had severe sepsis) (McAuley et al. 2014) and Community Acquired Pneumonia 
(where the 20 mg/day dose may have been too low) (Vlasus et al. 2014) were also negative. 
As simvastatin did improve the migratory accuracy of COPD neutrophils further 
implicates the PI3K signalling pathway as a mechanism (albeit indirectly as GTPases such as 
Ras and Rho are not directly influenced by PI3K but synergise many processes along its 
signalling pathway). Inhibition of Ras and Rho by simvastatin appears to have a downstream 
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effect of attenuating the over-active PI3K signalling that we propose as a key mechanism in 
the aberrant migration of COPD neutrophils. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
CHAPTER 6 
 
GENERAL DISCUSSION 
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COPD is a major disease and a leading cause of mortality and morbidity worldwide 
(WHO 2007). Its prevalence incurs a huge burden on healthcare and, in spite of its 
longstanding recognition, relatively little is understood about the pathogenesis of COPD and 
there are currently no therapies available that can fully reverse its pathological effects. COPD 
is a disease of chronic inflammation that occurs throughout the airways and the lung 
parenchyma (Saetta et al. 2001). Numerous inflammatory cells and mediators have been 
implicated in its pathogenesis, though the neutrophil is believed to be the predominant effector 
cell (Sapey et al. 2008). 
Neutrophil migration is fundamental to their inflammatory function. It is logical to infer 
that, without accurate migration, the ability of neutrophils to reach the site of inflammation and 
locate invading pathogens would be impaired. Migration is initially induced via the detection 
of a chemotactic stimulus by cell surface receptors, which results in the activation of various 
intracellular signalling pathways that lead to cytoskeletal rearrangement, polarisation and, 
ultimately, motility (see Section 1.2.3). 
The first studies of neutrophil migration in COPD used a Boyden Chamber and yielded 
variable results, with one study demonstrating an increased migration of neutrophils from 
COPD patients (Burnett et al. 1987), while a later study described a reduced chemotaxis of 
neutrophils from patients with more severe COPD (Yoshikawa et al. 2007). The Boyden 
Chamber assay is limited as it does not allow for the assessment of specific migratory 
dynamics on a cell-by-cell basis and can only assess net movement. A recent study by our 
group assessed the two-dimensional migratory dynamics of COPD neutrophils using an Insall 
Chamber (Sapey et al. 2011). The results indicated that COPD neutrophils consistently 
migrated with increased speed (chemokinesis) but reduced accuracy (chemotaxis) in the 
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presence of IL-8, GROα and sputum when compared to neutrophils from healthy donors. 
Although the data provided far more insight into how the cells were migrating, it was unclear 
whether the aberrant migration was a generic phenomenon or due specifically to a 
dysregulation of the IL-8 and GROα receptors, CXCR1 and CXCR2. Moreover, it was 
unclear whether or not it was an intrinsic cell defect or the result of the systemic 
inflammatory environment of COPD. 
Although migration is only one element of neutrophil-driven inflammation, its dysfunction 
in COPD could be of fundamental importance to the pathophysiology of the disease. Firstly, 
the area of collateral, proteolytic tissue damage may be increased if neutrophil migration 
through the parenchyma is inaccurate due to longer migratory tracks. As elastolytic destruction 
is central to the emphysematous process, it could be intensified by aberrant, inefficient 
neutrophil migration through the extracellular matrix. Secondly, an impaired ability of 
neutrophils to locate pathogens within the airspaces could lead to a further increase in bacterial 
propagation and, potentially, a more frequent exacerbation rate. Their role in COPD infers that 
neutrophils, together with their functional bi-products and inflammatory mediators could 
potentially be targets for novel therapies in COPD. However, the current understanding of the 
specific processes involved in neutrophil-driven inflammation and migration in COPD is 
limited. Therefore, this thesis sought to further define these processes with the aim of 
providing greater insight that may aid in the development of novel therapeutic strategies. 
 
6.1   ABERRANT NEUTROPHIL MIGRATION IN COPD 
Following the previous study by our group (Sapey et al. 2011), this study initially 
compared two-dimensional migration of neutrophils from COPD donors to those from age-
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matched healthy donors and patients with α1-ATD. α1-ATD mirrors many pathophysiological 
aspects of COPD but has a known genetic predisposition and a well described pathogenesis. 
The inclusion of patients with α1-ATD was important to account for other factors that may 
influence neutrophil migration, such as smoking status, lung disease/inflammation and 
pharmacological therapies. In addition to IL-8 and GROα used in the previous study (Sapey 
et al. 2011), this thesis also assessed migration to other endogenous and bacterial 
chemoattractants, including LTB4, C5a and fMLP. These were selected on the basis that they 
represent inflammatory chemokines from different sources and each have specific receptors 
on the neutrophil surface distinct from those for IL-8 and GROα. 
The data indicate that neutrophils consistently migrate with increased chemokinesis but 
reduced chemotaxis in the presence of all five chemoattractants. This is important as it 
suggests that the aberrant neutrophil migration in COPD is a generic phenomenon and not 
related to specific chemokines and their receptors, which could not be confirmed in previous 
studies (Yoshikawa et al. 2007, Sapey et al. 2011). There are many mammalian chemokines 
that induce neutrophil migration. Importantly, the migratory accuracy of COPD neutrophils 
was as poor in response to sputum Sol as it was to isolated chemokines such as IL-8. If this in 
vitro finding is mirrored in vivo, it could mean that neutrophils in COPD patients migrating 
towards sputum in the airspaces would also migrate inaccurately. As mentioned, this could be 
a major mechanism by which emphysematous damage and bacterial colonisation is amplified 
in COPD. 
Whether or not this dysfunction develops during neutrophil maturation in the bone 
marrow or after their release into the circulation has yet to be determined. The chemotaxis 
data shown here suggest that, although certain inflammatory mediators may be increased in 
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the plasma of COPD patients, the systemic inflammatory environment is unlikely to be the 
cause of altered neutrophil migration. It is possible that the time that the healthy neutrophils 
were exposed to COPD plasma (40 minutes) was not sufficient to have an effect and it may 
be preferable to expose cells for longer (several hours). However, neutrophils only remain 
viable for a relatively short time once isolated from peripheral blood (> 60% cell death after 
24hrs (Xu et al. 2013)), so they could not be incubated extensively in donor plasma. A more 
suitable experiment may be the adoptive transfer of radiolabelled neutrophils from healthy 
animal donor strain into a separate animal strain in which emphysema can be induced before 
re-extraction and assessment of migration but, again, this is not ideal and the relatively short 
half-life of neutrophils may prove limiting. Furthermore, the data on neutrophil activation 
markers suggest that systemic inflammation in COPD is unlikely to have a major effect on 
neutrophil activation status and migratory dynamics, as the surface expression of the majority 
of the markers studied were the same in COPD and health. 
Lastly, it cannot be excluded that aberrant neutrophil migration is in fact congenital in 
patients who are predisposed to developing COPD and it is only the continual, inaccurate 
migration through the lungs in response chronic inhalation of toxic particles that causes 
COPD to manifest. This could be investigated by studying a large cohort of young never-
smokers who, on the whole, appear to have accurate neutrophil migration (Sapey et al. 2014), 
to determine if there is a proportion that exhibit aberrant migration. Individuals that begin to 
smoke could then be followed longitudinally with HRCT and lung function tests to see which 
(if any) develop COPD. Unfortunately, gaining funding for such studies may be difficult. 
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6.2   MECHANISMS UNDERLYING ABERRANT NEUTROPHIL MIGRATION 
IN COPD 
The initial experiments suggested that the aberrant neutrophil migration in COPD is not 
influenced by external factors. Therefore, it is logical to assume that the dysfunction is 
related to the intrinsic factors that mediate chemotaxis, including chemokine receptor 
function and/or the intracellular signalling pathways used by these receptors. 
A slightly reduced expression of CXCR1, CXCR2 and C5aR was observed on quiescent 
COPD neutrophils compared to those from healthy controls. The mechanisms responsible for 
the reduced expression of these receptors in COPD are unclear. It has been shown that TNFα, 
which is present in higher concentrations in the plasma of COPD patients (Matsushima et al. 
1988), induces CXCR2 shedding as well as a suppression of chemotaxis in vitro (Asagoe et 
al. 1998). Whether this effect is paralleled in vivo and whether similar effects on CXCR1 and 
C5aR exist remain to be determined. The fact that there was no difference in the surface 
expression of any chemokine receptor between health and α1-ATD suggests that 
inflammation alone is not sufficient to cause this reduction. In support of this, evidence 
suggests that the concentration of inflammatory cytokines (such as IL-8 and LTB4) is actually 
higher in the sputum of α1-ATD compared to usual COPD (Stone et al. 2012). 
As migratory dysfunction of COPD neutrophils was observed in all five chemokine 
gradients, it seems logical that chemokine receptor expression should be universally 
decreased if that was the cause of altered migration. However, this was not observed in the 
experiments investigating chemokine receptor expression. Moreover, quiescent expression 
may not accurately reflect what occurs during migration, where neutrophils are activated and 
surface expression of chemokine receptors may alter due to internalisation, re-expression and 
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shedding. The rapid abolition of differences in quiescent CXCR1 and CXCR2 expression 
between COPD and healthy neutrophils following their stimulation supports the theory that 
chemokine expression does not impair migratory accuracy of neutrophils in COPD. Total 
surface expression of receptors only provides limited information as, for accurate cell 
migration, these receptors must be localised to the leading edge to allow for optimal gradient 
sensing and directionality. The data shown here suggest that both CXCR1 and CXCR2 
localise to the leading edge as efficiently in COPD compared to health. Although a relatively 
crude assessment, these experiments further support the proposal that chemokine receptor 
expression cannot be implicated in the aberrant neutrophil migration of COPD. However, it 
has previously been show that COPD neutrophils form fewer pseudopods than those from 
healthy controls (Sapey et al. 2011). In addition, studies on Dictyostelium have shown that 
abnormal or reduced pseudopod formation is associated with altered migration (Weber 
2006). It is possible that, although chemokine receptors may be localising to the leading edge 
on activated, migrating neutrophils as effectively and in similar numbers in COPD compared 
to health, impaired pseudopod extension could indirectly influence receptor-ligand binding. 
A more detailed investigation into chemokine receptor localisation on extending pseudopods 
using differential interference contrast (DIC) microscopy may provide further insight. 
PI3K is associated with numerous cellular functions, including directional migration 
(Knall et al. 1997, Sasaki et al. 2000, Sadhu et al. 2003). A universal trend for increased 
PI3KT458 phosphorylation was observed in both unstimulated and stimulated (with IL-8, 
GROα and fMLP) COPD neutrophils. Although the biological significance of these pilot data 
is unclear, they suggest that there could be differences in PI3K signalling in COPD 
neutrophils. Therefore, the hypothesis that PI3K over-activity may be causing aberrant 
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neutrophil migration in COPD is speculative (based on the limited data presented in this 
thesis) but is supported by a previous study by our group that demonstrated that a non-
selective PI3K inhibitor (LY29004) corrected the migratory defect (Sapey et al. 2011). 
Whether potentially increased PI3K activity could be a result of a genetic polymorphism 
resulting in increased susceptibility to COPD or a result of the disease itself remains to be 
determined. Regardless, its association with the altered neutrophil migration COPD is 
becoming more evident and it seems to be the only altered signalling pathway identified to 
date. 
Precisely how a hypothetical increase in PI3K activity could result in increased speed 
and poor directionality during neutrophil chemotaxis in COPD also remains unclear. As 
LY29004 is known to reduce migratory speed and affect pseudopod formation (Andrew et al. 
2007), it seems logical that there is a downstream effect of PI3K-dependant mediators. 
Further progress in the area may require mechanistic work in animal models. However, 
animal models of COPD are currently very limited and only include those with emphysema 
induced by the acute introduction of pro-inflammatory cytokines into the airways or 
inhalation of tobacco smoke. These do not truly reflect the chronic and insidious 
development of COPD in humans, which is also associated with both airflow obstruction and 
chronic bronchitis. The more recent zebrafish model (Renshaw et al. 2006) could eventually 
prove useful as it allows for real-time monitoring of neutrophil migration in vivo. It may be 
possible to induce PI3K over-expression in zebrafish by increasing SHIP-1 expression using 
micro RNA-155 (miR-155) (O'Connell et al. 2009). If aberrant neutrophil migration results, it 
would support our theory of PI3K involvement. Similarly, if PI3K knock-down animal 
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models develop less emphysema as a result of cytokine/smoke exposure than those with 
normal PI3K expression, it would add further support to this theory. 
No differences were observed in Akt phosphorylation (at either S473 or T308). Although 
PI3K binding is important for Akt activity, it is not essential and Akt can be activated in a 
PI3K-independent manner (Mahajan et al. 2010). In addition, once PI3K binding has 
occurred, further phosphorylation events are necessary for Akt to become fully activated. 
Therefore, despite potentially increased PI3K activity in COPD that could lead to a more 
rapid accumulation of Akt at the plasma membrane, Akt activity may be limited by its 
phosphorylation by mTORC2 (at S473) and/or PDK1 (at T308). It is important to note that 
this thesis studied neutrophil migration using adhered cells, whereas PI3K and Akt 
phosphorylation was determined from non-adherent cells. Personal communications from Dr. 
Philip Hawkins (The Babraham Institute, Cambridge) have suggested that Akt activity is only 
up-regulated once neutrophils become adhered. Although an upregulation of pAktS473 from 
non-adherent neutrophils was observed, it may explain why there was no difference in 
pAktT308 following stimulation. 
The migratory signalling pathway is extremely complex and comprises numerous 
mediators that each in turn influence and are influenced by other signals. There are many 
components in the PI3K signalling pathway that have yet to be investigated in COPD. Of 
particular interest are the regulators of PI3K activity and PIP3 generation (PTEN and SHIP1), 
which could potentially be dysregulated and a possible cause of increased PI3K activity in 
COPD neutrophils. Furthermore, new techniques have recently been developed by Dr. Phillip 
Hawkins that have been used to directly assess PIP3 production (unpublished data). As PIP3 
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production is catalysed by PI3K, this technique could provide a more direct quantification of 
PI3K activity in future studies of neutrophil migration. 
 
6.3   PHARMACOLOGICAL CORRECTION OF ABERRANT NEUTROPHIL 
MIGRATION IN COPD 
Current therapies for COPD are limited to symptom relief (primarily through 
bronchodilation) and the search for new strategies is ongoing. This thesis has demonstrated 
significant improvements in the accuracy of migrating neutrophils from COPD patients in 
vitro with two independent pharmacological interventions. 
CXCR1 and CXCR2 inhibition did not seem to improve chemotaxis. In contrast, there 
was, generally, a marked reduction in chemokinesis, which in some instances actually 
resulted in concurrent reductions in chemotaxis. The inclusion of Sol as a chemotactic 
gradient in these assays was deemed essential. Although the vast majority of chemokines 
signal through CXCR2, there are a number of other chemoattractants present in lung 
secretions (such as LTB4) that signal through other, specific receptors. Therefore, effects of 
CXCR1/2 inhibitors observed in vitro in response to IL-8 or CXCR2 ligands (such as GROα) 
may not fully represent their potential effects in vivo. The fact that effects of CXCR1/2 
inhibition on chemokinesis and chemotaxis were generally less pronounced in Sol supports 
this conclusion. It is difficult to postulate whether or not simply reducing migratory speed 
would be beneficial or detrimental in COPD. If inhibition of CXCR1/2 reduces the number of 
neutrophils that initially enter the extracellular matrix and subsequently transmigrate, it 
would most likely reduce tissue damage and, therefore, be of therapeutic benefit. However, if 
the same number of neutrophils transmigrate at a slower speed with no improvement in 
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migratory accuracy, the amount of time each cell remains within the extracellular matrix 
should be increased. If the rate of proteinase release is unaltered, it could theoretically lead to 
increase in tissue destruction. It may be possible in future to compare the total number of 
neutrophils that migrate through 3D matrices with and without CXCR1/2 inhibition. In 
addition, the resulting density of the matrix could be assessed by micro-CT, a technique that 
has previously been used to detect early pathophysiological changes in the small airways 
(Hogg et al. 2013). For example, a lower matrix density following transmigration of 
neutrophils pre-treated with CXCR1/2 inhibitors would support the hypothesis that reduced 
transmigratory speed results in increased matrix destruction. However, this may be difficult 
given the chronic nature of COPD and the time it takes for detectable pathophysiological 
change to occur. 
Specific γ- and δ-isoform inhibitors of PI3K improved chemotaxis, whereas the α- and β-
isoform inhibitors did not. This seems logical as PI3K has been shown to regulate cell 
migration (Hannigan et al. 2002, Sapey et al. 2014) and the -γ and -δ isoforms are dominant 
in leukocytes (Ferguson et al. 2007, Martin et al. 2010). To our knowledge, this is the first 
study to investigate the effects of specific PI3K isoform inhibition on the migratory dynamics 
of COPD neutrophils. The results are promising as, if the improvement in the chemotaxis of 
COPD neutrophils observed here in vitro with PI3Kδ- and γ-isoform inhibitors is mirrored in 
vivo, this could prove an effective therapeutic option for COPD. Clinical trials may be useful 
to determine firstly, if the short-term treatment (for example 2-4 weeks) of COPD patients 
with these inhibitors can improve the migratory accuracy of isolated neutrophils in vitro and, 
secondly, if long-term treatment could slow the progression of COPD and improve other 
factors such as exacerbation frequency. An aerosolised PI3Kγ/δ inhibitor could certainly be 
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of benefit in COPD (Doukas et al. 2010). Delivery by this method could theoretically 
improve the migratory dynamics of neutrophils already within the pulmonary airspace and 
lead to more effective pathogenic location. However, it may not necessarily allow the 
inhibitor to sufficiently penetrate the alveolar-capillary membrane and improve the 
chemotaxis of neutrophils migrating through the extracellular matrix from the pulmonary 
circulation. Future clinical trials of PI3Kγ/δ inhibitors are certainly warranted in COPD, 
although they may require a more systemic approach such as an oral or intravenous mode of 
delivery to achieve the optimal therapeutic effect. 
Simvastatin had a similar effect on neutrophil chemotaxis in COPD, where the inhibition 
of small GTPases appears to attenuate PI3K activity. Whether there is a concurrent over-
activity of GTPases in the neutrophils of COPD patients has yet to be determined. Further 
studies could investigate the activity of small GTPase, such as the Ras and Rho. In addition, 
the Rho GTPase, Cdc42 is a key regulator of cell polarity and lamellipodia formation 
(Etienne-Manneville 2004). It has recently been shown that Cdc42 regulates neutrophil 
migration through an intricate mechanism of crosstalk between the Wiskott–Aldrich 
Syndrome Protein (WASp), CD11b, and microtubules (Kumar et al. 2012). Investigations of 
these mechanisms may provide further insight into the downstream effects of increased PI3K 
activity in COPD neutrophils and the possible effects on other cellular functions. For 
instance, a number the Rho GTPase superfamily members are also involved other neutrophil 
functions such as phagocytosis and superoxide production (Bokoch 2005). If GTPase activity 
is increased in COPD, it may explain the increased neutrophil phagocytosis (Burnett et al. 
1987) and ROS production (Noguera et al. 2001) previously reported in COPD. Therefore, 
although simvastatin could potentially improve chemotaxis in COPD, it could possibly have 
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a detrimental effect on phagocytosis and ROS production. Hence, it would be important to 
assess the effect of simvastatin (and other pharmacological therapies that may influence 
GTPase activity) firstly on other neutrophil functions in vitro and, secondly, on factors such 
as exacerbation frequency and symptom scores in future clinical trials. 
Simvastatin is already widely used for the treatment of hypercholesterolemia. Because of 
its long-standing therapeutic use, the side-effects and toxicity range are well documented. 
Simvastatin is considered a safe and well-tolerated drug and the majority of side-effects are 
relatively mild (abdominal pain, diarrhoea, indigestion). However, there are a number of 
drugs that are not recommended to be taken in conjunction with it due to potential adverse 
interactions. These include a number of commonly used antibiotics 
(erythromycin, clarithromycin) and antiarrhythmic drugs (amiodarone, verapamil) (FDA 
2012). Our data suggest that future clinical trials investigating the effects of simvastatin on 
neutrophil migration should be with a high-dose (80 mg/day) in clinically stable COPD.  
If, as is hypothesised, aberrant neutrophil migration in COPD results in exaggerated 
parenchymal destruction (due to increased migratory tracks) and impaired pathogenic 
location within the pulmonary airspace, the improvement of their migratory dynamics with 
therapies such as PI3Kγ/δ inhibitors and simvastatin could have hugely beneficial effects. 
These could include slowing the progression of the disease by reducing the tissue destruction 
(due to improved migrational accuracy through the extracellular matrix) as well as reducing 
exacerbation frequency (due to improved bacterial clearance). For clinical trials, monitoring 
outcomes (such as lung function, symptoms and exacerbation frequency) would be relatively 
simple but current literature suggests that in order to accurately detect an improvement in the 
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rate of lung function decline (with FEV1 % predicted), 4 data points over 3 years are 
recommended (Vestbo et al. 2011). 
 
6.4   THEORETICAL MODEL OF COPD PATHOGENESIS 
A theoretical model of neutrophil migration in COPD and its influence on disease 
pathophysiology is shown in Figure 6.1. This model is predominantly based on findings from 
the current research project (including hypothetical PI3K over-activity) but also includes 
hypotheses based on published from our group and other groups. 
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Figure 6.1: A simplified theoretical model of altered neutrophil migration in COPD. 
 
Legend: Although COPD neutrophils appear to have normal chemokine receptor function, p38, Erk 
and Ca
2+
 signalling, they exhibit PI3K over-activity (A). This could be due to dysregulation (by 
SHIP1/PTEN) and individuals may be genetically pre-disposed. Increased PI3K activity appears to 
result in impaired migratory accuracy (B), possibly due to increased PIP3 production and the loss of a 
PIP3 gradient (Platek et al. 2007). If this effect is mirrored in vivo, it could increase collateral tissue 
damage during inaccurate transmigration. This may only induce significant pathological change if 
coupled with chronic inhalation of toxic particles (C). This thesis has demonstrated that both PI3K 
inhibitors (D) and Simvastatin (E) can improve chemotaxis and may, therefore, be therapeutically 
beneficial in slowing disease progress. Poor chemotaxis may also reduce the ability to locate (F) and 
phagocytose (G) pathogens, which could both impair bacterial clearance. Due to the morphological 
changes that occur with COPD, the mechanical ability of the pulmonary system to clear pathogens is 
also affected (H). Reduced bacterial clearance may then lead to increased exacerbation frequency (I), 
which can perpetuate COPD (J).  
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6.5   FUTURE WORK 
This thesis has provided insight into a number of features of neutrophil-driven 
inflammation and migration in COPD. The focus has predominantly been on mechanisms of 
the aberrant neutrophil migration (specifically chemokinesis and chemotaxis). Although the 
majority of data have yielded negative results, the exclusion of these mechanisms is still 
important. However, the data have provided strong evidence that implicates increased PI3K-γ 
and -δ activity in impaired neutrophil chemotaxis in COPD and the potential benefits of 
PI3Kγ/δ inhibitors and simvastatin in its treatment. However, further studies are required to 
clarify the exact mechanisms involved downstream of PI3K activation to further define the 
involvement of this pathway in COPD. Further studies could include; 
 
1. Assessment of three-dimensional neutrophil migration to determine if the aberrant 
migration observed in two-dimensional planes may still occur during migration through 
an extracellular matrix. In addition, the effects of therapies such as PI3K inhibitors, 
statins and CXCR1/2 antagonists could also be assessed in this way. This could be 
done either in vitro using gel matrices or in vivo if a suitable animal model (including a 
PI3K knock-up or knock-down model) is developed. 
 
2. Measurement of the plasma concentration of pro-inflammatory cytokines (such as 
TNFα, IL-1β, IL-6 and IL-8) as well as other soluble inflammatory markers (such as 
CRP) in COPD patients to confirm the presence or absence of systemic inflammation 
and relate this to neutrophil migration. 
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3. A more detailed investigation to determine if the chemokine receptors that seem to 
mobilise effectively to the leading edge of polarised COPD neutrophils are actually 
located on the extending pseudopods. This could be done by fluorescence labelling of 
chemokine receptors and subsequent observation under a DIC microscope. DIC 
microscopy would allow for the observation of receptor location not only on fixed 
neutrophils but also on migrating neutrophils. 
 
4. Assessment of the phosphorylation of additional PI3K subunits, with particular focus 
on the PI3Kγ p84/p101 regulatory and p110 catalytic subunits. 
 
5. Assessment of gene mutations that encode the regulatory and catalytic subunits of 
PI3K. 
 
6. The regulators of PI3K activity, SHIP1 and PTEN should also be investigated. These 
investigations should include western blotting of pSHIP1 and pPTEN, quantification of 
SHIP1/PTEN activity using commercial PIP3-phosphatase activity assays and, finally, 
assessment of migration following treatment with SHIP1 and PTEN inhibitors. Work 
on SHIP1 phosphorylation and inhibition has already begun within our group and is 
ongoing. 
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7. Now that a method of directly assessing PIP3 activity has been developed, it would be 
important to quantify this in COPD neutrophils as PIP3 generation is directly mediated 
by PI3K and an important mediator of chemotaxis. 
 
8. The data on the improvement in chemotaxis with simvastatin implicate small GTPase 
involvement in the aberrant neutrophil migration in COPD. Therefore, it would be 
important to confirm this with Small G-protein Activation Assays (“G-LISA”). It 
would also be important to determine if this is an effect of PI3K dysregulation or a 
separate phenomenon. 
 
9. Clinical Trials of both PI3Kγ/δ inhibitors and simvastatin in COPD would be important 
to determine if the improvement in migratory accuracy of COPD neutrophils can be 
achieved following a short period of treatment with these therapies (compared to 
placebo). This principle of this trial is relatively simple, involving in vitro assessment 
of neutrophil migration before and after a short course of treatment. In the long-term, 
assessment of clinical outcomes (including measures of symptoms and physiology) 
following extended periods of treatment would be important to determine if these 
therapies truly have a clinical effect. 
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6.6   CONCLUSIONS 
The studies within this thesis have provided novel evidence that peripheral neutrophils 
isolated from COPD patients have altered migratory dynamics. They consistently migrate with 
increased speed and reduced accuracy in a diverse array of chemotactic gradients. This appears 
to be an intrinsic cell defect that is not influenced by the systemic COPD environment, 
although it is unclear if this defect is congenital or influenced by chronic inflammatory insult. 
The aberrant neutrophil migration observed could theoretically affect the pathogenesis of 
COPD by delaying the inflammatory response, increasing collateral tissue destruction (due to 
longer migratory tracks through the extracellular matrix) and impairing bacterial clearance in 
the lungs. The data have also provided evidence for potential intracellular signalling 
mechanisms (while excluding others) through which pharmacological manipulation can 
improve the migratory accuracy of COPD neutrophils. This evidence will hopefully lead to 
future clinical trials of novel therapies that may be of benefit in COPD. 
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